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This thesis describes the interactronoC drug with metal ions and their 
determination by UV-visible spectrophotometry, spectrofluorimetry, resonance 
Rayleigh scattering (RRS), second order scattering (SOS) and frequency 
doubling scattering (FDS). They have been analysed in pharmaceutical 
formulations based on the formation of complex with metal ions. The 
sensitivity of these methods has also been compared with trivial analytical 
techniques. The stability constant and molar ratio of drug to metal has been 
determined. 
The absorbance and fluorescence spectral pattern of levosulpiride in 
absence and presence of first row transition metal ions has been studied at 
room temperature under physiological conditions. The fluorescence spectra of 
the drug in presence of different concentrations of transition metal ions showed 
enhancement in fluorescence intensity of levosulpiride. The photophysical 
changes owing to the direct interaction between metal ion and the amide 
nitrogen of levosulpiride has been discussed in terms of CHEF (chelating 
enhancement fluorescence) effect. The absorption spectra of the drug at 
different pH exhibited two isosbestic points at 255 and 
275 nm respectively, indicating the presence of different chemical species in 
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solution. The 2:1 (drug:metal) complex was determined spectrophotometrically 
and potentiometrically. The low value of stability constant suggests that 
complexes may dissolve and the drug can be absorbed. We have developed 
spectrofluorimetric method for the determination of levosulpiride in 
pharmaceutical formulations. The reaction condition were studied and 
optimized. The thermodynamic parameters obtained in this study revealed that 
the interaction process was spontaneous and AS-driven. 
In chapter two the interaction of Captopril (CPL) with biologically 
active metal ions Mg(II), Ca(II), Mn(Il), Co(II), Ni(II), Cu(Il) and Zn(II) has 
been investigated in acidic medium by fluorescence spectroscopy. The 
experimental results showed that the metal ions quench the intrinsic 
fluorescence of CPL by forming complex formation. It was found that static 
quenching was the main reason of fluorescence quenching. The quenching 
constant in the case of Cu(II) was highest of all quenchers, perhaps due to its 
high nuclear charge and small size. Quenching of CPL by metal ions follows 
the order Cu(II)>Ni(II)>Co(II)>Ca(II)>Zn(II)>Mn(II)>Mg(II). The quenching 
constant Kjv, bimolecular quenching constant Kq, binding constant K and the 
binding sites "n" were determined together with their thermodynamic 
parameters at 27 and 37 °C. The positive entropy change indicated the gain in 
configurational entropy as a result of chelation. The process of interaction was 
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spontaneous and mainly AS-driven. 
In the third chapter, three simple and highly sensitive methods were 
designed for the determination of Cephalosporin antibiotics (CF,) namely 
Cefpodoxime proxetil (CFPD), Cefdinir (CFDN) and Cefuroxime axetil 
(CFRX). The method is based on the enhancement in intensity of resonance 
Rayleigh scattering (RRS) and non-linear scattering such as second-order 
scattering (SOS) and frequency doubling scattering (FDS) intensities. All these 
antibiotics under this project react with Cd(Il) in BR buffer of pH 3.4 to form 
1:1 cationic chelate which further react with titan yellow to form 2:1 ion 
association complexes as a result of which RRS, SOS and FDS intensities were 
markedly enhanced. The increments of scattering intensities were directly 
proportional to the concentration of the drugs in a certain range. The detection 
limit for the three CFs were 1.73-2.38 ngmf' (RRS method), 5.12-5.67 ngmf' 
(SOS method), 6.25-7.26 ngmf' (FDS method) respectively. Among them the 
RRS method exhibited the highest sensitivity and the CFPD system was more 
sensitive than other antibiotic systems. The optimum reaction conditions, the 
effects of coexisting substances, the structure of ternary complexes and the 
reaction mechanism have been discussed. The methods were applied to the 
determination of CFs in pharmaceutical samples with satisfactory results. 
In next chapter the interaction between prulifloxacin (PUFX) with Y(III) 
\n 
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and anionic surfactants (AS) like sodium dodecyl benzene sulfonate (SDBS), 
sodium dodecyl sulfate (SDS) and sodium lauryl sulfonate (SLS) was studied 
by resonance Rayleigh scattering (RRS), second-order scattering (SOS) and 
frequency doubling scattering (FDS) techniques combined with absorption 
spectra. The Y(Ill) reacts with PUFX in Britton-Robinson (BR) buffer of pH 
6.5 to form a 1:2 cationic chelate which further reacts with AS to form 1:1 ion-
association complex. As a result, the RRS, SOS and FDS intensities were 
enhanced greatly. The maximum RRS, SOS and FDS wavelengths of three ion-
association complexes were located at 400/400 nm, 760/380 nm and 390/780 
nm, respectively. The intensities of the scattering were directly proportional to 
the concentrations of PUFX in certain ranges. The detection limits (3o) of 
PUFX for SDS, SLS and SDBS systems were 0.78 ngmf', 0.94 ngmf' and 1.1 
ngmr'(RRS method), 2.7 ngmf', 3.3 ngmf' and 3.5 ngmf' (SOS method) and 
4.2 ngmf", 4.3 ngmf' and 4.4 ngmf' (FDS method), respectively. Since the 
sensitivity of RRS method was higher than those of others the effect of 
coexisting substances on the reaction were investigated by this method. In 
addition, the composition of ion-association complex, the reaction mechanism 
and reasons for RRS enhancement have been discussed. 
In fifth chapter a highly sensitive RRS method based on the redox 
reaction of Levothyroxine (LVT) was developed. LVT reacts with Fe(III) in 
IV 
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presence of HCl solution to produce Fe(II) which further reacted with 
[Fe(CN)6]''' to form a charge neutralization Fe4[Fe(CN)6]3 complex (Prussian 
blue) which forms an aggregate {Fe4[Fe(CN)6]3}n by virtue of hydrophobic and 
Van der Waals forces. This resulted in a significant enhancement in resonance 
Rayleigh scattering (RRS), second-order scattering (SOS) and frequency 
doubling scattering (FDS). The increase in scattering intensity (A/) was found 
to be directly proportional to the concentrations of the LVT. The detection 
limits for the LVT were 2.8-8.0 ^gml"' (RRS method), 2.5-7.5 ngmf' (SOS 
method) and 2.6-7.2 ^gm^' (FDS method), respectively. The RRS method 
exhibited the highest sensitivity of all other methods. The spectral 
characteristics of spectra, the optimum conditions of the reaction and the 
factors governing spectral changes were investigated. In addition, the reaction 
mechanism has also been discussed. 
The final chapter of this thesis describes the complexation behavior and 
mechanism of fluorescence quenching of Telmisartan (TMST) by Y(III) and 
Nd(III) by fluorimetric method. The quenching was interpreted in terms of 
CHEQ (Chelation Enhanced Quenching). The experimental results showed that 
both Y(III) and Nd(III) quench the intrinsic fluorescence of TMST by complex 
formation without inducing any conformational change in TMST. It was found 
that static quenching was the main reason of fluorescence quenching. Linear 
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Stem-Volmer plots were obtained for both the complexes. pH of the solution 
was found to have a profound effect on quenching. The effective quenching 
was obtained at pH 7. The stiochiometry of TMST-metal complexes was found 
to be 2:1. The quenching constant Ksv and association constant were 
determined together with their thermodynamic parameters at 25 and 35 °C. The 
negative AG values indicated that the complexation process was spontaneous. 
A decrease in logK with an increase in temperature and, the negative values of 
AH for the complexation showed that reactions are exothermic and, the metal-
ligand binding is enthalpy driven. 
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CHAPTER-I 
Fluorescence Enhancement of Levosulpiride 
Fluorescence Enhancement of Levosulpiride in 
Presence of Metal Ions and Its Analytical 
Applications 
INTRODUCTION 
Levosulpiride, a levo enantiomer of sulpiride, chemically known as 
5-(aminosulfonyl)-N-[(l-ethyl-2-pyrrolidinyl)methyl]-2-methoxy benzamide 
is used as antipsychotic, antidyspeptic and antiemetic medicine (Fig.l). This 
drug has also been used for the treatment of male sexual disorder and a dose of 
25 mg/day for 60 days results in complete recovery. These studies are 
concerned mainly with the validation and determination of levosulpiride in 
human beings. The drug is fairly stable in human serum and urine which has 
been tested in different patients. It has been found that the drug can be detected 
in a concentration range of 0.25-200 ngml' in human serum and 0.2-20 ligml' 
in urine by HPLC [1,2]. The bioavailability of the drug at a dose of 100-200 
mg/day is approximately 20-30% only [3]. Levosulpiride has both antiemetic 
and prokinetic properties because it antagonizes dopamine receptor in the 
central nervous system and gastro-intestinal tract [4,5]. Recently, it has been 
shown that, levosulpiride has moderate agonistic effect on 5HT4 receptors in 
the nervous system and is useful in the treatment of depression or 
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Schizophrenia [6]. Patients treated for functional dyspepsia over a period of 
one month did not show any adverse effect except for fatigue, headache and 
drowsiness [7]. It is, therefore, considered as an effective and safe drug for the 
treatment of dyspepsia. It has been shown that the levosulpiride does not 
interfere with most of the drugs but, drinking during this period should be 
avoided. As a precaution, the drug should be avoided in pregnancy and during 
lactation period. 
The major work done on the sulpiride thus far, concerns its 
identification, determination, efficacy against dyspepsia, psychosis and male 
sexual disorder. However, absorption and fluorescence emission 
spectrophotometric behavior of the drug under physiological condition and its 
interaction with several cations has not been studied so far. 
In the present work an attempt has been made to study the interaction of 
the drug with metal ions by fluorescence emission, spectrophotometric and 
potentiometric measurements. Since enhancement in fluorescence intensity of 
the drug in presence of a metal ion occurs, the spectra of the drug in presence 
of different concentrations of several metal ions were scanned. The absorption 
spectra of the drug was run at different pH to see the zwitterionic condition, 
apparent ionization constant and the isosbestic point indicating the presence of 
different species in solution. Composition of the drug to metal ions and 
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stability constant of the complex were determined by Job's method. In this we 
have developed a simple, economic and highly sensitive fluorometric method 
for the determination of levosulpiride, with Al(lII) and Fe(IlI). The metal-drug 
interaction may result in the formation of stable complex which not only affect 
the bioavailability of 'the drug but may also deplete the blood with trace 
element. Both of these methods were applied for the determination of 
levosulpiride in dosage form. 
EXPERIMENTAL 
Instruments 
The absorption spectra were obtained with Elico-SL-169 double beam 
UV-vis spectrophotometer. Fluorescence emission spectra were scanned with 
Hitachi-F-2500FL-spectrophotometer. All potentiometric measurements were 
done with Elico-LI-120 pH meter. These instruments were used throughout. 
Materials and methods 
Double distilled water was used throughout. Levosulpiride (Sun 
Pharmaceutical Industries Ltd., Jammu, India), sodium hydroxide (Merck Ltd, 
Mumbai, India) zinc chloride (SDH Pvt. Ltd India), and HCl (Ranbaxy Fine 
Chem. Ltd, India) were used as received. 
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Preparation of solution 
-2 , Stock solution of levosulpiride and those of metal salts (1x10" M) were 
prepared in double distilled water. Stock solution of drug was stored at 4 C. 
Acetate buffer of pH 3.0-5.8 were prepared by mixing appropriate volume of 
acetic acid and 0.2M sodium acetate. 
Methods for determination of interaction of drug with metal ions 
Spectrophotometric method 
Working solution of equimolar concentration (1X10"''M) of 
levosulpiride and metal ions was prepared. The pH of the drug was adjusted 
between 2.31-10.60 by sodium hydroxide and hydrochloric acid (1X10~'M to 
lxlO~^M) to avoid interactions with buffer solution. The absorption spectra 
were recorded in the range 200-330 nm. The ratio of metal to levosulpiride 
was determined by Job's method. 
Potentiometric method 
For potentiometric study the following solutions were titrated against 
standard NaOH. The ionic strength was maintained at O.IM by NaCl and the 
total volume was kept at 50 ml by adding appropriate amount of water. 
(a) 5 ml (1X10~'M) HCl + 5 ml (IxlO-^M) NaCI + 40 ml water. 
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(b)5 ml (1X10" 'M) HCl + 5 ml (IxlO ' M ) NaCl + 10 ml (5xlO"^M) drug + 30 
ml water, 
(c) 5 ml (IxlO^'M) HCl + 5 ml (1X10"'M) NaCl + 10 ml (5xlO"^M) drug + 20 
ml (5X10"''M) metal ions + 10 ml water. 
Fluorescence spectrophotometric method 
Solution of the levosulpiride (7xl0~^M) and those of metal ions 
(1.2xl0~^-8.4xl0~^M) were prepared. The steady state fluorescence spectra of 
the drug were recorded at the X^^ = 270-430 nm with A,e>; = 275 nm. This 
wavelength was chosen in order to avoid the inner-filter effect and to obtain the 
most complete emission spectrum. 
Fluorescence Spectrophotometric method for the determination of 
levosulpiride 
Calibration graph of the complexes with Fe(III) andAl(III) 
A suitable aliquot containing different amounts of levosulpiride (0.310-3.414 
[igml"') and fixed amount of Fe(III) (1.0 ml of 3.6xl0"^M) and, similarly 
(0.310-2.730 figml"') of levosulpiride and fixed amount of Al(IIl) (1.0 ml of 
3.6xlO'^ M) were taken in 10 ml flasks. One ml acetate buffer of pH 5.6 was 
added and the volume was made up to the mark with distilled water. The 
fluorescence intensity of each solution was measured at X^^ I X^m. = 275/300. 
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Procedure for the assay of Tablets 
Twenty tablets were finely powdered, weighed according to the 
requirement and dissolved in 100 ml of water. It was filtered and stored at 4 ^ C 
and, further dilution was made from this stock solution. 
RSULTS AND DISCUSSION 
Determination of stoichiometry and association constant of the complexes 
Spectrophotometric study 
The absorption spectrum of levosulpiride (1 x IO'^'M) was recorded in the 
region 200-330 nm. It exhibited two peaks at 216 and 295 nm (Fig.2). Since 
the first peak is very strong it was selected for further absorption studies. When 
the spectra of the drug were run at varying pH, two isosbestic points, one at 
255 and another at 275 nm were observed which indicated the presence of 
different chemical species in solution [8] in equilibrium with each other 
(Fig.3). The apparent ionization constant (pKa') of the drug was calculated 
(Table 1) by the following equation. 
pKa' = pH+ log {(A, - AM)/(A - A^)} (1) 
where, A| = Absorbance of drug in basic medium, A^ == Absorbance of drug in 
acidic medium, A = Absorbance of drug in aqueous medium. The metal to 
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levosulpiride ratio was determined by continuous variation method (Fig.4) at 
their respective A-max (Table 1). It was found that two moles of the drug are 
bonded to one mole of the metal ion which seems quite reasonable because, of 
all the donor groups the amide nitrogen appears to be the most plausible site 
for coordination as it is the proper combination of hard acid and hard base. The 
stability constant of the complexes were calculated by the following equation: 
A/Aex Cx 
K = (2) 
(CM - A/Ae, Cx) (CL - nA/Ae, Cx)" 
where K = stability constant, n = X/(l-X) and X = mole fraction of the ligand 
at maximum absorption. A/Aex is the ratio of the observed absorbance to that 
indicated by the tangent for the same wavelength. Cx, CM and CL are the 
limiting concentrations of the complex, metal ion and the ligand, respectively 
[9, 10]. The value of logK is shown in Table 2. 
Potentiometric study 
The acid dissociation constant of the drug was first determined from the 
titration curve for HCl in the presence and absence of the drug (Fig.5). TheliA 
of levosulpiride at different pH corresponds to one dissociable proton. The 
formation curve was obtained by plotting the average number of ligand 
attached per metal ion ( l i ) versus free ligand exponent (pL) [11,12]. Since the 
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maximum value ofTT was about 2, it is presumed that complex is formed in 2:1 
(Drug: Metal) ratio. Low concentration of metal ion solution was used to 
prevent the formation of polynuclear complexes in solution [13]. All 
calculation of stability constant were made in the low pH region to prevent the 
formation of hydroxo species (e.g. [ML(OH)], [MSx-i(OH)]^ (where L is 
ligand, S is the solvent) The -ve value of AG indicates that the chelation 
process proceeds spontaneously. This is evaluated by both potentiometric and 
spectrophotometric methods. 
Fluorescence enhancement study 
The fluorescence emission spectrum of pure drug is markedly different 
from its absorption spectrum in UV region, which is attributed to its different 
geometry in the ground and excited states (Fig.6). When the emission spectrum 
of pure drug is run between 270-430 nm at excitation wavelength of 275 nm, a 
strong peak at 300 nm and two weak emission peaks at 342 and 406 nm were 
observed (Fig.7). 
It is ubiquitous fact that the addition of the metal ion to drug can cause 
either enhancement or quenching in the fluorescence intensity [14]. We have 
however, noted an enhancement in fluorescence intensity at 300 nm in each 
case (Mn-Zn). The shape and position of emission spectra of levosulpiride in 
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presence and absence of transition metal ions remains unchanged which 
suggests that no significant change occurs in the overall electronic structure of 
drug the upon addition of metal ions (Fig.8). The relative enhancement in the 
fluorescence intensity I/IQ are shown in table 3. 
The enhancement in emission intensity of levosulpiride in presence of 
various metal ions follows the order Fe(III)>Ni(II)>Cu(II)>Zn(II)>Co(II)>Mn(Il) 
(Fig.9). It does not follow any trend from Mn-Zn, although it is minimum in 
the case of Mn probably due to its half filled 'd' orbital. Although the transition 
metal ions are known to effectively quench fluorescence [15,16,17] we 
observed over two fold increase in intensity as a consequence of photo 
induced charge transfer besides the chelation of the amide nitrogen resulting in 
CHEF (Chelating enhancement fluorescence) effect [18,19,20]. It is known 
that aromatic compounds containing amide groups are strongly quenched by 
intersystem crossing to a triplet state and/or by the rotational relaxation linked 
to excited state rotation around the CO-NH and N-alkyl bonds [21]. An 
increase in rigidity of the system by metal ion complexation may be the reason 
for fluorescence enhancement. It may also be due to an increase in the redox 
potential of the donor so that the relevant HOMO energy decreases to a lower 
level than that of fluorophore. Consequently, the excited state energy of 
fluorophore is dumped as a visible emission [14]. The reason of this 
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enhancement lies in strong perturbation of the excited state upon coordination 
of the metal ion. A low lying internal charge transfer state due to the presence 
of electron donor and acceptor group in the levosulpiride is the lowest excited 
state. This is however, a less emitting state and is in equilibrium with TI-TI 
excited state of the molecule. The PCT interaction becomes weaker since the 
electron withdrawing group is now electron rich moiety due to the 
deprotonation of-NH group necessary for coordination of metal ion. 
Spectrofluorimetric method for the determination of levosulpiride 
The fluorescence emission spectra of levosulpiride showed enhancement 
in intensity (Fig. 10) upon addition of Al(III) without any change in emission 
wavelength and shape of the peak. Al(III) showed maximum enhancement 
followed by Fe(III). Only these two metal ions are utilized for the 
determination of levosulpiride due to their maximum sensitivity. The influence 
of several variables on the formation of levosulpiride-metal complexes has also 
been discussed. 
Influence of metal ion concentration 
The influence of metal ion concentration was studied in the range 
0.3xlO"^-8.0xlO"*M at 25 and 35 °C, while the concentration of levosulpiride 
was held constant at 7xlO"^M. It was observed that fluorescence intensity 
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increases linearly with concentration of metal ions up to 3.6x10 ''M and, above 
this concentration there is no further significant change. 
Influence of temperature and order of addition of reagents 
The influence of temperature (Fig. 11) on the formation of complexes 
was studied between 25 to 80 °C .Since the tluorescence emission intensity 
between 25-50 °C remains almost constant the subsequent experiments were 
done at 25 °C. The fluorescence intensity decreases above 50 °C due to 
dissociation of complexes at higher temperature. 
In all experiment the order of addition of the reagents was the same viz, 
levosulpiride, metal ion and buffer solution. 
Influence ofpH and buffer type 
The influence of pH (Fig. 12) on fluorescence intensity of the complexes 
was investigated over the pH range 2.5-8.0. The results were similar for all 
complexes. The fluorescence intensity of complexes increase up to pH 5.6 and 
remained almost constant between 5.5 and 7. For pH>7 the fluorescence 
intensity greatly decreased due to hydrolysis of metal ions. Maximum 
fluorescence intensity was observed at pH 5.6 in acetate buffer and therefore 
this pH was maintained in all experiments. 
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Analytical performance 
Validation of the proposed methods 
The validity of the method for hnearity, specificity, accuracy and 
precision according to ICH Q2B recommendations was tested (Table 4) [22]. 
The limits of detection (LOD) were determined by establishing the minimum 
level at which the analyte can be reliably detected. The LOQ and LOD were 
calculated according to the following equation: 
LOQ=10o/S (3) 
LOD= 3.3 a /S (4) 
where 0 = standard deviation of the intercept of regression line and S = slope of 
the calibration curve. The proposed methods were evaluated for the accuracy as 
percent relative error (% Er) and the precision as percent relative standard 
deviation (% RSD) (Table 5). 
Accuracy 
The accuracy of both the methods was established by performing five 
replicate on solutions containing three different amounts (within linearity 
range) and calculating the percentage error (Table 5). 
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Precision 
The precision assay was done by replicate analysis (n = 5) 0.5, 1.5, 3.0 
Hgmf' (with Fe(lII)) of levosulpiride while 0.8, 1.7, 2.6 ^gmf' ( with Al(III)) 
were taken for analysis. It is clearly visible from the results (Table 5) that the 
%RSD value for precision are lower than 0.800 for Fe(III) and 0.867 for 
Al(III). 
Repeatability 
To test the repeatability of the proposed method, five replicate analyses 
were done. The mean percentage recovery was found to be 100.3 ± 0.007 and 
100.5 ±0.011 using Fe(III) and Al(III) respectively. 
Robustness of the method 
The robustness of the method is demonstrated by the consistency of the 
fluorescence intensity with the deliberate minor changes in the experimental 
parameters such as volume of metal ions (1.0 ± 0.1) ml and those of buffers 
(1.0±0.1 ml). These minor changes did not affect the fluorescence intensity of 
the reaction product. 
CONCLUSION 
The effect of cation binding on the photophysical properties of 
13 
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levosulpiride has been studied. A dramatic enhancement in fluorescence 
intensity was observed upon binding of metal ions. This was interpreted in 
terms of the control of photoinduced charge transfer (PCT) and CHEF 
(Chelating enhancement fluorescence). The stability constants calculated 
spectrophotometrically and potentiometrically suggest that the complexes are 
fairly stable in solution. Methods for the spectrofluorimetric determination of 
levosulpiride were developed using its fluorescence enhancement of drug with 
Fe(III) and Al(III). The methods are simple, sensitive and economical with 
good accuracy and precision; do not require any pretreatment of the drug and 
tedious extraction procedure. 
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OCH: 
Fig.l Structure of levosulpiride 
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Fig.2 Absorption spectrum of levosulpiride (l^KT'^M) at pH 5.6 at room 
temperature 
200 220 240 260 280 300 320 
Wavelength (nm) 
Fig.3 Absorption Spectra of levosulpiride (IxlO^M) at different pH at room 
temperature 
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Fig.4(A) Continuous variation plot of levosulpiride with Mn(II) at 25 °C 
0.2 0.4 0.6 0.8 
Mole fraction of drug 
Fig.4(B) Continuous variation plot of levosulpiride with Fe(in) at 25 °C 
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Fig.4(C) Continuous variation plot of levosulpiride with Cofll) at 25 °C 
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Fig.4(E) Continuous variation plot of levosulpiride with Cu(II) at 25 °C 
u 
c 
V 
o 
en 
< 
1.7 -1 
1.5 -
1.3 -
l.J -
0.9 -
0.7 -
0.5 -
(F)Zn(Il) 
0 0.2 0.4 0.6 
Mole frati on of drug 
1 1 
0.8 1 
Fig.4(F) Continuous variation plot of levosulpiride with Zn(II) at 25 °C 
Fluorescence Enhancement of Levosulpiride 
3I*?»*** 
Ligand Titration 
•k—ComplexTiration with 
MndO 
^—Complex Titration with 
Ni(l 
—X—Complex Titration with 
Fe(ll 
—•—ComplexTitration with 
Co(ll) 
—I—Complex Titration with 
Zn(ll) 
—-—Complex Titration with 
Cu( 
2 3 
Volume of NaOH (ml) 
Fig. 5 Potentiometric titration curve of levosulpiride with transition metal 
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Fig.8(A) Fluorescence enhancement (Xem = 300 nm) of levosulpiride with 
Mn(n) at room temperature 
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Fig.8(C) Fluorescence enhancement (Xem = 300 nm) of levosulpiride with 
Co(II) at room temperature 
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Fig. 11 Effect of temperature on the fluorescence intensity of levosulpiride 
metal complexes 
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Fig. 12 Effect of pH on the fluorescence intensity of levosulpiride metal 
complexes 
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Table 1. Apparent ionization constant (pKa') of the drug 
Potentiometrically Spectroph otomeirically 
8.753 8.980 
Table 2. The Stability constant of metal complex of levosulpiride 
Metal 
ions 
Mn(II) 
Fe(III) 
Co(II) 
Ni(II) 
Cu(II) 
Zn(II) 
Potentiometrically 
logK 
8.82 
8.91 
9.03 
8.90 
9.17 
9.04 
-AG(J/mol) 
50325.57 
50821.39 
51512.39 
50753.51 
52345.44 
51609.39 
Spectroph otomeirically 
logK 
9.39 
9.40 
9.43 
9.40 
9.54 
9.44 
-AG(J/mol) 
53615.00 
53652.32 
53822.12 
53634.90 
54441.20 
53860.92 
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Table 3. The relative intensity and limiting concentration 
Metal ions I/I„ Limiting concentration 
3.6 ^M 
3.6 nM 
3.6 ^M 
3.6 ^M 
3.6 |iM 
3.6 ^M 
Mn(II) 
Fe(III) 
Co(II) 
Ni(II) 
Cu(II) 
Zn(II) 
1.24 
3.13 
1.52 
2.41 
2.37 
1.53 
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CHAPTER-II 
Interaction ofCaptopril with Metal Ions 
Interaction ofCaptopril with Metal Ions: A 
Fluorescence Quenching Study 
INTRODUCTION 
Captopril, l-[2 (s) -3-mercapto-2-methyl-l-oxopropyl ]-L-proline, 
[Fig.l] is an angiotensin converting enzyme inhibitor drug for the treatment of 
hypertension, heart failure following myocardial infarction and diabetic 
nephrotherapy [1]. It inhibits the active sites of a zinc glycoprotein, the 
angiotensin converting enzyme (ACE), blocking the conversion of 
Angiotensin(I) to Angiotensin(II), the level of which is elevated in patients 
with hypertension. Captopril (CPL) has three different potential donor groups 
(Sthioi, Oacid. and Oamide) which may bind with metal ions to form 1:1 complex in 
acidic medium and 1:2 complex [2] in nearly basic medium (pH 6.0-8.2). The 
key functional group in the metabolism of the drug is the sulfhydryl group [3]. 
It is oxidized after dissolution in water to form its disulfide and is found in 
human urine after CPL administration. It maintains equilibrium between cis 
and trans isomers although, the trans isomer is the active form when bound to 
the enzyme [4]. It also acts as free radical scavenger [5]. Over the last decade, 
close attention has been paid to the interaction of CPL with various metal ions 
[6] as drug metal interaction may result in the formation of a stable complex, 
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which may deplete the blood with trace element. The side effect [7] may well 
be caused by its interaction with other metal ions present in the plasma [8]. In 
order to gain a deeper insight into the mechanism of inhibition and side effect 
of CPL, equilibrium and structural studies were done with several metal ions 
[9]. Studies have also been done on the use of transition metal ions for 
quantitative spectrophotometric determination of CPL in pharmaceutical 
formulations [10]. It has also been assayed spectrofluorometrically after 
reacting with fluorogenic reagents [11] or reducing Ce(IV) to fluorescent 
Ce(III) [12]. 
The fluorescence spectroscopy has been widely used to monitor the 
molecular interaction because of its high sensitivity, reproducibility and 
relatively easy use. Since no detailed fluorescence study on the binding 
interaction of CPL with Mg(II), Ca(II). Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) 
has been done so far, a thorough investigation was therefore made using this 
technique. Such interactions between CPL and these metal ions can cause 
fluorescence quenching and hence valuable informations such as binding 
mechanism, binding constant and binding sites have been obtained. In addition, 
the thermodynamic parameters have also been evaluated. 
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EXPERIMENTAL 
Methods and materials 
CPL (Across organics), sodium hydroxide, metal chloride (Merck Ltd, 
Mumbai, India), and HCl (Ranbaxy Fine Chem. Ltd, India) were used as 
received. The procedure for lifetime measurement was described in reference 
[15]. Double distilled water was used throughout. 
Preparation of solution 
The stock solution of CPL in aqueous acidic medium (lxlO"^M) was 
stored at 4 °C. Solutions of metal salts (lxlO~^M) were prepared in distilled 
water. The working solution of the CPL (8xlO~^M) and those of metal ions 
(IxlO'^M to 18xlO"^M) were prepared from their stock. The steady state 
fluorescence spectra of the drug were recorded in the A-em. = 320-360 nm region 
with excitation at A,ex.= 305 nm. It was chosen such that absorbance at this 
wavelength was less then 0.02 in order to minimize the inner-filter effect and to 
obtain the most complete emission spectrum. 
RSULTS AND DISCUSSION 
Fig.2 shows the emission spectra of CPL in presence of various 
concentrations of metal ions. It was observed that the fluorescence intensity of 
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captopril decreased regularly with increasing concentration of metal ions 
without any change in emission maxima and shape of the peak. As there was 
no significant X,em shift, it indicated that metal ion can quench intrinsic 
fluorescence of CPL and the interaction between drug and metal ion indeed 
existed without inducing any conformational change in it. Quenching can occur 
by a variety of molecular interactions, viz. excited-state reactions, molecular 
rearrangement, energy transfer, ground state complex formation (static 
quenching) and collisional or dynamic quenching. Static and dynamic 
quenching can be distinguished from their different dependence on temperature 
and excited state life time. Dynamic quenching is diffusion controlled because 
the quencher must diffuse to the fluorophore during the life time of excited 
state. Since high temperature will result in large diffusion coefficient, the 
bimolecular quenching constants are expected to increase with temperature. If 
the Ksv decreased with increasing temperature it may be concluded that the 
quenching process is static rather than dynamic [13,14]. Static quenching 
implies either the existence of a sphere of effective quenching or the formation 
of a ground state non-fluorescent complex, whereas collisional or dynamic 
quenching involves the collision followed by the formation of a transient complex 
between an excited state fluorophore and a ground state quencher. The excited 
state complex dissociates upon radiative and non-radiative deactivation. In 
order to confirm the quenching mechanism the procedure of fluorescence 
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quenching was first assumed to be dynamic. For dynamic quenching the 
mechanism can be described by the Stem-Volmer equation [15]. 
F o / F = l + K q . T o I Q ] = l + KsvlQ] (1) 
where, FQ and F are the fluorescence intensities in the absence and presence of 
the quencher, respectively. Kq is the bimolecular quenching rate constant; Kjv is 
the dynamic quenching constant and TQ is the average life time of the molecule 
without quencher. Fig.3 displays the Stem-Volmer plots of quenching of CPL 
by metal ions at different temperature. 
Based on the experimental data (Fig.3), the dynamic quenching and 
bimolecular quenching constants at different temperatures are shown in Table 
1. It is evident that the Kq value in each case is considerably larger than those 
possible for diffusion controlled quenching in solution (about 10 M~'.ns~'). 
Usually, large Kq beyond the diffusion-controlled limit indicates that some type 
of binding interaction exists between fluorophore and quencher [16]. It is 
observed that Kjv decreased with increasing temperature for all metal ions. It is 
therefore, concluded that the quenching is not initiated by dynamic, but 
probably by static process. Among all Cu(II) quenches CPL more effectively 
than other metal ions. The quenching constant for different metal ions follows 
the order 
38 
Interaction ofCaptopril with Metal Ions 
Cu(II)>Ni(II)>Co(II)> Ca(II)>Zn(II)>Mn(II)> Mg(II) 
j 9 x The Cu(II) is a strong quencher because of its electronic structure (d ). 
Probably the quenching involves the donation of an electron from the 
fluorophore to the quencher and the ion dipole interaction between Cu(II) and 
the drug molecule. The larger nuclear charge and the relatively smaller size of 
the Cu(II) compared with other metals, usually introduces easily accessible low 
energy levels, which can give rise to energy. It is capable of quenching the 
fluorescent excited state of the molecule [17]. 
The larger Ksv and Kq values of Ni(II) in comparison to Co(II), Mn(II) 
and Zn(II) can be explained in terms of its smaller ionic radius and larger 
nuclear charge. In the case of Mn(II) and Zn(II) the Kjv and Kq are quite small 
which is obviously due to their half filled and completely filled "d" orbitals 
respectively. The Ksv and Kq values for Ca(II) are larger than that of Mg(II) 
probably because of its larger size, greater reactivity and low ionization 
potential. 
Binding Constant and Binding sites 
For static quenching, the relationship between intensity and the 
concentration of quencher can be described by the binding constant formula: 
[18,19] 
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Iog(Fo- F)/F= log K+ nlog [Q] (2) 
where K is the binding constant, n is the number of binding sites per CPL. 
After the fluorescence quenching intensity of CPL at 340 nm was measured, 
the double-logarithm algorithm was assessed by equation (2). Fig.4 shows 
double-logarithm curve and table (2) gives the corresponding calculated results. 
Since the linear correlation coefficient for all the curves is larger than 0.970, it 
indicates interaction between metal ions and CPL. The binding constant for 
these CPL-metal complexes follows the same order as mentioned in case of K^ v 
and Kq values which is in agreement with the Irving-Williams series in case of 
transition metal series. 
Thermodynamic parameters and nature of binding forces 
Considering the dependence of the binding constant on the temperature 
a thermodynamic process was considered to be responsible for this interaction. 
They were therefore, analyzed in order to further characterize the forces acting 
between CPL and metal ions. The enthalpy (AH), entropy (AS) and free energy 
(AG) are the main parameters to determine the binding mode. If the 
temperature does not vary significantly, the enthalpy changes (AH) can be 
regarded as constant. The AG can be estimated from the following equation, 
based on the binding constant at different temperatures. 
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G = -2.303RTlogK (3) 
where R = the gas constant T = the temperature and K = the binding constant. 
From the value of stabihty constant at different temperature the enthalpy 
changes can be calculated by using equation: 
Log K2/K, = (1/T,-1/T2]AH/2.303R (4) 
The entropy changes can be calculated by using equation: 
AG = AH-TAS (5) 
The negative value of AG suggests that the interaction process is 
spontaneous (Table 3). The +ve AS value is the characteristic of chelation. It 
occurs because the water molecules that are normally arranged in an orderly 
fashion around the CPL and metal ions acquire a random configuration as a 
result of chelation. This is referred to as gain in configurational entropy [20]. 
The +ve value of AH indicates that the processes is endothermic and, binding 
between metal ions and CPL is mainly AS-driven, with little contribution from 
the enthalpy factor. 
CONCLUSION 
In this paper we have investigated the nature and magnitude of the 
interaction of CPL with biologically important metal ions namely 
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Mg(II), Ca(II), Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) by fluorescence 
spectroscopy. Since the Stern-Volmer quenching constant, Ksv in all 
cases is inversely proportional to temperature it suggests that the 
mechanism is initiated by static quenching. Of all the metal ions Cu(II) 
has been found to be the best quencher. The thermodynamic parameters 
showed that the interaction between CPL and the metal ions is 
spontaneous and entropically favored in which entropy increases 
followed by a decrease in Gibbs free energy. The positive value of AS 
indicates the gain in configurational entropy. 
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HOOC 
Fig.l Structure ofCPL 
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Fig.2(A) Fluorescence quenching (Xex305 nm) ofCPL with Mg(II) at 25 °C 
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Fig. 2(B) Fluorescence quenching (Xg^ 305 nm) ofCPL with Ca(II) at 25 °C 
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Fig.2(C) Fluorescence quenching (Xex 305 nm) ofCPL with Mn(II) at 25 °C 
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Fig.2(D) Fluorescence quenching (X^ 305 nm) ofCPL with Co(II) at 25 °C 
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Fig.2(E) Fluorescence quenching (k^^ 305 nm) ofCPL with Ni(II) at 25 °C 
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Fig.2(F) Fluorescence quenching (Xg^ 305 nm) ofCPL with Cu(II) at 25 °C 
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Fig.3(A) Stern-Volmerplot ofCPL with Mg(II) 27and 37 °C 
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Fig.3(B) Stern-Volmerplot ofCPL with Ca(II) 27and37 °C 
Fig.3(C) Stern-Volmer plot ofCPL with Mn(II) 27 and 37 °C 
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Fig.3(D) Stern-Volmerplot ofCPL with Co(II) 27and37 °C 
Fig.3(E) Stern-Volmer plot ofCPL with Ni(II) 27 and 37 °C 
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Fig.4(A) Double reciprocal plots ofCPL with Mg(II) at 27 and 37 °C 
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Fig.4(B) Double reciprocal plots ofCPL with Ca(II) at 27 and 37 °C 
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Fig.4(F) Double reciprocal plots ofCPL with Cu(II) at 27 and 37 °C 
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Table 1. Stern- Volmer and bimolecular quenching constant at 27 and 37 "C 
Metal Ksv/lmor Kq/lmor's' 
27 "C 37 "C 27 "C 37 "C 
4.08x10'^ 3.63x10'^ 
8.47x10'^ 7.71x10'^ 
5.67x10'^ 5.49x10'^ 
9.16x10'^ 8.19x10'^ 
12.34x10'' 10.99x10'^ 
19.3x10'^ 15.28x10'^ 
7.98x10'^ 6.96x10'^ 
Mg(II) 
Ca(II) 
Mn(II) 
Co(II) 
Ni(II) 
Cu(II) 
Zn(II) 
1.36x10' 
2.82x10^ 
1.89x10^ 
3.05x10^ 
4.11x10^ 
6.42x10^ 
2.66x10" 
1.21x10" 
2.57x10' 
1.83x10' 
2.73x10' 
3.66x10' 
5.09x10' 
2.32x10' 
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Table 2. Binding constant, binding site and regression coefficient at 27 and 3 fC 
Metal ions logK n R 
27"C 37'C 27"C IfX! 27 "C 37''C 
Mg(II) 1359 YA92 O 3 9 043 0.998 0.960 
Ca(II) 2.319 2.580 0.58 0.61 0.996 0.997 
Mn(II) 1.285 1.710 0.35 0.44 0.985 0.993 
Co(II) 2.887 2.828 0.65 0.66 0.998 0.997 
Ni(II) 3.416 3.450 0.74 0.76 0.999 0.998 
Cu(II) 4.811 5.049 1.00 1.07 0.999 0.998 
Zn(II) 2.535 2.922 0.58 0.68 0.999 0.997 
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Table 3. Thermodynamics parameters at 27 and 37 "C 
Metal ions 
Ca(II) 
Mg(II) 
Mn(II) 
Co(II) 
Ni(II) 
Cu(II) 
Zn(II) 
^G/kJ.moF' 
27 "C 
-13.32 
-7.808 
-7.386 
-16.58 
-19.62 
-27.63 
-14.56 
37 "C 
-14.82 
-8.575 
-9.828 
-16.24 
-19.82 
-29.00 
-16.78 
^H/kJ.mor' AS/kJ.mor'lC 
27 "C 37 "C 
46.59 0.199 0.1981 
23.76 0.105 0.1043 
75.50 0.276 0.2752 
67.59 0.280 0.2704 
6.160 0.085 0.0838 
42.32 0.233 0.3371 
68.93 0.261 0.2604 
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CHAPTER-III 
Resonance Rayleigh Scattering Spectra and Non-linear Scattering 
Resonance Rayleigh Scattering and Non-linear 
Scattering Spectra of selected Cephalosporins-
Cd(II) Chelate with Titan Yellow and their 
Analytical Application 
INRODDCTION 
Cephalosporins (CFs) referred to as the (3-lactam antibiotics are among 
the oldest and most frequently prescribed antimicrobial agents. The key 
intermediate for semisynthetic production of a large number of CFs is 
aminocephalosporanic acid, which is formed by hydrolysis of cephalosporin C 
produced by fermentation of Caeremonium [1]. CFs are penicillinase-resistant 
antibiotics with significant activity against both gram-positive and gram-
negative bacteria. They are widely used in the clinical field as a group of highly 
efficient and low toxic antibiotic. They are very useful in pre and post operative 
chemotherapy against infections in abdominal, pelvic, orthopedic cardiac, 
pulmonary, oesophageal and vascular surgery [2]. The cephalosporins destroy 
the cell wall of bacterium killing them during period of reproduction. 
Cefpodoxime proxetil (CFPD), Cefdinir (CFDN) and Cefuroxime Axetil 
(CFRX) are some typical representations of the second (CFRX) and third 
(CFPD, CFDN) generation CFs. It is significant to quantitatively determine 
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these drugs in the pharmaceutical preparations. 
Various analytical procedures are available in the literature for the 
analysis of CFs. The common methods are spectrophotometric [3-6], 
polarographic [7,8], stripping voltammetric [9,10] fluorimetric [11.12], 
capillary zone electrophoresis [13], liquid chromatographic [14] and HPLC 
[15,16,17]. Although HPLC is the most widely employed method it needs 
complicated pretreatment and operation. Spectrophotometry has also gained 
better popularity because of its low cost, simple manipulation and high 
accuracy. However, their sensitivity is not high enough to determine trace 
amounts of cephalosporins. It is therefore, desirable to develop a more 
sensitive, convenient and rapid method for determining the trace amount of 
CFs. 
Resonance Rayleigh scattering (RRS) technique, has been applied to the 
determination of macromolecules like nucleic acids [18,19] proteins [20,21] 
polysaccharides [22,23] inorganic ions [24,25], and organic compounds [26]. 
In recent years, RRS has been widely applied to determine some drugs in 
commercial samples [27,28]. At the same time, non-linear scattering such as 
second order scattering (SOS) and frequency doubling scattering (FDS) have 
also been applied successfully as a new analytical technique [29,30]. To the 
best of our knowledge resonance Rayleigh scattering (RRS) technique has not 
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been frequently used to determine these combinations of drugs in given sample. 
In this work a highly sensitive, simple and selective RRS, SOS 
and FDS methods have been developed for the determination of trace CFs. The 
method is based on the ternary complex formation of CFs, Cd(II), and Titan 
Yellow (TY). The mechanism for the ion association reaction and probable 
reason for the RRS enhancement have also been discussed. These methods 
were also applied for the determination of determination of CFs in 
pharmaceutical preparations. 
EXPERIMENTAL 
Reagents 
The concentrations of the working solutions of CFs (Lupin 
Pharmaceuticals Ltd) (20 ^gmf') TY were maintained (2.0>^10'^ M). The 
working solution of cadmium, copper and zinc chloride had the same 
concentration (2.0x10'V). Britton-Robinson (BR) buffer of different pH were 
prepared by taking a mixture of acids (composed of 0.04M H3PO4. HAc and 
H3BO3) with 0.2M NaOH in proportion. All reagents were of analytical grade 
and double distilled water was used throughout. 
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General Procedure 
One ml BR buffer of pH 3.4, 0.6 ml (2xlO"^M) of TY and 0.5 ml of 
3xlO'"*M metal ion solutions were taken in a 10 ml flask and suitable amount 
of drug solution was added. The mixture was made up to the mark with water, 
shaken thoroughly and then set aside for 15 min. RRS spectra of the above 
systems were recorded with synchronous scanning Xex = Kmi AX). The SOS and 
FDS spectra were recorded by scanning at X^^ = 1/2 A-en,. and Xe\ ^ 2 }^eni 
respectively. The experiments were carried out with the slits (Ex/Em) of 5.0/5.0 
nm. The sample and reagent blank scattering intensities (IRRS, ISOS, IFDS. I°RRS-
I°sos and I°FDS) were measured at their own maximum scattering wavelengths, 
AIRRS = IRRS ~ I^RRS, AISOS ^ Isos ~ I°sos, AIFDS "" IFDS ~ I°FDS- The absorption 
spectra were recorded simultaneously. 
RESULTS AND DISCUSSION 
RRS Spectra 
The RRS spectra of CFPD-Cd(II), CFPD-Cu(II) and CFPD-Zn(II) with 
TY is presented in fig. I (A). Although the RRS intensities of free CFPD and its 
binary metal chelates are weak their ternary ion association complexes with TY 
showed marked enhancement. All the three reaction products have similar 
spectral characteristic and their intensity follows the order 
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Cd(II)>Cu(n)>Zn(II). Since the Cd(II) is the most sensitive probe it was 
selected for further studies. 
All the spectral peaks of CFs-Cd(II)-TY systems are common and 
located at 470, 410 and 515 nm (Fig.lB). The intensities of reaction products 
are different and follows the order CFPD>CFDN>CFRX. The intensity of 
CFPD-Cd(II)-TY (Fig.lC) system is proportional to the concentration of 
CFPD. The RRS method can therefore, be applied for the determination of 
trace amounts of CFPD, CFDN and CFRX. 
SOS and FDS spectra 
The SOS and FDS intensities (Fig.2) of CF ,^ Cd(II) and TY separately 
are very weak but the ion association complex CFs-Cd(II)-TY exhibits strong 
SOS and FDS intensities. The maximum AIsos and AIpps are all located at Xsos 
(560 nm) and Xpos (390 nm), respectively. These two types of scattering 
intensities are proportional to the concentrations of CFj in a certain range. The 
SOS and FDS methods can therefore be applied for the determination of CFs 
Because the sensitivity of RRS method is higher than those of SOS and FDS, 
the effects of coexisting substances were investigated using RRS technique. 
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Optimum Reaction Conditions 
Effect of Acidity 
The influence of different buffer solutions (BR, citrate sodium-HCl, and 
HAc-NaAc) on RRS intensity of the reaction systems was tested. The results 
showed that BR is better than the other buffer solutions and the optimum pH 
range for determination was kept between 2.8-4.2 for CFPD, 2.5-4.0 for 
CFDN, 2.5-4.0 for CFRX (Fig.3). Since the RRS intensity decreases if the pH 
selected falls out side the above range, pH 3.4 was chosen for all these systems. 
Effect of TY Concentration 
The influence of the concentration of TY on the RRS intensity of Cd(II)-
CFs-TY system were investigated (Fig.4). The results showed that the RRS 
intensity enhanced gradually with increasing concentration of TY. However, 
the intensities decreased when TY concentration was too low or too high. 
When the concentration of TY was kept at 1.2X10"''M IRRS reached a maximum 
and remained stable in the range 0.8xlO"^-1.5xlO""'M. Thus, 1.2xlO"'M was 
chosen as a suitable TY concentration. 
Effect of Cd(Il) Concentration 
It can be seen (Fig. 5) that RRS intensity reached a maximum and 
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remained stable when the concentration of Cd(II) was maintained between 
lxl0~^-2.2 xlO"^M The experimental concentration of metal ions was, 
therefore, kept at 1.5 x 10 ^M. 
Effect of Ionic Strength 
When the NaCl concentration was lower than 4.0x10'^M, AIRRS 
remained constant, but with its increasing concentration, AIRRS gradually 
decreases. The ion-association reaction, therefore, occurs under a low ionic 
strength condition. It also indicated that the electrostatic interaction is an 
important factor in such reactions. 
Reaction speed and the stability 
The reaction was completed in 15 min at ambient temperature. The RRS 
intensity reached the maximum during this time and signal did not change even 
after 2 h. 
Sensitivity of the method 
Different concentrations of all the CFs were allowed to react with Cd(II) 
and TY to form ternary complexes. Subsequently, their scattering intensities 
AIRRS, AISOS and AIFDS were separately measured at their maximum scattering 
wavelengths after 15 min. The calibration graphs of AIRRS, AISOS and Alpos 
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against the concentrations of CFs were ploted. It can be seen (Table 1) that 
these three methods have high sensitivity and their detection limits (3(7) are 
between 1.73-2.38 ngmf' for (RRS). 5.12-5.67 ngmf' (SOS), 6.25-7.26 
ngmf' (FDS method) respectively. However, RRS method is faster, simpler, 
and more sensitive then others (Table 2). The sensitivity of CFPD is highest 
among the three CFs and so we chose CFPD as an example for the 
investigation of reaction mechanism. 
Structure of complex and reaction mechanism 
The composition of binary chelate Cd(II)-CFPD (1:1) and ternary 
complex, Cd(II)-CFPD-TY (2:2:1) was established by Job's method (Fig. 6). 
and can be formulated as [Cd»CFPD]2TY. The structure of the complex and 
reaction mechanism is described as follows: 
1. As reported in the literature [31], CFPD in weak acidic medium can react 
with Ca(II), Mg(II), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), and Zn(n) to 
form 1:1 chelate. Generally, CFj have several potential donor atoms that 
may coordinate with metal ions. In the present case binding is believed to 
involve nitrogen of amide group and oxygen of P-lactum carbonyl group 
[31]. The drug reacts with Cd(ll) to form cationic chelate [Cd»CFPD]' 
(Fig.7A). 
2. At pH 3.4 two -SO3H groups of TY are disassociated completely such 
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,2-that TY exists as a negatively charged anion TY ~. It reacts with 
[Cd'CFPD]* to form a ternary ion association complex by electrostatic 
attraction and hydrophobic forces: 
2[Cd.CFPD]''+ TY "^ ^ [Cd.CFPDJzTY 
The structure of [Cd'CFPDljTY is shown in Fig.7B. 
Reasons for RRS enhancement 
It can be seen from Fig.l that the formation of an ion association 
complex results in marked enhancement in RRS intensity. The possible reasons 
are as follows: 
1. Resonance enhanced Rayleigh scattering effect: When Rayleigh 
scattering occurs close to the molecular absorption band, the scattering 
can absorb the light energy through resonance to produce a re-scattering 
process. As a result, the scattering intensity is greatly enhanced [32]. It is 
clear (Fig.8) that the highest RRS peak at 470 nm is located in its 
absorption band and, therefore, scattering intensity is remarkabl> 
increased due to the absorption re-scattering process. The resonance 
enhanced effect is attributed to scattering enhancement of the ternary ion 
association complex. 
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2. Enhancement of hydrophobicity: Since all these species (Cd" ,^ 
[Cd'CFPD]" ,^ and TY^~) are hydrophilic in nature they are easily 
dissolved and do not form interface with water. When [Cd'CFPD]^, reacts 
with TY^" to form the neutral ternary ion association complex 
[Cd»CFPD]2TY, a hydrophobic liquid-solid interface appears owing to 
the presence of the hydrophobic aryl framework of the ternary complex. 
The formation of the hydrophobic interface is profitable for the 
enhancement of RRS signal [33]. 
3. Enhancement of molecular volume: It is known that larger the 
molecular volume, the higher the RRS intensity. If molecular volume is 
not easy to calculate, it can be substituted by molecular weight, i.e., 
I^KCMIo [34]. When we move from binary chelate [Cd^CFPD]^ to 
ternary complex [Cd»CFPD]2TY, the molecular weights increase from 
695.720- 2035.772 (for CFPD system), 507.83-1711.382 (for CFDN 
system), and 558.781-1813.282 (for CFRX system) respectively. The 
increase in the molecular volume (or weight) is proportional to the 
enhancement in RRS intensity. 
All the factors coupled together enhance the RRS intensities of the product.. 
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Selectivity ofRRS method and its analytical application 
Effects o/coexisting substances 
Taking CFPD as an example we investigated tiie effect of coexisting 
substances in pure form and its formulations using the RRS method (Table 3). 
The result showed that this method does not suffer any interference from 
common excipients and additives in the preparation of tablets such as 
carboxymethylcellulose calcium, hydroxypropylcellulose, lactose hydrous, 
magnesium stearate, propylene glycol, sodium lauryl sulfate, titanium dioxide 
and saccharides. Some common inorganic ions (NO"^~,Cr) and metal ions (K ,^ 
Na"^ , Ni^ "^ , Ca^ "^ , Fe^* and AP^) also did not interfere with the determination of 
the drug. 
Analytical application 
The accuracy and precision of the proposed methods were evaluated by 
five replicate determination of cephalosporin at three different concentrations 
(Table 4). The result showed that % recovery was in the range 98.66-102.27 
with % relative error ranging from 0.4-2.22 reflecting high accuracy of the 
procedure in addition to the precision as indicated by the very low values of the 
% R.S.D (1.3-3.45). The method is, therefore, recommended for the 
determination of CFs in pharmaceutical formulation. For the determination of 
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CFPD (Table 5) all the three methods (RRS, SOS and FDS) were successfully 
applied. Since the sensitivity of RRS method is higher than those of SOS and 
FDS only RRS method was applied for the determination of remaining CF; 
antibiotics. 
CONCLUSION 
The above methods were employed for the determination of CF; on the 
basis of enhancement in RRS, SOS and FDS intensity. The methods are simple, 
rapid and highly sensitive with satisfactory results. These methods may also be 
extended for the detection of these CFj antibiotics in serum and urine samples. 
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250 350 450 550 
Wawlength (nm) 
650 
Fig.l(A) RRS spectra: M(II)-CFPD-TYsystems. From top to bottom Cd(II)- CFPD-
TY, Cu(II)-CFPD-TY, Zn(II)-CFPD-TY, Cd(II)-CFPD, Cu(II)-CFPD, 
Zn(II)-CFPDandCFPR Cone. ofCF.lO^gmT^ 
250 350 450 550 
Wavelength (nm) 
650 
Fig.l(B) RRS spectra: Cd(II)-CFrTYsystems: From top to bottom: Cd(II)-CFPD-
TY, Cd(II)-CFDN-TY, Cd(II)-CFRX-TY, Cd(JI)-CFPD, Cd(II)-CFDN, 
Cd(II)-CFRX, CFPD, CFDNandCFRX Cone. ofCF, lOjugmF' 
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250 350 450 550 
Wavelength (nm) 
650 
Fig.l (C) RRS spectra: Cd(II)-CFPD-TY system: From top to bottom. Cone, 
of CFPD: 3.6, 2.6, 1.9, 1.4, 0.95, 0.6, ^gmt', cone, of Cd(n) 
l.SxlO'^M and cone. ofTY. 1.2xlO~^M 
Xsos 440 490 540 590 640 690 740 790 
X, 220 245 270 295 320 345 370 395 
Wavelength (nm) 
Fig.2(A) SOS spectra of Cd(II)-CFrTY systems from top to bottom, Cd(II)-CFPD-
TY, Cd(II)-CFDN-TY, Cd(II)-CFRX-TY. CFPD, CFDNandCFRX Cone 
ofCFslO/igmT', cone ofCd(II) 1.5^10~^M, and cone ofTY. 1.2^10'^M 
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Fig.2(B) FDS spectra ofCd(II)-CFs-TY systems from top to bottom: Cd(II)-CFPD-
TY, Cd(IJ)-CFDN-TY, Cd(II)-CFRX-TY. CFPD, CFDN, CFRX Cona of 
CF^lOMgmT', cone ofCd(lI) LS^IO'^M, and cone. ofTY. U^IO'^M 
3500 
3000 
2500 
2000 
1500 
1000 
500 
0 
1.5 2.5 3.5 4.5 
PH 
Fig.3 Effect of the acidity: CF,-Cu(n)-TY system: Cone, of CF, 2.0 figmF', 
cone. ofCd(II) 1.5^10'^M, and cone. ofTY. 1.2x10~^M 
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Fig.4 Effect of fTYJ: CF,-Cu(II)-TY system Cone, of CF, 2.0 ^gmF' and 
cone. ofCd(II) 1.5^10'^M 
Fig.5 Effect offCd(H)J: CF,-Cu(II)-TY system Cone. ofCF, 2.0 jugmf' and 
conc.ofTYJ.2xI0^M 
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Fig.6 The composition of ion-association complex, CFPD-Cd(II)-TY system 
as established by Job's method of continuous variation: (A) TY excess, 
(B) Cd(II) excess and (C) CFPD excess. 
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Fig. 7 Possible structure of complex, (A) Cd(II)-CFPD (B)Between formed 
chelate [CFPD'Cd(Il)] and TY 
250 350 450 550 650 750 
Wavelength (nm) 
Fig.8(A) Absorption spectra, (B) RRS spectra. Concentration of CFPD 2.0 
jugmr' Cd(II)1.5^10~^M and TY, 1.2X10''M 
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CHAPTER-IV 
Effect of the Y(IIl)-Prulifloxacm-AS System 
Effect of the Y(III)-Prulifloxacin-AS System On 
Resonance Rayleigh Scattering Intensity and its 
Analytical Application 
INTRODUCTION 
Prulifloxacin (PUFX) chemically known as (±)-6-Fluoro-l-methyl-
7-[4-(5-methyl-2-oxo-l,3 dioxolen-4-yl)methyl-l-piperazinyl]-4-oxo-
4//-[l,3] thiazeto [3,2-a]quinoline-3-carboxylic acid (Fig.l) is the prodrug 
of ulifloxacin. It belongs to the class of fourth generation synthetic 
fluoroquinolone antibiotics which is active against various Gram-negative and 
Gram-positive bacteria. It acts directly on bacterial DNA gyrase, inhibiting cell 
reproduction that leads to cell death [1]. PUFX contains a quinolone skeleton 
with a four- member ring in the 1,2 position including a sulfur atom to increase 
antibacterial activity and, anoxodioxolenylmethyl group in the 7-piperazine 
ring to improve oral absorption. If administered orally, prulifloxacin is 
absorbed by the intestine and enters into the circulatory system, where it is 
immediately and quantitatively transformed into its active metabolite 
ulifloxacin [2] and other metabolites, accounting for less than 15% of the 
administered dose [3]. Several methods have been reported for the 
determination of PUFX, such as HPLC coupled with UV detection [4] 
86 
Effect of the Y(IIl)-Prulifloxacin-AS System 
fluorescence detection [5] mass spectrometry [6] headspace capillary gas 
chromatography [7] capillary electrophoresis [8] spectrofluorimetry [9,10] and 
chemiluminescence [11,12]. Of all these techniques HPLC, has good 
sensitivity, accuracy and precision but the sample processing is complicated, 
the analytical condition is harsh, and the instrument is expensive. The method 
of headspace capillary gas chromatography used for chemiluminescence has 
some limitations: running of equipment is costly and life span is short. To 
overcome these disadvantages, other methods, such as tluorometric and 
chemiluminescence have been developed but they also have some deficiencies 
in the sensitivity or selectivity. It was therefore, necessary to develop a new 
and fast spectral method with high sensitivity, good selectivity and simplicity 
for the determination of trace amount of prulifloxacin. 
Resonance Rayleigh scattering (RRS) is a sensitive and simple detection 
technique. It has been applied to determine macromolecules like nucleic acids 
[13] proteins [14] heparin [15] metals [16] non-metal ions and organic 
compounds [17,18]. In recent days, RRS method has been increasingly used in 
drug analysis [19-21]. At the same time, non-linear scattering like second order 
scattering (SOS) and frequency doubling scattering (FDS) have also been 
applied as a new analytical technique [22,23]. To the best of our knowledge 
resonance Rayleigh scattering (RRS) technique has not been employed for the 
87 
Effect of the Y(III)-Prulifloxacin-AS System 
determination of PUFX. 
In the present study iiighly sensitive, simple and selective RRS, SOS 
and FDS methods have been employed for the determination of trace amounts 
of PUFX. The method is based on the ternary complex formation of PUFX 
with Y(III) and anionic surfactants (SDBS, SDS and SLS). The mechanism for 
the ion association reaction and probable reason for enhancement in RRS 
intensity have also been discussed. These methods were also applied for the 
determination of PUFX in other commercial samples. 
EXPERIMENTAL 
Reagents 
Stock solution of 100 ngmf' PUFX (Ranbaxy Laboratories Ltd) and 
2.0xlO"^M of anionic surfactants (SDBS, SDS and SLS) were prepared in 
distilled water. Solution of Y(III) (2.0xlO''M) was prepared by dissolving 
Y2O3 (99.99%) in 1:1 HCl and evaporating it to dryness before diluting to 100 
ml with water. The working standard solutions were prepared by making 
appropriate dilutions with water. Britton-Robinson (BR) buffer of different pH 
were prepared by mixing (0.04M H3PO4, HAc and H3BO3) with 0.2M NaOH in 
proportion. The pH was adjusted by the pH meter. All reagents were of 
analytical- reagent grade and double distilled water was used throughout. 
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General Procedure 
One ml of BR buffer solution was taken in a 10.0 ml flask followed by 
the addition of 0.2 ml of 2.0x10~V AS, 1.5 ml of lxlO"^M Y(III) solution and 
suitable amounts of PUFX solution. The mixture was diluted to the mark with 
water and shaken thoroughly and set aside for 15 min. RRS spectra of the 
systems were recorded with synchronous scanning at l^^ = X^^i ^^), and the 
SOS and FDS spectra were recorded at X-ex "^  1/2 A-em and X^^ = 2 X^m 
respectively. The sample and reagent blank scattering intensities (IRRS, ISOS-
IpDS: l°RRs5 I°sos and I°FDS) were measured at their own maximum scattering 
wavelength, AIRRS = IRRS^I^RRS, Alsos = Isos-l^sos, AIFDS = IFDS-1"FDS- The 
absorption spectra were recorded simultaneously. 
RSULTS AND DISCUSSION 
RRS Spectra 
The RRS intensity of PUFX (Fig.2A) and AS themselves are very weak 
and binary chelates Y(III)-PUFX only result in little enhancement of their 
intensities. When they further react with anionic surfactants to form ternary 
complexes, RRS intensities are markedly enhanced. The three reaction 
products have similar spectral characteristics as the X^^K for RRS spectra 
appears at 400 nm and the other weaker peaks are located at 470 and 495 nm. 
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The intensity of IRRS at 400 nm is larger tiian those at 470 and 495 nm. Further 
experiments were, therefore, done at 400 nm. The intensity ofthe systems with 
different surfactants follows the order SDBS > SDS > SLS. The enhancement 
in intensity for Y(III)-PUFX-SDBS system is proportional to the concentration 
of drug (Fig.2B). Since the method based on the enhancement of RRS intensity 
is very sensitive it was selected and applied for the determination of PUFX. 
SOS and FDS spectra 
The SOS and FDS intensities (Fig.3) of PUFX, Y(III), and AS themselves are 
insignificant but the ion association complex, Y(11I)-PUFX-AS exhibits strong 
signals. The SOS spectra shows the peaks located at 460, 600 and 760 nm. The 
enhancement of Isos at 760 nm is greater than that at 460 and 600 nm and 
therefore 760 nm was selected for further investigation. The AIFDS is located at 
390 nm. These two kinds of increasing scattering intensities are proportional to 
the concentrations of PUFX in a certain range. Therefore, the SOS and FDS 
methods can also be used for the determination of PUFX 
Optimum Reaction Conditions 
Effect of pH 
It can be seen that RRS intensity (Fig. 4; increases with an increase in 
pH, and attains a maximum between pH 5.4-7.4 but above pH 7.5 it sharply 
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decreases. Perhaps the decrease in RRS intensity is due to the hydrolysis of 
Y(III) ion in strongly alkaline medium. Of all the buffers examined BR appears 
to be most effective and useful (pH 6.5). It was, therefore, selected for the 
assay and, the optimum volume of BR buffer was kept at 2.0 ml. 
Effect of anionic surfactant concentration 
The concentration of anionic surfactant influences the intensity of 
spectrum. In Y(III)-PUFX-AS system, the AS acts not only as a surfactant but 
also as a probe reagent to assay PUFX. It is evident that the RRS intensity 
enhances gradually with increasing concentration of AS (Fig.5). When the 
concentration of SDBS, SDS, SLS were kept between (2x10'-5.0xlO"-')M, 
(1.5xlO"M.5xlO"^)M and (2.5xlO"^-5.5xlO'^)M respectively, the AIRRS 
intensity remained stable but below or above these concentrations it decreases. 
At lower concentration of surfactants, its reaction with [Y'PUFX]"^ chelate is 
incomplete and when the concentration was too high, the three component 
complex aggregate redissolves due to the formation of micelles. As a 
consequence RRS intensity decreases again. For further investigations in all the 
three systems we fixed the concentrations of PUFX at 3.0 ixgml"' and those of 
surfactants at 4x10"^]^. 
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The Effect of ¥(111) Concentration 
The RRS intensities of the Y(III)-PUFX-AS systems (Fig.6) increases 
with increasing concentration of Y(III) and then becomes nearly constant in a 
certain range. Further addition of Y(III) causes gradual decrease in the 
intensity. The experimental concentration of Y(in) (1.5xiO"''*M ) was, 
therefore, selected from the region where the intensity remains nearly 
unchanged. 
The Effect of Ionic Strength 
When the concentration of NaCl was lower than 4.0>^10~^M, M^^s 
remained nearly constant, but with increasing concentration of NaCl, AIRKS 
gradually decreased. It is therefore thought that the ion-association reaction 
occurs under a low ionic concentration and the electrostatic interaction is an 
important factor in such reactions. When the concentration of NaCl 
increases, the effects of the electrostatic shielding of charges reduce the 
combination of Y(III)-PUFX-AS complex. 
Reaction speed and the stability 
The reaction was completed in 15 min under ambient conditions. The 
RRS intensity attained a maximum which remained stable even after 3 h. 
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Sensitivity of the method 
Different concentrations of the PUFX reacted with Y(III) and AS to 
form ternary complexes under optimum conditions. The scattering intensities 
AI RRS, AIsos and AIpDs were measured separately at their maximum scattering 
wavelengths after 15 min. The calibration graphs of AIRRS, Alsos and Alpos 
against the concentrations of PUFX were plotted. It can be seen (Table 1) that 
these three methods have high sensitivities and their detection limits (3o") fall 
between 0.78-1.1 ngmf', 2.7-3.5 ngmf', 4.2^.4 ngmf' for RRS, SOS and 
FDS methods respectively (Table 1). The RRS method is superior to others as 
it is most sensitive, faster, simpler and economical (Table 2). 
Structure of complex and reaction mechanism 
The composition of binary Y(II1)-PUFX and ternary complex Y(in)-
PUFX-AS were established by Job's method (Fig.7). It is shown that the ratio 
of the Y(III)-PUFX is 1:2 for and 1:2:1 for Y(III)-PUFX-AS system. The 
mechanism of ternary ion association complex, [Y»PUFX2]AS is shown as 
follows: 
Y(III) + 2PUFX . [YPUFXjr 
[Y PUFX2]^  + AS- . -- [Y PUFXjJAS 
Y(III) can react with PUFX to form 1:2 cationic chelate [Y•PUFX2]^There are 
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two coordinating sites in PUFX, nitrogen and oxygen. The oxygen atom tends 
to form a stable complex with a rare earth element, due to its strong affinity for 
Y(in). On the other hand, the stability of a rare earth complex formed with a 
nitrogen donor atom is relatively poor. Usually, oxygen atom in an organic 
ligand coordinates with a rare earth in two ways; the negatively charged 
oxygen forms a stable ionic bond while neutral oxygen forms a coordinate 
bond [24]. Based on these informations a structure of the complex has been 
proposed (Fig.8). AS in near neutral aqueous solution and at very low 
concentration exist as monovalent anions. They can react with [Y*PUFX2]^ to 
form a ternary ion association complex by electrostatic attraction and 
hydrophobic forces. 
Reasons for RRS intensity enhancement 
It can be seen that (Fig.9) when Y(lll) was added to PUFX its X,mu at 
285 nni, was blue shifted to 275 nm with an appreciable increase in absorbance 
and, a new peak appeared at 350 nm indicating the formation of Y(III)-PUFX 
complex. When it further reacts with anionic surfactant to forni ternary 
complex, negligible change occurs in the intensity of the peak and. therefore, 
spectrophotometric method in this case is not effective. 
94 
Effect of the Y(UI)-Prulifloxacin-AS System 
Effect of absorption spectra on RRS 
Resonance Rayleigh scattering effect: Resonance enhanced Rayleigh 
scattering produced by Resonance scattering is located at the molecular 
absorption band. From a comparison between RRS and absorption spectra it is 
observed that the RRS peaks lie at the red side of the absorption peaks of 
Y(III)-PUFX-AS system (Fig. 10) and, correspond to absorption maxima. The 
X,nax of RRS are located at 400 nm and, the absorption peaks is located at 
275 nm respectively. Although there is some space between RRS and 
absorption peak, the RRS band is still located nearby the absorption band 
because when the scattering molecules absorb the light energy at 275 nm, 
absorption-rescattering process takes place. The small loss of energy during the 
absorption-rescattering process makes RRS peak red shifted from 275 to 400 
nm. It is worth observing that when Rayleigh scattering occurs at or near the 
absorption band of the scattering molecules, the intensity increases by several 
orders of magnitude and, no longer follows the Law of Rayleigh of I co 1/ X 
[25]. 
The formation of hydrophobic surface 
Enhancement of hydrophobicity: Since Y(III), [Y»PUFX]^, and AS are 
water soluble they cannot form an interface with water. Reaction of 
[Y'PUFX]"^ with AS~ leads to the formation of neutral ion association complex 
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[Y*PUFX]AS and produces a hydrophobic liquid-solid interface in the 
presence of long carbon chain alkyl and aryl framework. The hydrophobic 
interface is profitable for the enhancement of RRS signal [26]. 
Effect of molecular volume 
The molecular volume, is proportional to RRS intensity. If molecular 
volume is not easy to calculate, it can be substituted by molecular weight, i.e.. I 
= KCMIo [27]. When the binary chelate [Y«PUFX2]^ reacts with anionic 
surfactant to form the ternary complex [Y*PUFX2]AS, the molecular weight 
increase from 1011.82 to 1991.22, 1759.92 and 1807.92 for SDBS, SDS and 
SLS respectively. The increase in molecular volume (or weight) is the main 
factor for the enhancement of RRS intensity. 
The energy transfer between absorption, fluorescence and RRS 
There is a relationship of 'As one falls, another rises' between the 
absorbance, fluorescence and RRS intensity. On moving from pure PUFX to 
ternary ion-association complex of Y(III) and AS, the absorbance decreases 
and the fluorescence intensity quenches, but RRS enhances notably (Fig. 11). 
Resonance Rayleigh scattering is a resonance enhanced scattering produced by 
the resonance between Rayleigh scattering and absorption of the same 
frequency. 
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During this process, scattering enhances because it absorbs light energy 
and part of it is transferred to scattering through the resonance effect. There is a 
relation between the energy released and the energy absorbed. The absorbed 
energy (EA) is equal to the sum of the energy of light emitted (fluorescence)( Ei), 
resonance scattering (ERRS) and non-radiation (EN), viz, 
EA = EL + ERRS + E^ 
The resonance scattering in the transparent solution of small molecular 
system has been seldom studied but the existence of resonance scattering in the 
large molecule or ion-association systems could not be ignored. When the RRS 
spectrum lies in its fluorescence band, there is an energy transfer from 
fluorescence to resonance scattering. The fluorescence quenching is not only 
the transfer of the radiation to non-radiation energy, but also the transfer 
between fluorescence and resonance scattering. A part of radiant fluorescence 
is transferred to resonance scattering through the resonance effect to produce a 
resonance light scattering. The synchronous change of fluorescence quenching 
and scattering enhancement can be seen from Fig. 11. It is a very common 
phenomenon that fluorescence quenching can be observed in the study of RRS 
of fluorescence systems. It is believed that the enhancement of RRS is the 
consequence of the energy transfer from light absorption and light emission to 
the scattering [28]. 
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Selectivity of RRS method and its analytical application 
Effects c/coexisting substances 
The influence of foreign substances such as metal ions, non metal ions, 
amino acids and saccharides (Table 3) on the determination of (S.Ongml" ) 
PUFX was examined. As shown in Table 1, the RRS method can be employed 
to determine PUFX directly in samples in high interfering background. The 
RRS method is very selective and does not interfere \\\i\\ foreign matters. 
Analytical application 
Determination of PUFX in pharmaceutical formulation: Different 
aliquot of PUFX was transferred into a 10.0 ml volumetric flask according to 
the general procedure. The accuracy and precision of the proposed methods 
were evaluated by five replicate determination of PUFX at three different 
concentrations (Table 4). The result showed that % recovery was in the range 
98.88-101.3 with % relative error ranging from 0.266-1.345 reflecting high 
accuracy as indicated by the very low value of the % R.S.D. (1.4-3.57). Since 
the sensitivity of RRS method is higher than those of SOS and FDS we adopted 
RRS method for the determination of the drug (Table 5). 
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CONCLUSION 
The RRS, SOS, FDS methods have been developed for the 
determination of PUFX in pharmaceutical samples. It is demonstrated that 
PUFX reacts with Y(lll) and As to form 1:2;1 ternary ion association complex. 
As a result the RRS, SOS and FDS intensities of complex enhanced 
remarkably. The increment in intensities (AI) is directly proportional to the 
concentration of drug. Since these methods are highly sensitive and selective 
they can also be applied for the detection of trace amounts of PUFX in serum 
and urine samples. 
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Fig.l Structure of Prulifloxacin (PUFX) 
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Fig.2(A) RRS spectra of Y(III)-PUFX-AS systems: From 1 to 8: (1) SDBS, 
(2) SDS, (3) SLS, (4) PUFX, (5) Y(III)-PUFX, (6) Y(IU)-PUFX-
SLS, (7) Y(in)-PUFX-SDS and (8) Y(III)-PUFX-SDBS. Cone, of 
PUFX: 3.5jugntr',AS: 4.0^10~^MandY(III): LS^IO'^M 
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Fig.2(B)RRS spectra of Y(IJI)-PUFX-SDBS system: From J to 7: the 
concentration of PUFX: 0.003, 0.1, 0.8,1.2, 1.7, 2.8 and 3.6 ngmC' 
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Fig.3(A) SOS spectra of Y(III)-PUFX-AS systems: From 1 to 8: 
(1) SDBS, (2) SDS, (3) SLS, (4) PUFX, (5)Y(III)-PVFX, (6)Y(III) - PUFX-
SLS, (7) Y(in)-PUFX-SDS and (8) Y(III)-PUFXSDBS Cone of PUFX: 
3.0 ftgmf', AS: 4.0xlO~^M and Y(III): LSxJO'^M. h is the incident 
wavelength and Xsosis the second-order scattering wavelength 
Flg.3(B) FDS spectra of Y(IJI)-PUFX-AS systems:From 1 to 8: (J) SDBS, (2) SDS 
(3) SLS, (4) PUFX, (5) Y(III)-PUFX, (6) Y(III)-PUFXSLS, (7) Y(1II)-
PUFX-SDS and (8) Y(III)-PUFXSDBS Cone, of PUFX: 3.0 ngmC', AS: 
4.0xlO'^Mand Y(III): 1.5x10''M. X, is the incident wavelength and VDS 
is the frequency doubling scattering wavelength 
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Fig J Effect of the acidity: (1) Y(III)-PUFX-SDBS, (2) Y(III)-PUFX-SDS and 
(3) YaiI)-PUFX-SLS. Cone, of PUFX: 3.0 figmF', Y(III): I.S^IO'^M 
,-5, 
and AS: 4.0^]0~'M 
Fig.5 Effect of the AS concentration: (1) Y(III)-PUFX-SDBS, (2) Y(fll)-
PUFX-SDS, (3) Y(III)-PUFX-SLS. Cone, of PUFX: 3.0 jugmf', AS: 
4.0^10~^Mand Y(III): 1.5>^10'^M 
103 
Effect of the Y(IlI)-Prulifloxacm-AS System 
9000 -
7500 -
6000 -
A 4500 -
< 
3000 -
1500 -
0 -
/ / , ^ ~ " * ^ 
//y~~^ 
// 
1 1 
[) 1 2 
|Y(III)|xio'*IVI 
\ \ ^ 
3 4 
F\g. 6 Effect of the Y(in) concentration: (1) Y(ni)-PUFX-SDBS, (2) Y(ni)-PUFXSDS and 
(3) Y(ni)-PUFXSLS.ConaofPUFX: 3.0^gmr',AS: 4.0x10'M and Y(III): 
LS^IO'^M 
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Fig. 7 The composition of ion-association complex: Y(III)-PUFX-SDBS established 
by Job's method: (a) SDBS excess, (b) Y(III) excess (c)PVFX excess 
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[SDBS] 
Fig.8 Possible structure of ternary ion-association complex 
Fig. 9 Absorption spectra ofPUFX in different systems, all absorption spectra have 
subtracted the background absorption from the entire reagent by using a 
reference solution, except PUFX, which is being evaluated (1) PUFX (2) 
PUFX-Y(III) and (3) Y(III)-PUFX-SDBS. Cone of PUFX: S.OjugmC', AS: 
4.0^10~^Mand Y(III): LS^IO'^M 
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CHAPTER- V 
Determination of Levothyroxine by Resonance Rayleigh Scattering 
Determination of Levothyroxine by Resonance 
Rayleigh Scattering of Fe4[Fe(CN)6]3 in 
Pharmaceutical Formulation 
INTRODUCTION 
Levothyroxine sodium (LVT) is the sodium salt of levo isomer of the 
thyroid hormone thyroxine which controls the growth and development of 
protein, lipid and carbohydrate metabolism [1,2]. They stimulate the oxygen 
consumption of body cells, resulting in increased energy expenditure, heat 
production and possess a cardiostimulatory effect that may be the result of a 
direct action on the heart. The production of levothyroxine hormone is 
regulated by the hypothalamus-pituitary axis through a negative feedback 
system. When hormone level becomes inadequate, the hypothalamus secretes 
thyroid stimulating hormone which stimulates the thyroid gland to produce 
levothyroxine. 
Synthetic LVT is primarily used in the treatment of hypothyroidism and 
as a thyroid stimulating hormone (TSH) suppressant, in the treatment or 
prevention of various types of euthyroid goiters [3]. It is sensitive to light, 
temperature, moisture, pH and oxidation [4-6]. It has reported that LVT 
degradation in solution is pH-dependent, showing less degradation [4] at high 
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pH. The proposed degradation pathway in solution follows deiodination, 
whereas in the solid state, degradation was predominantly by deamination. In 
fact, it has been shown that in addition to T4 and T3, 3,5-diiodothyronine (T2); 
3,3',5,5'-tetraiodothyroacetic acid (TTAA4); 3,3',5-triiodothyroacetic acid 
(TTAA3); 3,5-diiodothyroacetic acid (TTAA2) (see Fig. 1) can be found in 
samples as a consequence of levothyroxine degradation [5-7]. Since the first 
synthetic LVT product was introduced in the United States in 1955 by Flint 
under the brand name Synthyroid [8], frequent recalls were initiated from the 
discovery of tablets being sub-potent before the labeled expiration date. This 
lack of stability and inconsistency in potency causes serious health 
consequences to patients. Adequate analytical methodologies are therefore 
required to assure the quality of the commercial samples. The usual methods 
for the determination of LVT are enzyme immunoassays 
[9,10] fluorescence [11] time resolved fluroscence [12] radioimmunoassay(RJA) 
[13] capillary electrophoresis with laser-induced fluroscence [14] HPLC [15] 
HPLC coupled with plasma mass spectrometry (ICP-MS) [16] 
chemiluminescence(CL) [17] flow-injection chemiluminescence (FIC) [18] cyclic-
voltammetric (CV) [19]. However, these methods are expensive and time 
consuming. 
Recently, RRS technique has aroused a great deal of interest among 
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chemists and biochemists due to its high sensitivity, simplicity, rapidity and 
convenience in performance. To the best of our Icnowledge the Resonance 
Rayleigh scattering (RRS) technique has not been used for the determination of 
LVT. The RRS technique is based on the following phenomenon: when the 
wavelength of the incident beam of light is close to the absorption band of 
molecular particles which exist as aggregates, the Rayleigh scattering intensity 
of some wavelengths will be much higher than normal light scattering [20] 
Since its first introduction to the study of the aggregation of porphyrins, using a 
conventional spectrofluorometer [21], the RRS has become a useful technique 
for the determination of biological macromolecules like nucleic acids and 
proteins [22,23]. This technique has also been used for the determination of 
drugs [24,25], inorganic ions [26] and surfactants [27]. The RRS method is 
generally based on the interaction of drugs with the probe. The most widely 
used RRS probes for pharmaceutical analysis include dyes and surfactants. 
In this project we have used, for the first time, inorganic oxidant Fe(III) 
as RRS probe and applied redox reaction for the determination of LVT. Our 
aim is to study the effect of redox reaction of LVT with Fe(III) and 
complexation of reduced Fe(II) with [Fe(CN)6]^ ~ which is ascertained from its 
absorption, RRS, SOS and FDS spectra and to develop highly sensitive, simple, 
fast and economical methods. We have employed these methods and developed 
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it particularly for the determination and identification of LVT 
The spectral characteristics of absorption and emission (RRS, SOS and 
FDSO spectra and the influencing factors were investigated. 
EXPERIMENTAL 
Materials and method 
Stock solution (100|igmr') of levothyroxine (Sigma Aldrich) was 
prepared in water and kept in dark at 5 °C. The working solution (20 figmf') 
was prepared from the stock solution. The Fe(III)solution (3.0X10~"'M) was 
prepared by dissolving ferric ammonium sulfate (NH4Fe(S04)2.12H20) in 1.0 
ml concentrated H2SO4 and make up to 100 ml with water and [Fe(CN)(,]"'" 
(3.0xlO~'M ) was prepared in 250 ml distilled water. 
General procedure 
To a 10.0 ml flask were added certain amount of LVT, 0.2 ml of HCl 
(0.05M) solution and 1.0 ml (1.6X10"''M) Fe(III). The mixture was heated in a 
boiling water bath for 25 min and cooled to room temperature, then added l.O 
ml (0.8xlO"V) of [Fe(CN)6]^". Finally, it was made up to the mark and mixed 
thoroughly. The RRS spectra were recorded after 20 min with synchronous 
scanning at A,ex = A,em, and the SOS and FDS spectra were recorded by scanning 
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at A,ex ^  l/2X,em and Xex = 2X,eni, respectively. The scattering intensity IRRS, ISOS 
and IFDS for the reaction product and I°RRS, TSOS and I°FDS for the reagent blank 
at their X^ax were measured (AI = I-Io). The absorption spectra were recorded 
simultaneously. 
RESULTS AND DISCUSSION 
The absorption spectra 
The UV absorption spectrum of LVT (Fig.2A) exhibits a broad peak at 
270 nm. When ferric ammonium sulfate is added to it a new peak appears at 
310 ascribed to the reduction of Fe(III) to Fe(II). Subsequently [Fe(CN)6]^" 
was added to this mixture, which resulted in the formation of Prussian blue 
complex {Fe4[Fe(CN)6]3} [28]. It was verified by the appearance of a strong 
peak (Fig.2B) in the visible region at 710 nm with molar absorptivity (e) 9.1 
xlO'L mof cm which is the characteristic of the Prussian blue complex. 
Since this method has not been reported so far we have applied it for the 
determination of LVT. 
Resonance Rayieigh scattering spectra 
The RRS spectra of the LVT-Fe(III)-[Fe(CN)6]^~ systems are shown in 
Fig.3. When Fe(TTI) was reduced by the LVT to produce Fe(II) in HCl and it 
further reacted with [Fe(CN)6]^" to form Fe4[Fe(CN)6]3, RRS intensities were 
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enhanced greatly. It is directly proportional to the concentration of drug. 
Second-order scattering (SOS) and frequency double scattering (FDS) 
spectra 
The SOS and FDS spectra of LVT-Fe(III)-[Fe(CN)6]^" systems (Fig.4,5) 
show that their intensity changes with the change in incident wavelengths. 
When W^em was kept at 350/700 nm, the SOS intensity attained a maximum 
but the intensity of FDS reached maximum when 'k^J'k^m was maintained at 
760/380 nm. In this condition, the two kinds of scattering intensities (Alsos and 
AIpDs) were directly proportional to the concentration of the LVT in a certain 
range. 
Sensitivity of the methods 
A plot of AI versus the concentration of LVT, the linear ranges, 
correlation coefficients and detection limits of RRS, SOS and FDS methods 
were investigated. The linear range and other parameters are given in Table 1. 
The sensitivity of RRS method is not only 1-3 orders of magnitude higher than 
the trivial spectrophotometric method but also higher than those of 
fluorescence, chemiluminescence and HPLC (Table 2). The RRS method was 
therefore taken as an example for further studies including optimum conditions, 
influencing factors, effects of coexisting substances and analytical applications. 
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Optimum conditions for the reaction 
Effect of acidity 
The effects of HCl concentrations on the RRS of five systems were 
investigated. An optimum a concentration of HCl (0.05M) was, therefore, 
maintained (Fig.6). 
Effect of reagent's concentration 
The results' of Fe(III) and [Fe(CN)6]^" concentration on the AIRRS is 
given in Fig.7-8. The maximum intensities of scattering was obtained when the 
Fe(III) concentration ^was kept between 1.2-2.0 X10~''M. The Fe(III) 
concentration was, therefore, maintained at 1.6xlO~'*M for the LVT systems. 
The optimum concentration of [Fe(CN)6]''~ was about 0.8x10'"*]^. The AIRRS 
decreased when the reagent concentrations were too low owing to incomplete 
reaction. The AIRRS also decreases even when concentration was too high. 
(Fig.8). 
The complexation and formation ofFe^FefCNJ^Js 
The LVT reduces Fe(III) to Fe(II) which further reacts with [FeCCN)^ ]^  
to form a Prussian blue Fe4[Fe(CN)6]3 complex: 
LYX(x) + Fe3+ • Fe2+ + LVT<'^ -') 
Determination of Levothyroxine by Resonance Rayleigh Scattering 
Fe2+ + [Fe(CN)6]^- • Fe^^ + [Fe(CN)6]^-
4Fe3^ + 3[Fe(CN)6]^- • Fe4[Fe(CN)6]3 
Fe4[Fe(CN)6]3 as a charge neutralization complex is strongly hydrophobic. 
Under the extrusion action of water, they drew close to each other and formed 
aggregate by Van der Waals force: 
n{Fe4[Fe(CN)6]3} • {Fe4[Fe(CN)6]3}n 
It may be deduced that the formation of {Fe4[Fe(CN)6]3}n was the main reason 
for the enhancement in RRS, SOS and FDS intensities. 
Selectivity of RRS method and its analytical application 
Selectivity 
We have investigated the effect of some common metal ions, salt and 
coexisting substances associated with the LVT in tablet form on the RRS 
method (Table 3). The results showed that this method does not suffer any 
interference from commonly associated excipients and additives in the tablets. 
Analytical application 
The accuracy of the RRS method was checked by performing recovery 
experiment through standard addition method (Table 4). The result showed that 
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% recovery was in the range (98.6-103.8) reflecting high accuracy and 
precision as indicated by the very low values of the %R.S.D (1.261-2.492). 
The method is, therefore, recommended for the determination of LVT in 
pharmaceutical formulation (Table 5). 
CONCLUSION 
We have developed a highly sensitive, simple and economical RRS 
method for the determination of LVT based on its redox reaction with Fe(IlI). 
LVT reduces Fe(lll) to Fe (II) in acidic medium which further reacted with 
[Fe(CN)6]"'~ to form a prussian blue complex, Fe4[Fe(CN)6]3 which resulted in 
the enhancement of RRS, SOS and FDS intensities. The methods were 
successfully applied to the determination of trace amounts of LVT in 
pharmaceutical formulations. It may also be used for its determination in serum 
and urine samples. 
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Fig.l Structure of Levothyroxine (LVT) 
124 
Determination of Levothyroxine by Resonance Rayleigh Scattering 
200 250 300 350 
Wavelength (nm) 
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Fig.2(A) Absorption spectrum of LVT (measured against the reagent blank) 
(1) Pure L VT (2) L VT-Fe(III) 
Fig.2(B) Absorption spectra of LVT-Fe(ni)-Fe(CN)t- The concentrations of 
LVT: 6.0 ngmr', concentration of Fe(III): l.e^IO^M, and 
concentration ofFe(CN)i~: 0.6>^10~^M 
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Fig.3 RRS spectra of LVT-Fe(III)-Fe(CN)t system: 1. LVT. 2-9 LVT-
Fe(ni)-Fe(CN)6- (The concentration of LVT) ZOfigmf', S.Ojugmr', 
4.0 ^ gmT', 5.0 jiigmr', 6.0 figmF', 7.0 figmT', 8.0 ^ gmf' for spectrum 2 
to 9 respectively) The concentrations ofFe(III): 1.6^ 10"*M; concentration 
ofFe(CN)t: 0.6xl0~*M 
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Fig.4 SOS spectra of LVT-Fe(III)-Fe(CN)/- system: The concentration of 
LVT 2.5 ngmr\ 3.5 ^gmC', 4.5 ^gmC', 5.5 ngmC', 6.5 Mgntf', 7.0 
Mgmr', 7.5 jugmT'for spectrum 2 to 7 respectively) The concentrations of 
Fe(III): L6>^10~*M; concentration ofFe(ClS)t: 0.6^10~*M 
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Quenching of Telmisartan with Y(IH)and Nd(III) 
INTRODUCTION 
Telmisartan (TMST), 4-[(2-n-propyl-4-methyl-6-( 1 -methylbenzimidazole-2-
yl)-benzimidazole-l-yl)-methyl]-biphenyl-2-carboxylic acid (Fig.l), is an 
antihypertensive drug. It belongs to the group of angiotensin II receptor 
antagonists [1,2] and highly selective for angiotensin II (ATI) receptors. It 
inhibits the angiotensin II receptor in a way that the effect of angiotensin II is 
blocked resulting in a decrease of blood pressure [3, 4]. The key advantages of 
the non-peptide ARA II antagonists are related to their specificity of action and 
minimization of untoward effects [5]. TMST undergoes minimal 
biotransformation in the liver to form TMST 1-0-acylglucuronide [6], its major 
inactive metabolite. Maximum plasma concentration (Cmax) occurs within about 
3 h (Tmax) after its oral administration, giving plasma levels of 50 ^gl"' for a 
40 mg dose. Renal excretion is a minor elimination pathway for TMST, and a 
small amount of the drug is excreted in urine (less than 1%). The mean 
elimination half-life (ti/2) is approximately 24 h, in contrast with the rapid 
absorption process of the drug. The rest of the parent compound (more than 
98%) is excreted in the faeces [7]. TMST has also been shown to form a double 
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helical metallocycle upon reaction with copper. It's catalytic properties towards 
the oxidative couple of 2,6-di-tert-butylphenol has also been investigated.[8 j . 
In recent years, there has been an increased interest in the study of the 
rare earth complexes. Owing to their unique properties they have often been 
effectively employed as substitute for Ca(II) and Mg(II) in metalloproteins [9], 
as chiral NMR shift reagents, MRI contrast agents [10] and, as luminescent 
probe of metal binding in biological systems [11]. Rare earth complexes have 
also been found to exhibit anticancer and antifungal properties. Their biological 
properties primarily based on their similarity to calcium, is the basis for 
research into potential therapeutic applications [12-14]. 
The interaction of metal ions with drugs administered for therapeutic 
purposes is a subject of considerable interest [15-18]. It is known that some 
drugs work by chelation [15] or inhibiting the formation of metalloenzymes 
[16]. The metal ions may, therefore, play a vital role during the biological 
process of drug utilization in the body. The interaction of rare earth ions and 
drugs can produce special antibacterial or anticancer effects [17]. The 
coordination ability of aromatic carboxylic acids towards rare earth ions has 
received considerable attention because of the strong coordination ability and 
variety of bridging modes of the carboxylate group with regard to the formation 
of extended framework [18,19]. TMST in its molecular structure has 
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carboxylate group which may provide suitable site for rare earth coordination. 
In this project, we have studied the interaction of TMST with Y(III) and 
Nd(III) through absorption and fluorescence spectroscopy. Because of its high 
sensitivity, reproducibility and relatively easy handling, the fluorescence 
spectroscopy has been widely used to monitor the molecular interaction. In 
addition the thermodynamic study of the complexation behaviour of these rare 
earth ions with TMST has also been done to understand some other physico-
chemical aspects of these complexes. 
EXPERIMENTAL 
Materials and Method 
The stock solution of TMST (Sigma Aldrich), (IxlO'^M) was prepared 
by dissolving it in O.IM NaOH. Solutions of Y(III) and Nd(III) chlorides, 
(2.0xlO'^)M were prepared by dissolving Y2O3 and Nd203 (CDH Pvt. Ltd) in 
1:1 HCl and evaporating it to dryness before diluting to 100 ml with water. The 
working standard solutions were prepared by making appropriate dilutions with 
water. Britton-Robinson (BR) buffer of different pH were prepared as 
described earlier. 
Appropriate amount of TMST (1 x ] O'^ M) and different amount of 
metal chloride solutions were transferred in a 10 ml flask to give a final 
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concentration between 0.5x10 -1.5x10 M. After the addition of 1ml BR 
buffer (pH 7.0) the volume was made up to the mark with distilled water. The 
steady state fluorescence spectra of the TMST alone and in presence of 
different amounts of ¥(111) and Nd(III) were recorded in the X-em = 320-550 nm 
region at A.ex.= 300 nm. The synchronous fluorescence spectra were scanned at 
AX = 65 nm (AA. = X^m-^id- The absorption spectra of TMST (1 x 10"''M) alone 
and in presence of Y(III) and Nd (III) (IxlO'^M) were scanned in 190-350 nm 
region. 
RESULTS AND DISCUSSION 
Absorption spectra 
\ - 4 T I The absorption spectrum of TMST (1x10" M) shows two peaks at 230 
nm and another one at 295 nm (Fig.2) corresponding to two chromophores. 
When Y(III) and Nd(III) were added to it the peak at 295 nm moved to shorter 
wavelength with an increase in intensity, although the position of the peak at 
230 nm did not change. The pKa of TMST (4.45) corresponds to the acid-base 
equilibrium in which the carboxylic group is involved [22]. Its deprotonation 
therefore, occurs at pH 7 and it exists as an anion. Its complexes with trivalent 
metal ions are formed by ion-dipole interaction because any significant 
absorption band due to orbital-orbital interaction is not observed. The increase 
in intensity due to addition of Y(III) and Nd(III) to TMST is an indication of 
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complex formation. 
Fluorescence emission spectra 
TMST contains two fluoropiiores biphenyl and benzimidazole [23,24] 
wliich exhibit strong fluorescence in basic medium [22]. When excited at 300 
nm at pH 7, the maximum fluorescence was observed at 365 nm. When 
different amounts of Y(III) and Nd(III) were titrated against a fixed 
concentration of TMST, its fluorescence intensity decreased regularly without 
any change in A.eni (Fig.3), which indicated that both Y(III) and Nd(III) quench 
the intrinsic fluorescence. Quenching is the decrease in quantum yield of 
fluorescence of a fluorophore induced by a variety of molecular interactions, 
such as excited-state reactions, energy transfer, electron transfer, ground-state 
complex formation and collisional quenching [25]. The physical origin of 
fluorescence quenching arising from the addition of a quencher to the TMST 
fluorescence can be divided into two distinct mechanistic classes namely, 
dynamic and static quenching. They can be distinguished from their 
dependence on temperature and excited state life time. Dynamic quenching is 
diffusion controlled because the quencher must diffuse to the fluorophore 
during the life time of excited state. Since high temperature will result in large 
diffusion coefficient, the bimolecular quenching constants are expected to 
increase with temperature. If the Ksv decreased with temperature the quenching 
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process is static rather than dynamic [26,27]. It implies the existence of a 
sphere of effective quenching or the formation of a ground state non-
fluorescent complex whereas; the dynamic quenching involves collision 
followed by the formation of a transient complex between an excited state 
fluorophore and a ground state quencher. Such complex dissociates upon 
radiative and non-radiative deactivation. Quenching can also occur via many 
trivial processes, such as attenuation of the excitation light by the fluorophore 
itself or other absorbing species. The quenching mechanism involves 
interaction between the excited state of a fluorescent species and the quencher, 
referred to as contact quencher. It can be mathematically expressed by the 
Stem-VolmerEq. (1)[28,29]. 
Fo/F=l + Kq.To[Q] = l+K,vlQl (1) 
Here FQ and F are the fluorescence intensities in the absence and presence of 
the quencher, respectively. Kq is the bimolecular quenching rate constant; TQ is 
the average life time of the molecule without quencher; [Q] is the concentration 
of the quencher, and Kjv is the Stem-Volmer quenching constant. In our case 
the fluorescence intensity is reduced from FQ to F in the presence of a quencher 
Y(III) and Nd(III). The ratio (FQ/F) is directly proportional to the quencher 
concentration [Q]. 
Evidently, 
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Ksv = Kq .To (2) 
YJ¥= 1 + Ksv [Q] (3) 
According to Eq. (3), a plot of (FQ/F) versus [Q] shows a straight line 
graph with an intercept of 1 and a slope of Kjv [30]. Fig.4 displays the Stem-
Volmer plots of quenching at 25 and 35 °C, The results show (Table 1) that 
Ksv is inversely proportional to temperature. It indicates that the probable 
quenching mechanism was not initiated by dynamic quenching but by complex 
formation [31]. 
It is also possible to distinguish between these two mechanisms of 
quenching by simple examination of the absorption spectra of the system under 
study. Since collisional quenching affects only the excited state of the 
fluorophore there are typically no changes in fluorophore absorption spectrum 
whereas ground state complex formation and subsequent static quenching 
frequently results in marked changes in the absorption spectrum. Fig.2 shows 
that the absorption peak of TMST at 295 nm is blue shifted with increase in 
absorption intensity upon addition of Y(III) and Nd(III), which suggests that 
the interaction of TMST with these metal ions is mainly a static quenching 
process. 
The fluorescence intensity of TMST is quenched without any shift in the 
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position of the peak. It is concluded that the metal ions quench the intrinsic 
fluorescence of TMST without inducing any conformational change in it. The 
absence of any new emission band upon complexation excludes the possibility 
of the formation of exciplex (excited state complex) [32] which were veritled 
from the synchronous spectra of TMST (Fig.5). 
The fluorescence quenching of TMST complex with rare earth ions can 
be interpreted in terms of chelation enhanced fluorescence quenching (CHEQ). 
In such cases the fluorophore (drug) itself is fluorescent (TMST) when the 
receptor site is free (carboxylic group). The fluorescence intensity of drug is 
diminished due to chelate formation which is a non-fluorescent complex and. 
therefore, the net fluorescence is quenched. The Nd(III) is a better quencher 
than Y(III) because Nd(III) is paramagnetic while Y(III) is diamagnetic [28]. 
However, quenching by Y(III) may be explained in terms of Closed shell heavy 
atom effect [33]. This evidence accounts for the larger Ksv for Nd(III) than 
Y(III). 
Effect of pH on complex formation 
The experimental results (Fig.6) indicated that quenching factor (FQ/F) 
increases steadily up to pH 7 and suddenly falls above this pH. It may be due to 
the complex formation of drug with lanthanides ions. Obviously, it was 
disadvantageous to coordinate TMST with Y(III) and Nd(III) ion in the acidic 
143 
Complexation and Mechanism of Fluorescence 
environment. Also, in strong alkaline medium formation of metal hydroxide 
may prevent the coordination of TMST with the metal ions resulting in 
decrease of FQ/F. Since the change in pH influences the stability of the 
fluorescent complexes and results in changes in the fluorescence characters, 
selection of pH was important. pH 7.0 was therefore, selected for further 
research. 
The experiments indicated that the buffers also had an appreciable 
influence on fluorescent intensity of the system. Of all the buffers used in the 
present study, BR appears to be most effective and useful. 
Stoichiometry and association constant 
The association constant of the complexes was determined by Benesi-
Hildebrand plot using fluorescence quenching data [34,35]. The plots were 
examined to characterize the TMST-metal complexes. In the case of a 1:1 
complex, the following equation is applicable: 
1/Fo-F = l/(Fo-F,,)K [Me]o + l/(Fo-F^) (4) 
In this approach, a graph of l/(Fo-F) versus l/[Me]o, was made where F 
is the observed fluorescence at each concentration tested, Fo is the fluorescence 
intensity of analyte in the absence of metal ion, F ,^ is the fluorescence intensity 
at the saturation and [Me]o is the concentration of metal ion. A linear plot is 
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required for this double reciprocal plot in order to conclude 1:1 stoichiometry. 
In the case where 2:l(Iigand:metal) stoichiometry is predominant the 
following equation is used. 
1/ Fo-F = l/(Fo-Foc)K [Melo"' + l/(Fo-F^) (5) 
A plot of l/(Fo-F)) vs l/[Me]o "^  should give a straight line. 
The data when fitted according to Benesi-Hildebrand plot assuming 2:1 
stoichiometry, eq. (5) gives a straight line while a downward concave curvature 
is obtained when fitted for 1:1 stoichiometry using eq. (4). It is, therefore, 
concluded that drug to metal rafio in the complex is 2:1. Fig.7 shows double 
reciprocal curve and Table.2 gives the corresponding calculated results. The 
linear correlation coefficient for all the curves are larger than 0.997, indicating 
that the interaction of metal ions with TMST agrees well with the site- binding 
model underlying equation (5). 
Of the two coordinating sites in TMST (nitrogen and oxygen) the 
oxygen atom tends to form a stable complex with a rare earth ion, as it has 
greater affinity for it. On the other hand, the stability of the rare earth complex 
formed with nitrogen atom is relatively poor. Usually, oxygen atoms bind with 
the rare earth ions in two ways. The negatively charged oxygen form a stable 
ionic bond while neutral oxygen forms a coordinate bond [36]. Based on the 
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above discussion, a structure of the complex lias been proposed (Fig. 8). Since 
tlie estimated pKa' value of TMST is about 4.5 [22], the deprotonation 
probably occurs at the carboxylic group at pH 7. 
Thermodynamic parameters and nature of binding forces 
A thermodynamic process was considered to be responsible for the 
dependence of the binding constant on the temperature. The enthalpy (AH), 
entropy (AS) and free energy (AG) were calculated from the following 
equation: 
AG = -2.303RTlogK (6) 
where R = gas constant, T = temperature and K = binding constant. If the 
enthalpy change (AH) does not vary significantly over the given temperature 
range, it can be regarded as constant. From the value of stability constant at 
different temperatures the enthalpy changes can be calculated by using 
equation: 
Log K2/K, = [lAr,-l/T2lAH/2.303R (7) 
The entropy changes can be calculated by using equation: 
AG = AH-TAS (8) 
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\S={/SB-\G)/T (9) 
The negative AG indicates that the complexation was spontaneous process and 
spontaneity decreased with increasing temperature. A decrease in logK with 
increasing temperature and, the negative values of AH show that the 
complexation reaction is exothermic and, the metal-ligand binding process is 
enthalpy driven. The low logK also suggests that the metal complexes are 
soluble in water and may readily dissociate. 
CONCLUSION 
We have investigated the interaction of TMST with Y(III) and Nd(III) 
by spectroscopic methods, including fluorescence quenching spectra and UV-
vis absorption spectra. The experimental results indicated that the intrinsic 
fluorescence of TMST was quenched through a static quenching mechanism. 
The stoichiometry 2:l(drug:metal) and association constants (logK) were 
evaluated according to the Benesi-Hildebrand Method. The negative values of 
thermodynamic parameters (AG, AH and AS) indicated that the complexation 
process was spontaneous, exothermic and entropically unfavorable. 
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Fig.l Structure ofTMST 
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Fig.3(A) Fluorescence emission spectra (X^x 300 nm) of TMST with Nd(III) at 
25 °C (1) IxlO'^ M TMST, from (2) to (9): 0.5, 1, 10, 30, 60, 90,120, 
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Fig.4(4) Stern-Volmer plots of TMST with ¥(111) at 25 and 35 °C 
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Fig.5(A) Synchronous spectra (A A= 65 nm) ofTMST with Y (III) at 25 °C (1) 1^10'^ M 
TMSTJrom (2) to (9): 0.5,1,10, 30, 60, 90,120,150 juM of metal ions. 
151 
Complexation and Mechanism of Fluorescence 
(800 
1500 -I 
§ 600 
300 
(B)Nd(lll) 
260 280 300 320 
Wavelength (nm) 
340 
Fig.S(B) Synchronous spectra (A X= 65 nm) ofTMST with Ndflll) at 25 °C (J) 
1>^10~^ MTMSTJrom (2) to (9): .5,1,10, 30, 60, 90,120, 150 juM of 
metal ions 
1 -l 
6 -
5 -
4 -
^ 3 -
2 -
1 -
n . 
I 3.5 
1 
5 
1 
6.5 
pH 
—•- Nd(Iir) 
- ^ Y ( n i ) 
1 1 
8 9.5 
Fig.6 Effect ofpH on quenching factor (F/F) with Yflll) and Nd(III) 
152 
Complexation and Mechanism of Fluorescence 
0.005 -
0.004 -
0.003 -
fa 
0.002 -
0.001 -
0 -
(A) 
mjT ^^ -^-'''^  
9 500 1000 
i/|Y(noi"^ 
• 25 °C 
• 35 °C 
1500 
Fig. 7(A) Double reciprocal plots of TMST with ¥(111) at 25 and 35 °C 
0.004 -
0.003 -
h. 
u£ 0.002 -
0.001 -
0 ^  
( 
(B) 
m y^ ^^^-"^''^ 
^^ X^ *^ -^''^ ^ 
1 1 
) 500 1000 
l/fNd(IIT)|"^  
• 25 °C 
• 35 °C 
1 
1500 
Fig. 7(B) Double reciprocal plots of TMST with Nd(III) at 25 and 35 °C 
153 
Complexation and Mechanism of Fluorescence 
Fig.8 Proposed structure of TMST complex (M = Y(III), Nd(III)) 
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Table 1. Stern- Volmer constant at 25 and 35 °C 
Metal Ions 
Y(III) 
Nd(III) 
Ksv/lmoF 
25 °C 
30251 
34798 
/ 
35 °C 
16551 
19882 
Regression 
25 °C 
0.9986 
0.9984 
coefficient (r) 
35 °C 
0.9991 
0.9985 
Table 2. Stability constant and regression coefficient at 25 and 35 °C 
Metal Ions 
Y(III) 
Nd(III) 
25 °C 
2.000 
2.301 
logK 
35 °C 
1.367 
1.699 
Regression 
25 °C 
0.9983 
0.9977 
coefficient (r) 
35 °C 
0.9983 
0.9986 
Table 3. Thermodynamics parameters at 25 and 35 "C 
Metal ions 
Y(m) 
Nci(III) 
AG/kJ.mor' 
25 "C 35 "C 
-11.410 -8.061 
-13.123 -10.119 
AH/kJ.mor' 
-111.244 
-105.620 
AS/kJ.mor'lC' 
25 "C 
-0.3350 
-0.3104 
35 "C 
-0.3350 
-0.3104 
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SPECTROSCOPY 
Fluorescence Enhancement of Levosulpiride 
Upon Coordination with Transition Metal Ions 
and Spectrophotometric Determination of 
Complex Formation 
K. S, Siddiqi, Shaista Bano, Ayaz Mohd, and 
Aftab Aslam Parwaz Khan 
Department of Chemistry, Aligarh Muslim University, Aligarh, India 
Abstract: Absorbance and fluorescence spectral pattern of levosulpiride in 
absence and presence of first row transition metal ions (Mn-Zn) has been studied 
at room temperature under physiological condition. The fluorescence spectra of 
the drug in presence of different concentrations of transition metal ions showed 
enhancement in fluorescence intensity of levosulpiride. The photophysical 
changes owing to the direct interaction between metal ion and the amide nitrogen 
of levosulpiride has been described in terms of CHEF (chelating enhancement 
fluorescence) effect. The absorption spectra of the drug at different pH exhibited 
two isosbestic points at 255 and 275 nm respectively, indicating the presence of 
three chemical species in solution. The ratio of the drug to metal ions is found 
to be 2:1 and the logK of the resulting complex was determined spectrophotome-
trically and potentiometrically. The apparent ionization constant of levosulpiride 
is found to be 8.98. The low value of stability constant suggests that complexes 
may dissolve and the drug can be absorbed. 
Keywords: Absorption study and stability constant, fluorescence enhancement, 
levosulpiride 
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1. INTRODUCTION 
Levosulpiride, a levo enantiomer of sulpiride, chemically known as 
5-(amino sulfonyl)-N-[( 1 -ethyl-2-pyrrolidinyl)methyl]-2-methoxy benza-
mide is used as antipsychotic, antidyspeptic and antiemetic medicine 
(Fig. 1). This drug has also been used for the treatment of male sexual 
disorder and a dose of 25mg/day for 60 days resulted in complete 
recovery. The studies are mainly concerned with the validation and 
determination of levosulpiride in human beings. The drug is fairly stable 
in human serum and urine which has been tested in different patients. It 
has been found that the drug can be detected in a concentration range of 
0.25-200 ng/ml in human serum and 0.2-20 |ig/ml in urine by HPLC 
(Cho and Lee 2003; Geo, Balbi, and Speranza 2002). The bioavailability 
of the drug at a dose of 100-200 mg/day is approximately 20-30% only 
(Jin et al. 2004). Levosulpiride has both antiemetic and prokinetic prop-
erties because it antagonizes dopamine receptor in the central nervous 
system and gastro-intestinal tract (Mansi et al. 2000; Nagahata et al. 
1995). Recently, it has been shown that levosulpiride has moderate 
agonistic effect on 5HT4 receptors in the nervous system and is useful 
in the treatment of depression or Schizophrenia (Tonini et al. 1999). 
Patients treated for functional dyspepsia over a period of one month 
did not show any adverse effect. The doses of levosulpiride range between 
50-75 mg/day over a period of 30 days and showed no adverse effect 
except for fatigue, headache, and drowsiness (Lozano et al. 2007). It is, 
therefore, considered an effective and safe drug in the treatment of 
dyspepsia. It has been shown that the levosulpiride does not interfere 
with most of the drugs, but drinking during this period should be 
avoided. As a precaution, the drug should be avoided in pregnancy 
and during lactation period. 
The major work done on the sulpiride thus far, concerns its identi-
fication, determination, and efficacy against dyspepsia, psychosis, and 
male sexual disorder. However, absorption and fluorescence emission 
spectrophotometric behavior of the drug under physiological condition 
and its interaction with several cations has not been studied so far. 
• 0 C H 3 
Figure 1. Structure of levosulpiride. 
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In this communication, we are, therefore, reporting the electronic 
and fluorescence emission spectra of the drug in the presence and absence 
of transition metal ions at different- pH, ranging from 2.38 to 10.6 in 
order to find the effect of pH on the absorption of drug in aqueous 
medium. Fluorescence emission spectra of the drug in presence and 
absence of metal ion has been recorded to examine if quenching or 
enhancement in fluorescence intensity occurs. Stability constant and 
other physical parameters of the complexes formed in solution have also 
been calculated. 
2. EXPERIMENTAL 
2.1. Instruments 
The absorption spectra were obtained with Elico-SL-169 double beam 
UV-visible spectrophotometer. Fluorescence emission spectra were 
scanned with Hitachi-F-2500FL-spectrophotometer. All potentiometric 
measurements were done with Elico-LI-120 pH meter. 
2.2. Methods and Materials 
Double distilled water was used throughout. Levosulpiride (Sun 
Pharmaceutical Industries, Jammu, India), sodium hydroxide (Merck 
Ltd, Mumbai, India) anhydrous zinc chloride (SDH Pvt. Ltd India), 
and HCl (Ranbaxy Fine Chem. Ltd, India) were used as received. 
2.3. Preparation of Solution 
v - 7 Stock solution of levosulpiride and metal salts of 1 x 10 "M were 
prepared in double distilled water. Stock solution of drug was stored 
at 4°C. 
2.4. Spectrophotometric Method 
Solution of equimolar concentration (1 x 10""* M) of levosulpiride and 
metal ions was prepared. The pH of the drug was adjusted between 
2.31 to 10.6 by the use of only sodium hydroxide and hydrochloric acid 
(1 X 10~' M to 1 X 10~^M) to avoid interactions with buffer solution. 
The absorption spectra were recorded in the range 200-330 nm. The ratio 
of metal to levosulpiride was determined by Job's method. 
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2.5. Potentiometric Method 
For potentiometric study the following solutions were titrated against stan-
dard NaOH. The ionic strength was maintained at 0.1 M by NaCl and the 
total volume was kept at 50 ml by adding appropriate amount of water. 
(a)5ml(l X 10"'M)HCl + 5ml(l x 10"'M) NaCl+ 40ml water. 
(b) 5ml (1 X 10-' M) HC1 + 5ml (1 x lO"' M) NaCl + 10ml (5 x 10"^ M) 
drug + 30 ml water. 
(c)5ml(l X 10"'M)HCl + 5ml(l x lO"'M) NaCl +10 ml (5 x lO'-^M) 
drug+ 20 ml (5 x I O ' ^ ' M ) metal ions+ 10 ml water. 
2.6. Fluorescence Spectrophotometric Method 
Solution of the levosulpiride (TxlO'^M) and those of metal ions 
(1.2 X 10"^ M to 8.4 X 10"^ M) were prepared. The steady state fluores-
cence spectra of the drug were recorded in the /.gm = 270-430 nm with 
excitation at the maximum centered on /exc = 275nm. This wavelength 
was chosen in order to avoid the inner-filter effect and to obtain the most 
complete as possible emission spectrum. 
3. RESULTS AND DISCUSSION 
3.1. Spectrophotometric Study 
The levosulpiride solution (1 x lO'^^M) was prepared in double distilled, 
demineralized water, and its absorption spectrum was run in the region 
200-330 nm. It exhibited two peaks at 216 and 295 nm (Fig. 2). Since 
the first peak is very strong, it was selected for further absorption studies. 
When the spectra of the drug were run at varying pH in the region 
200-330 nm, two isosbestic points, one at 255 nm and another at 
275 nm, were observed which indicated the presence of three chemical 
species in solution in equilibrium with each other (Fig. 3) (Park et al. 
2000). 
The apparent ionization constant (pKa') of the drug was calculated 
(Table 1) by the following equation: 
pKa' = pH + log{(A, - A M ) / ( A - AM)} (1) 
where Aj = Absorbance of drug in basic medium, AM = Absorbance of 
drug in acidic medium, and A = Absorbance of drug in aqueous medium. 
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200 230 260 290 
Wavelength (nm) 
320 
Figure 2. Absorption spectrum of levosulpiride ( 1 x 1 0 •*M) at room tempera-
ture (pH 5.6). 
The metal to levosulpiride ratio was determined by continuous 
variation method (Fig. 4) at their respective Amax (Table 1). It was found, 
in each case, that two moles of the drug are bonded to one mole of the 
metal ion which seems quite reasonable because, of all the donor groups, 
200 230 260 290 
Wavelength (nm) 
320 
Figure 3. Absorption Spectra of levosulpiride (1 x 1 0 ~ ' ' M ) at different pH (room 
temperature). 
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Table I. Apparent 
Potentiometrically 
8.753 
ionization constant (pKa ') of the drug 
Speclrophotomelricc 
8.98 
illy 
the amide nitrogen appears to be the most plausible site for coordination 
as it is the proper combination of hard acid and hard base. 
The stability constant of the complexes were calculated by the follow-
ing equation: 
r.^ A / A e x C x .21 
(CM - A/AexCx)(CL - nA/AexCx)" ^ ^ 
where K is the stability constant of the metal chelate formed in solution, 
M = metal, L = drug, n = X/(l - X ) , and X is the mole fraction of the 
ligand at maximum absorption. A/Agx is the ratio of the observed absor-
bance indicated by the tangent for the same wavelength. Cx, C^ and CL 
are the limiting concentrations of the complex, metal ion, and the ligand, 
respectively (Salem 2005; El-Kommas et al. 2007). The value of logK is 
shown in Table 2. 
3.2. Potentiometric Study 
To calculate the stabihty constant of metal chelates, the acid dissociation 
constant of the drug was first determined from the titration curve for HCl 
0 0.2 0.4 0.6 0.8 1 
Molefraction of drag 
-H^Mnai) -*-Fe(III) - - i -Codl) 
-*f-Ni(Il) -i.-Cu(II) -—Zn(II) 
Figure 4. Continuous variation curve of levosulpiride with metal ions. 
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Table 2. The stability constant potentiometrically and spectrophotometrically 
Metal ions 
Mn(II) 
Fe(IIl) 
Co(II) 
Ni(II) 
Cu(II) 
Zn(II) 
Potentiometrically 
logK 
8.82 
8.907 
9.028 
8.895 
9.174 
9.045 
-AG (KJ/moI) 
50325.57 
50821.39 
51512.39 
50753.51 
52345.44 
51609.39 
Spectrophotometrically 
logK 
9.3965 
9.3981 
9.4328 
9.4000 
9.5413 
9.4396 
-AG (KJ/mol) 
53615.00 
53652.32 
53822.12 
53634.90 
54441.20 
53860.92 
in the presence and absence of the drug. The average number of proton, 
nA associated with levosulpiride at different pH was calculated and max-
imum value of riA is 1 which suggests that it has one dissociable proton. 
The formation curve was obtained by plotting the average number of 
ligand attached per metal ion (n) versus free ligand exponent (pL) (Jeragh 
et al. 2007; Irving and Rassotti 1953). The apparent ionization constant 
and the average value of stability constant are shown in Tables 1 and 2, 
respectively. According to average value in Table 2, the following general 
remarks can be made: 
1. The maximum value of n was about 2, so it is presumed that complex 
is formed in a 2:1 (Drug: Metal) ratio. 
2. The very low concentration of metal ion solution used in the present 
study was 5 x 10"'* M and precludes the possibility of formation of 
polynuclear complexes (Sanyal and Sengupta 1990). 
3. The metal titration curve is displaced to the right hand side of the 
ligand titration Curves along the volume axis (Fig. 5), indicating a 
proton release upon complex formation. 
4. All calculation of stability constant has been successful for the low pH 
region. Therefore the formation of hydroxo species (e.g. [ML (OH)], 
[MSx-i (OH)]"^ where L is Hgand, S is the solvent molecule, and x is 
the number of solvent molecule bound) could be neglected. 
The value of AG is -ve indicating that chelation process proceeds 
spontaneously. This is evaluated by both method potentiometrically 
and spectrophotometrically. 
3.3. Fluorescence Study 
The fluorescence emission spectrum of the pure drug is markedly 
different from its absorption spectrum in the UV region, which is 
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Acid Tiration 
Ligand Titration 
•*—Complex Tiration 
vvithMn([r) 
Cotnpfcx Titration 
withNi(B) 
•X — Co mp lex Titral lo n 
withFedU) 
• — C o m p l e x Titration 
withCo(ll) 
Complex Titration 
with ^n(U) 
Complex Titration 
with Cut It) 
0 1 2 3 4 
Volume of NaOH (ml) 
Figure 5. Potentiometric titration curve of levosulpiride with metal ions. 
attributed to its different geometry in the ground and excited states 
(Fig. 6). When the emission spectrum of the pure drug is run between 
270-430 nm at an excitation wavelength of 275 nm, a strong peak at 
300 nm and two weak emission peak at 342 and 406 nm were observed 
(Fig. 7). The 5-aminosulfonyl 2-methoxy benzamide group of levosulpir-
ide acts as an electron acceptor where as the pyrrolidinyl group acts as 
electron donor. The peak in absorption spectra is due to the intramolecu-
lar charge transfer between the acceptor and donor groups. The addition 
of the metal ion to the drug can cause either enhancement or quenching 
in the fluorescence emission spectrum (Quang et al. 2007). We have noted 
an enhancement of fluorescence intensity at 300 nm in each case 
(Mn-Zn). The shape and position of emission spectrum oC levosulpiride 
in presence and absence of transition metal ions remains unchanged, 
which suggests no significant change in the overall electronic structure 
of drug upon addition of metal ions (Fig. 8). The relative enhancement 
in the fluorescence intensity I/IQ is shown in Table 3. 
The enhancement in emission intensity of levosulpiride in the 
presence of various metal ions follows the order Fe > Ni > Cu > 
Zn^ "^  > Co^ "^  > Mn^ "^  (Fig. 9). The enhancement in emission intensity 
does not follow any trend from Mn-Zn, although it is minimum in the 
case of Mn, probably due to its half filled 'd' orbital. Although the transi-
tion metal ions are known to effectively quench fluorescence (Ghosh and 
2200 K. S. Siddiqi et al. 
r^^t 
+ 
OH 
+ 
H 
^OCHj 
Anion 
Figure 6. Showing different ionic species in the solution at different pH. 
Bharadwaj 1996; Varnes, Dodson, and Wehry 1972; Rurack et al. 1993; 
Kemlo and Shepherd 1977), we observed over two fold increase in inten-
sity as a consequence of photo induced charge transfer besides the chela-
tion of the amide nitrogen resulting in CHEF (Chelating enhancement 
fluorescence) effect (Choi et al. 2006; Kim et al. 2007; Kim et al. 2003). 
300 
270 320 370 
Wavelength(nin) 
420 
Figure 7. Fluorescence Emission spectra of levosulpiride (7 x 10"^  M) at room 
temperature. 
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Figure 8. Fluorescence enhancement (at 300nm) of levosulpiride with Mn(II), 
Fe(III), Co(II),.Ni(II), Cu(II), and Zn(II) at room temperature. 
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Table 3. The relative intensity and limiting concentration 
Metal ions I/Io Limiting concentration 
Mn(II) 
Fe(ni) 
Co(II) 
Ni(H) 
Cu(II) 
Zn(Il) 
1.24 
3.13 
1.52 
2.41 
2.37 
1.53 
3.6 nm 
3.6|.im 
3.6|.im 
3.6 nm 
3.6|.im 
3.6 [am 
It is accepted that aromatic compounds having amide groups are strongly 
quenched by intersystem crossing to a triplet state and/or by the rota-
tional relaxation linked to excited state rotation around the CO-NH 
and N-alkyl bonds. This may explain why, when complexed by cations, 
these rotors are less available for relaxation (Kawakami et al. 2002). 
An increase of rigidity of the system by metal cation complexation may 
therefore be an explanation for the fluorescence enhancement. In general, 
the phenomenon of enhancement is observed because the complexation 
by cations causes increase in the redox potential of the donor so that 
IMn(II) •Fe(III) •Co(I!) •Ni(II) 
Tran<;it-.ion met.al 
ICu(II) •2n(n) 
Figure 9. The enhancement in emission intensity of levosulpiride in presence of 
various metal ions follows the order Fe^ "^  > Ni^ "^  > Cu^^ > Zn^^ > Co""^  > Mn" .^ 
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the relevant HOMO energy decreases to a level lower than that of 
fluorophore. Consequently the excited state energy of fluorophore is 
dumped as a visible emission (Quang et al. 2007). The reason for this 
enhancement lies in strong perturbation of the excited state upon 
coordination of the metal ion. A low-lying internal charge transfer state, 
due to the presence of electron donor and acceptor group in the levosul-
piride, is the lowest excited state. This state is, however, a less emitting 
state. And, in equilibrium with the n-n* excited state of the molecule, 
upon coordination with metal cation, the PCT interaction becomes 
weaker since the electron withdrawing group is now an electron rich moi-
ety due to the deprotonation of-NH group necessary for coordination of 
metal cation. 
In the present work, an attempt has been made to study the interac-
tion of the drug with metal ions by fluorescence emission, absorption 
spectrophotometric, and potentiometric measurements. Since quenching 
or enhancing in fluorescence intensity of the drug in presence of the metal 
ions occurs, the spectra of the drug in presence of different concentra-
tions of several metal ions were scanned. The ratio of the drug to metal 
ions was determined by Jobs method. The absorption spectra of the drug 
was run at different pH to see the zwitterionic condition, apparent ioniza-
tion constant, and the isosbestic point indicating the presence of different 
species in solution. The stability constant of the complex formed between 
the drug and metal ion was also evaluated. 
4. CONCLUSION 
The effect of cation binding on the photophysical properties of levosul-
piride was studied. A dramatic fluorescence enhancement was observed 
upon binding of transition metal ions. This was interpreted in term of 
the control of photoinduced charge transfer (PCT) and CHEF. The sta-
bility constants, which is calculated by spectrophotometrically and poten-
tiometrically, suggest that the complexes are fairly stable in solution. 
REFERENCES 
Cho, H.Y., and Y. B. Lee. 2003. Improvement and validation of a liquid chroma-
tographic method for the determination of levosulpiride in human serum and 
urine. / Chromatogr. 796; 243-251. 
Choi, J. K., S. H. Kim, J. Yoon, K. H. Lee, R. A. Bartsch, and J. S. Kim. 2006. A 
PCX-Based, Pyrene-Armed calyx[4] crown fluoroionophore. J. Org Chem 11 
8011-8015. 
2204 ^- S- Siddiqi et al. 
El-Kommas, M. E., G. A. Saleh, S. M. El-Gizawi, and M. A. Abou-Elwafa. 2003. 
Spectrofluorometric determination of certain quinolone antibacterials using 
metal chelation. Talania 60: 1033-1050. 
Ghosh, P., and K. Bharadwaj. 1996. Ni(n), Cu(II), and Zn(II) cryptate-enhanced 
fluorescence of a trianthrylcryptand: A potential moleculer photonic OR 
operator. / Am. Chem. Soc. 118: 1553-1554. 
Geo, E., P. P. Balbi, and J. C. Speranza. 2002. Levosulpiride: A new solution for 
premature ejaculation. Int. J. importance research 14: 308-309. 
Irving, H., and H. S. Rassotti. 1953. Methods for computing successive stability 
constants from experimental formation curves. / Chem. Soc. P: 3397-3405. 
Jeragh, B., D. Al-wahaib, A. A. El- Sherif, and A. El- Dissouky. 2007. Potentio-
metric and thermodynamic studies of dissociation and metal complexation 
of 4-(3-Hydroxypyridin-2-ylimino)-4-phenylbutan-2-one. / Chem. Eng. Data 
52: 1609-1614. 
Jin, S. E., E. Ban, Y. B. Kim, and C. K. Kim. 2004. Development of HPLC 
method for the determination of levosulpiride in human plasma. / Pharm. 
Biomed. Anal. 35: 929-936. 
Kawakami, J., R. Miyamoto, A. Fukushi, K. Shimozaki, and S. Ito. 2002. 
/ Photoch. Photobio. A: 146-163. 
Kemlo, J. A., and T. M. Shepherd. 1977. Quenching of excited singlet states by 
metal ions. Chem. Phys. Lett. Al: 158-162. 
Kim, J. S., K. H. Noh, S. H. Lee, S. K. Kim, and J. Yoon. 2003. A New Calix [4 
azacrown bearing two different binding sites as a new fluorescent ionophore. J. 
Org. Chem. 68: 597-600. 
Kim, J. S., O. J. Shon, J. A. Rim, S. K. Kim, and J. Yoon. 2002. Pyrene-Armed 
calix[4]azacrowns as new fluorescent lonophores: "Molecular Taekowndo" 
process via fluorescent change. / Org. Chem. 67: 2348-2351. 
Lozano, R., M. G. P. Concha, A. Montealegre, L. de Leon, J. O. Villaiba, H. O. 
L. Esteban, M. Cromeyer et al. 2007. Effectiveness and safety of levosulpiride 
in the treatment of dysmotility like functional dyspepsia. Therapeutics and 
Clinical Risk Management 3: 49. 
Mansi, C, P. Borro, R. Biagini, M. R. Mele, and N. Pandolfo. 2000. Compara-
tive effects of levosulpiride and cisapride on gastric emptying and symptoms 
in patients with functional dyspepsia and gastroparesis, Aliment. Pharmacol. 
Ther. 14: 561-569. 
Nagahata, Y., Y. Azumi, N. Kawakita, T. Wada, and Y. Saitoh. 1995. Inhibitory 
effect of dopamine on gastric motility in rats. ScandJ Gastroenterol. 30: 880-885. 
Park, H. R., K. Y. Chung, H. C. Lee, J. K. Lee, and K. M. Bark. 2000. Ionization 
and divalent cation complexation of quinolone antibiotics in aqueous solution. 
Bull. Chem. Soc. 21: 849-854. 
Quang, D. T., H. S. Jung, J. H. Yoon, S. Y. Lee, and J. S. Kim. 2007. Coumarin 
appended calix[4]arene as a selective fluorometric sensor for Cu^- ion in 
aqueous solution. / Bull. Korean Chem. Soc. 28: 682-684. 
Rurack, K., U. Resch, M. Senoner, and S. Dachne. 1993. A new fluorescence 
probe for trace metal ions: Cation-dependent spectroscopic properties. / Fluor-
escence 3: 141-143. 
Fluorescence Enhancement of Levosulpiride 2205 
Salem, H. 2005. Spectrofluoremetric, atomic absorption spectrometric and 
spectre photo metric determination of some fluoroquinolones. Am. J. App. 
ScL 3: 719-729. 
Sanyal, P., and G. P. Sengupta. 1990. Potentiometric studies of some trivalent 
rare earth complexes with p-sulphono-2-hydroxy-l-naphtalidene anil. / Ind. 
Chem. Soc. 67: 342 
Tonini, M., V. Spelta, and R. De Giorgio et al. 1999. A re-assessment of the 
pharmacodynamics of levosulpiride in the guineapig gastrointestinal tract. 
Gastroenterology 116: A1093 (Abstract). 
Varnes, A. W., R. B. Dodson, and E. L. Wehry. 1972. Transition Metal Ion Com-
plexes of 2,2'-BipyridyI-3,3'-dioI and 2,2'-Bipyridyl-3-oI: Spectroscopic proper-
ties and solvent-dependent binding modes. / Am. Chem. Soc. 94: 946-950. 

Chinese Journal of Chemistry, 2009. 27. 1755—1761 Full Paper 
Binding Interaction of Captopril with IVIetal Ions: 
A Fluorescence Quenching Study 
SIDDIQI, K. S * BANO, Shaista MOHD, Ayaz KHAN, Aslam Aftab Parwaz 
Department oj Chemistry, Aligarh Muslim University, Aligarh-202001. India 
The binding interaction of captopril (CPL) with biologically active metal ions Mg'^ *, Ca^*, Mn^*, Co"*. Ni *, 
Cu^ * and Zv?* was investigated in an aqueous acidic medium by fluorescence spectroscopy. The experimental re-
sults showed that the metal ions quenched the intrinsic fluorescence of CPL by forming CPL-metal complexes. It 
was found that static quenching was the main reason for the fluorescence quenching. The quenching constant in the 
case of Cu"' was highest among all quenchers, perhaps due to its high nuclear charge and small size. Quenching of 
CPL by metal ions follows the order Cu^* >Ni^* >Co^* >Ca^'^>Zn-*>Mn^* >Mg'". The quenching constant K,,. 
bimolecular quenching constant K^, binding constant K and the binding sites "n" were determined together with 
their thermodynamic parameters at 27 and 37 *C. The positive entropy change indicated the gain in configurational 
entropy as a result of chelation. The process of interaction was spontaneous and mainly A5-driven. 
Keywords captopril (CPL). fluorescence quenching, metal-drug complex, stability constant 
Introduction 
Captopril, l-[2(5)-3-mercapto-2-methyi-l-oxopropyl]-
Z,-proline (Figure 1), is an angiotensin converting en-
zyme inhibitor drug for the treatment of hypertension, 
heart failure following myocardial infarction and dia-
betic nephrotherapy.' It inhibits the active sites of a zinc 
glycoprotein, the angiotensin converting enzyme (ACE), 
blocking the conversion of angiotensin(I) to angio-
tensin(II), the level of which is elevated in patients with 
hypertensions. CPL has three different potential donor 
groups (Sthioi, Oacid and Oamidc) which may bind with 
metal ions to form 1 '. 1 complexes in acidic medium 
and 1 '. 2 complexes" in nearly basic medium (pH 6— 
8.2). The key functional group in the metabolism of 
CPL is the sulfhydryl group.' CPL is oxidized at its 
sulfhydryl group after dissolution in water to form its 
disulfide and is found in human urine after CPL admini-
stration. It has an equilibrium conformation between cis 
and trans isomers, however, the trans isomer is the ac-
tive form when bound to the enzyme." It also acts as a 
free radical scavenger.^ 
o 
SH 
HOOC 
Figure 1 Structure of CPL. 
Over the last decade, close attention has been paid to 
the interaction of CPL with various metal ions'* as drug 
metal interaction may result in the formation of a stable 
metal-drug complex, which may deplete the blood with 
trace element. On the other hand the side effect that can 
arise during CPL treatment may well be caused by the 
interaction of CPL with other metal ions present in the 
plasma.'* Therefore, to gain a deeper insight into the 
mechanism of the inhibition and side effect of CPL, 
equilibrium and structural studies were earlier per-
formed with several metal ions. Studies have also been 
done on the use of transition metal ions for quantitative 
spectrophotometric determination of CPL in pharma-
ceutical formulations.'" CPL has also been assayed 
spectrofluorimetrically after reacting with fluorogenic 
reagents'' or reducing Ce(IV) to fluorescent Ce(IIl).'^ 
The fluorescence spectroscopy has been widely used 
to monitor the molecular interaction because of its high 
sensitivity, reproducibility and relatively easy use. Since 
no detailed fluorescence study on the binding interac-
tion of CPL with Mg'*, Ca-^ Mn"", Co"", N i ' \ Cu^'' 
and Zn has been done so for, a thorough investigation 
was therefore made using this technique. Such interac-
tions between CPL and these metal ions can cause fluo-
rescence quenching. Therefore, valuable information 
such as binding mechanism, binding constant, and 
binding sites can be obtained using fluorescence 
quenching study of CPL by these metal cations. In addi-
tion the themiodynamic parameters of the process were 
also proposed in this work. 
Experimental 
Instruments, methods and materials 
The fluorescence emission spectra were scanned 
with a Hitachi-F-2500FL spectrophotometer. The phase 
modulation method was used to obtain fluorescence 
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lifetime by an SLM48000S spectrofluorometer (SLM 
Aminco, Rochester, NY). The procedure for hfetime 
measurement was described in reference." Doubly dis-
tilled water was used throughout. CPL (Across organ-
ics), sodium hydroxide, metal chloride (Merck Ltd, 
Mumbai, India), and HCl (Ranbaxy Fine Chem. Ltd, 
India) were used as received. 
Preparation of solution 
The stock solution of CPL in aqueous acidic medium 
(1 X lO""-* mol'L"') was stored at 4 °C and metal salts 
of 1X10~" mol'L' ' were prepared in doubly distilled 
water. 
The working solution of the CPL (8X10 mol'L_ ) 
and those of metal ions (1 X 10 ^ to 18X 10 ^ mol-L ') 
were prepared. The steady state fluorescence spectra of 
the drug were recorded in the X^^ of 320—360 nm with 
excitation at the maximum centered at Acx = 305 nm. 
The excitation wavelength was chosen such that ab-
sorbance at this excitation wavelength was less then 
0.02 to minimize the inner-filter effect and to obtain the 
most complete emission spectrum as possible. 
Results and discussion 
Figure 2 shows the emission spectra of CPL in the 
presence of metal ions of various concentrations. It was 
observed that the fluorescence intensity of captopril de-
creased regularly with the increasing concentration of 
metal ions without any change in emission maxima and 
shape of peaks. As there was no significant Aem shift 
with the addition of metal ions, it was indicated that 
metal ion could quench intrinsic fluorescence of CPL 
and that the interaction between CPL and metal ion in-
deed existed without inducing any conformational 
change in it under the condition studied here. 
Quenching can occur by a variety of molecular in-
teractions, viz. excited-state reactions, molecular rear-
rangement, energy transfer, ground state complex for-
mation (static quenching) and collisional or dynamic 
quenching. Static and dynamic quenching can be dis-
tinguished by their different dependence on temperature 
and excited state life time. Dynamic quenching is diffu-
sion controlled because the quencher must diffuse to the 
fluorophore during the life time of excited state. Since 
high temperature will result in large diffusion coeffi-
cient, the bimolecular quenching constants are expected 
to increase with temperature. If the A^sv decreased with 
increased temperature, it could be concluded that the 
quenching process was static rather than dynamic' ' 
Static quenching implies either the existence of a sphere 
of effective quenching or the formation of a ground 
state non-fluorescent complex, whereas collisional or 
dynamic quenching involves the collision and subse-
quent formation of a transient complex between an ex-
cited state fluorophore and a ground state quencher. The 
excited state complex dissociates upon radiative and 
SIDDIQI el al 
non-radiative deactivation. In order to confirm the 
quenching mechanism the procedure of fluorescence 
quenching svas first assumed to be dynamic. For dy-
namic quenching the mechanism can be described by 
the Stem-Volmer equation. ' 
Fo/F=l+/:<,r„[Q]=l+/:sv[Q] (1) 
where, F„ and F are the fluorescence mtensities in the 
absence and presence of the quencher, respectively, K^ 
is the bimolecular quenching rate constant, K^^ is the 
dynamic quenching constant and r^ is the average life 
time of the molecule without quencher. Figure 3 dis-
plays the Stem-Volmer plots of quenching of CPL by 
different metal ions and at different temperatures. 
Based on the experimental data in Figure 3, the dy-
namic quenching constants and bimolecular quenching 
constants at different temperatures are shown in Table 1 
It is evident from the table that the K^ values in each 
case are considerably larger than those possible for dif-
fusion controlled quenching in solution (about 10 L-
inor ' ' ns~ ' ) . Usually, large K^ beyond the diffu-
sion-controlled limit indicates that some type of binding 
interaction exists between fluorophore and quencher. 
It was observed that /C„ decreased with increasing tem-
perature for all metal ions. It can be therefore, con-
cluded that the quenching is not initiated by a dynamic, 
but probably by a static process. Among all the metal 
quenchers, Cu""^  quenches CPL the most effectively. 
The quenching constant by Cu^^ is larger than those by 
other metal quenchers and that of Mg" is the minimal, 
which follows the order Cu^''>Ni'^^>Co^^>Ca^''> 
Zn^'^>Mn^'*^>Mg^^. Cu^ "^  is well known as a strong 
quencher because of its electronic structure (d ). 
Quenching by this type of substance most likely in-
volves the donation of an electron from the fluorophore 
to the quencher, and the ion dipole interaction between 
Cu '^^  and the molecule will also be strong due to the 
large nuclear charge and the relatively small size com-
pared with other metals. Cu^' usually introduces easily 
accessible low energy levels, which can give rise to en-
ergy and electron transfer processes and is capable of 
quenching the fluorescent excited state of the mole-
Table t 
27 and 37 
Stem-Volmer and b 
•c 
^„./(L'mor') 
27 "C 37 'C 
imoleciilar quenching 
K^(L-mo\'' 
27 "C 
constant 
•s-') 
37 'C 
at 
Ca 2.82X10' 2,57X10" 8.47X10'- 7.71 XIO'^ 
Mg 1.36X10" 1.21X10" 4.08X10'- 3.63X10'^ 
Mn 1.89X10" 1.83X10" 5.67X10'" 5.49X10'^ 
Co 3.05X10" 2.73X10" 9 16X10'- 8.19X10'^ 
Ni 4.11X10" 3.66X10" 12.34X10'' 10.99X10'^ 
Cu 6.42X10" 5.09X10" 19.3X10'- 15.28X10'^ 
Zn 2.66X10" 2.32X10" 7.98X10'" 6.96X10'-
© 2009 SIOC, CAS, Shanghai, & WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
Captopril 
Chin. J. Chem.. 2009 Vol. 2^ No. 9 1757 
Wavclength/nm 
600-1 
500-
400-
300-
200 
100 
0 
Mn(ll) 
320 330 340 350 
Waveleneth/nm 
340 350 
Wavelenglh/nm 
600 
360 
1 
320 330 340 350 
Wavelength/nm 
320 330 340 350 
Wavelength/nm 
340 350 
Wavelength/nm 
340 350 
Wavelength/nm 
360 
Figure 2 
perature. 
Fluorescence enhancement (at A„ 305 nm) of CPL with Ca(II), Mg(II), Mn(II), Co(II), Nii 
: 7.0 nmol'L"' CPL, from 2 to 8: 2. 3, 6. 8, 10, 12, 18 nmol-L"' of metal ions. 
360 
(II), Cu(II) and Zn(Il) at room tem-
) 2009 SIOC, CAS, Shanghai, & WILEY-VCH Verlag GmbH & Co, KGaA, Weinheim 
1758 Chin. J. Chem.. 2009. Vol. 27, No. 9 
1 7 -] 
1.6 
1.5 
1.4 i 
1.3 
I 7H 
I.I -
1.0 
SIDDIQI et al. 
u. 
0 
1.7-1 
1.6-
1.5-
1.4 -
I..1-
1.2-
1.1 -
10-
1.7 n 
1.6 
1.5 
1.3 
1.2 
I.I 
1.0 
37 C 
5 10 15 
lCa|/(nmol-L') 
27'C 
20 
5 10 15 
[Mnl/(Mmol-l' ') 
20 
27'C 
—1— 
10 
—1— 
15 20 
tNil/(nmol-L-') 
1.7n 
l.b 
15 
14 
1.3 
1.2 
l . H 
1.0 
0 
1.5 
1.4-
13 
1.2 
1 I 
1,0 
;? 
1.9-| 
1.8-
1.7 
16 
1.5-
1.4-
1.3 
1.2 
I I 
10 
u. 
If 
0 
17 
16 
15 
1.4 
1.3 
12-1 
1.1 
1.0 
0 
27 r 
37 C 
10 15 
[Zn)/(nniol-L') 
20 
27 C 
10 
[Mg]/(nmol-l.' 
27 T 
"T 
10 
"T 
15 
|('o|/(Mniol-l, ') 
5 10 15 
fCul/(mmol-L ') 
20 
Figure 3 Stem-Volmer plots of CPL with Ca(n), Mg(II). Mn(II), Co(II), Ni(II), Cu(II) and Zn(n) al 27 and 37 "C 
> 2009 SIOC. CAS, Shanghai, & WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
Captopril Chin. J. Chem.. 2009 Vol. 2" No. 9 1759 
cule." The larger A:SV and K^ values of Ni^^ in com-
parison to Co^^, Mn^ "^  and Zn^^can be explained in 
terms of its smaller ionic radius and larger nuclear 
charge. In cases of Mn^^ and Zn * the K^^. and A^q are 
quite small due to their half filled and completely filled 
"d" orbitals, respectively. The K^^ and K^ values for 
Ca^ "^  are larger than those of Mg '^^  probably because 
of its higher reactivity and lower ionization potential. 
Binding constant and binding sites 
For static quenching, the relationship between inten-
sity and the concentration of quencher can be described 
by the binding constant formula. 
lg(Fo-F)/F=lg/:+«lg[Q] 
18,19 
(2) 
where K is the binding constant, and n is the number of 
binding sites per CPL. After the fluorescence quenching 
intensities of CPL at 340 nm were measured, the dou-
ble-logarithm algorithm was assessed by Eq. (2). Figure 
4 shows double-logarithm curve and Table 2 gives the 
corresponding calculated results. The linear correlation 
coefficients for all the curves are larger than 0.970, in-
dicating that the interaction between the metal ions and 
CPL agrees well with the site-binding model underlying 
Eq. (2). The value of binding constant for these 
CPL-metal complexes follows the same order as men-
tioned in cases of A^sv and K^^ values and is in agreement 
with the Irving-Williams series in cases of transition 
metal series. 
Table 2 Binding constant, binding site and regression coeffi-
cient at 27 and 37 "C 
Metal 
Ca 
Mg 
Mn 
Co 
Ni 
Cu 
Zn 
igA: R 
27 "C 37 r 27 r 37 "C 27 "C 37 "C 
2.319 
1.359 
1.285 
2.887 
3.416 
4.811 
2.535 
2.580 
1.492 
1.710 
2.828 
3.450 
5.049 
2.922 
0.58 
0.39 
0.35 
0.65 
0.74 
1.00 
0.58 
0.61 
0.43 
0.44 
0.66 
0.76 
1.07 
0.68 
0.996 
0.998 
0.985 
0.998 
0.999 
0.999 
0.999 
0.997 
0.960 
0.993 
0.997 
0.998 
0.998 
0.997 
Thermodynamic parameters and nature of binding 
forces 
Considering the dependence of the binding constant 
on the temperature a thermodynamic process was con-
sidered to be responsible for this interaction. Therefore, 
the thermodynamic parameters dependent on tempera-
ture were analyzed in order to further characterize the 
forces acting between CPL and metal ions. The ther-
modynamic parameters enthalpy changes (AH), entropy 
changes (A5), and free energy changes (AG) are the 
main evidences to determine the binding mode. If the 
temperature does not vary significantly, the enthalpy 
changes (AH) can be regarded as constant. The free en-
ergy change (AG) can be estimated from the following 
equation, based on the binding constant at different 
temperatures. 
AG=-2.303/?71g/^ (3) 
where R is the gas constant, T is the experimental tem-
perature, and K is the binding constant at the corre-
sponding temperature. 
From the values of stability constant at different 
temperatures the enthalpy changes can be calculated by 
using equation; 
ig(/^2/A:i) = (!/7|-l/7"2)AW/2.303/? (4) 
The entropy changes can be calculated by using 
equation: 
AG=AH~TAS (5) 
The thermodynamics parameters for the interaction 
of metal ions and CPL are shown in Table 3. The nega-
tive value of AG means that the interaction process is 
spontaneous. The positive AS value obtained for all in-
vestigated complex is characteristic of chelation, which 
occurs because the water molecules that are normally 
arranged in an orderly fashion around the CPL and 
metal ions have acquired a random configuration as a 
result of chelation. This is referred as gain in configura-
tional entropy."" The positive value of AH indicate that 
the processes are endothermic and binding between the 
metal ions and CPL is mainly AS'-driven, with little con-
tribution from the enthalpy factor. 
Table 3 Thennodynamics parameters at 27 and 3"^  'C 
AG/(kJ-mor') , AS/(kJ-mor'-K~') 
Metal —AH/{k}'mo\')-27 'C 37 r 27 "C 37 "C 
Ca 
Mg 
Mn 
Co 
Ni 
Cu 
Zn 
-13.32 -14.82 
-7.808 -8.575 
-7.386 -9.828 
-16.58 -16.24 
-19.62 -19.82 
-27.63 -29.00 
-14.56 -16.78 
46.59 
23.76 
75.50 
67.59 
6.160 
42.32 
68.93 
0.199 
0.105 
0.276 
0.280 
0.085 
0.233 
0.261 
0.198! 
0.1043 
0,2752 
0.2704 
0.0838 
0.3371 
0.2604 
Conclusion 
in this paper we have investigated the nature and 
magnitude of the interaction of CPL with biologically 
important metal ions Mg"*, Ca""", Mn"*, Co"*, Ni"*, 
Cu and Zn" by fluorescence spectroscopy. Since the 
Stem-Volmer quenching constants, K^^ in all cases are 
inversely proportional to temperature, it indicates that 
probable quenching mechanism is initiated by static 
quenching. Cu^' is the best quencher among all the 
metal ions. The thermodynamic parameters showed that 
the interaction between CPL and metal ions was spon-
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taneous and entropically favored in which entropy in-
creased and Gibbs free energy decreased. The positive 10 
value of M indicates the gain in configurational en-
tropy. 11 
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Abstract The kinetics and mechanism of oxidation of 
levofloxacin (LF) by manganese(Vll) in alkaline medium 
at constant ionic strength was studied spectrophotometri-
cally. The reaction exhibits 2:1 Mn:LF stoichiometry and is 
first order in permanganate but fractional order in both LF 
and alkali. Decrease in the dielectric constant of the med-
ium results in a decrease in the rate of reaction. The effects 
of added products and ionic strength have also been 
investigated. The main products identified were hydroxyl-
ated LF and Mn(VI). A mechanism involving free radicals 
is proposed. In a composite equilibrium step, levofloxacin 
binds to Mn04~ to form a complex that subsequently 
decomposes to the products. Investigations of the reaction 
at different temperatures allowed the determination of the 
activation parameters with respect to the slow step of the 
propcsed mechanism. 
Introduction 
Potassium permanganate is widely u.sed as an oxidizing agent 
as well as in analytical chemistry. These reaction.s are gov-
erned by the pH of the medium. Of all the oxidation states of 
manganese from +2 to +7, permanganate, manganese(VII), 
is the most potent oxidant in acid as well as in alkaline media. 
Permanganate oxidation finds extensive applications in 
organic synthesis [1,2], especially since the advent of phase 
transfer catalysis [3-5]. Kinetic studies are important sources 
of mechanistic information on such reactions, as demonstrated 
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by the results referring to unsaturated acids both in aqueous 
[3-6] and in non-aqueous media [7]. The mechanism of oxi-
dation depends on the nature of the substrate and pH of the 
system [8]. In strongly alkaline medium, the stable reduction 
product [9-11] of permanganate is manganate ion, MnOj^". 
MnOi appears only after long time, i.e., after the complete 
consumption of Mn04~. No mechanistic information is 
available to distinguish between a direct one-electron reduc-
tion to Mn(Vl) and a mechanism in which a hypomanganaie 
ion is formed in a two-electron reduction followed by its rapid 
re-oxidation [12, 13]. 
Levofloxacin (LF), (—)-(S)-9-fluoro-2,3-dihydro-3-methyl-
IO-(4-methyl-l-piperazinyl)-7-oxo-7H pyrido [1,2,3-del-
l,4-benzoxazine-6-carboxylic acid hemihydrate, is one of 
the commonly used fluoroquinolone antimicrobials, being 
the active S-isomer isolated from racemic ofloxacin. Lev-
ofloxacin possesses a broad spectrum of activity against 
various bacteria, including Cram-positive and Gram-
negative microorganisms [14]. It is also active against the 
cau.ses of atypical respiratory infection such as Chlamydia 
pneumoniae and Mycoplasma pneumoniae [15]. Because of 
its effective antibacterial activity and low frequency of 
adverse effects on oral administration, levofloxacin has 
been widely used for the treatment of infectious diseases, 
such as community-acquired pneumonia and acute exac-
erbation of chronic bronchitis [16]. The antibacterial action 
of the quinolones is not linearly proportional to their con-
centration, and the optimum concentration must be main-
tained to prevent the surviving bacteria from regrowing 
[17). The intrinsic fluorescence of fluoroquinolones is used 
for their determination in biological samples after their 
preliminary extraction with organic solvents [181. .\ 
method was proposed for determining the,se antibiotics m 
biological fluids using a mixed-ligand complex formed by 
terbium and triphenylphosphine oxide [19]. The interaction 
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of fluoroquinolones with metal ions has attracted consid-
erable interest not only for the development of analytical 
techniques, but also to provide information about the 
mechanism of action of the pharmaceutical preparation 
[20). Since the metal ions cause fluorescence quenching of 
the drug, spectrofluorimetric methods for the quantitative 
determination of the quinolone type drugs have been 
developed [21] besides titrimetric [22], spectrophotometric 
[23], electrochemical [24], electrophoretic [25] and chro-
matographic [26] techniques. The accumulation of fluoro-
quinolone antibiotics in aquatic environments, even in low 
concentrations, may cause threats to the ecosystem and 
human health by inducing multiplication of drug resistant 
bacteria as a result of long-term exposure. Chemical oxi-
dation of pollutants in drinking and waste water by per-
manganate ion has been widely used. The present .study is 
an attempt to explore the mechanism of oxidation of lev-
ofloxacin by permanganate in alkaline medium on the basis 
of kinetic parameters. 
concentration range, and « was found to be 2083 ± 50 dm 
mor ' cm"' (compared to the literature, F. = 2200 [9]). The 
first-order rate constants /c„hs were evaluated from plots of 
log [permanganate] versus time. The plots in all ca.ses were 
linear up to 75% of the reaction (Fig. 1), and <:,>hs values were 
reproducible at 526 nm, notwithstanding the increasing 
absorbance of Mn(VI) at 610 nm during the course of the 
reaction (Fig. 3). The effect of dis.solved oxygen on the rate 
of reaction was checked by following the reaction in nitrogen 
atmosphere. No significant difference between the results 
obtained under nitrogen and in the presence of air was 
observed. In view of the all-pervading contamination of basic 
solutions by carbonate, the effect of carbonate on the reaction 
was also studied. Added carbonate had no effect on the 
reaction rate. Nevertheless, fresh solutions were used during 
the experiments. Regression analysis of the experimental data 
to obtain the regre-ssion coefficient r and the standard devia-
tion S was performed using Microsoft Excel 2007. 
Experimental 
All chemicals used were of analytical reagent grade, and 
double distilled water was used throughout the work. A 
solution of levofloxacin (Sigma-Aldrich) was prepared by 
dissolving a known amount of its hydrochloride salt in 
distilled water. The permanganate (Ranbaxy Fine Chem. 
Ltd, India) solution was prepared and standardized against 
oxalic acid by a standard procedure [27]. Potassium man-
ganate solution was prepared as de.scribed by Carrington 
and Symons [28]. KOH (Merck Ltd.) and KNO, (Merck 
Ltd.) were employed to maintain the pH and ionic strength, 
respectively. 
The absorption spectra were obtained with an Elico-SL-
169 double beam UV-vis spectrophotometer. All potenti-
ometric measurements were carried out with an Elico-LI-
120 pH meter, and the products were analyzed using a 
Nicolet 5700-FT-IR spectrometer (Thermo, USA). 
Kinetic measurements and procedure 
The oxidation of LF by permanganate was followed under 
pseudo first-order conditions where LF was greater than 
manganese(VII) at 25 °C. The reaction was initiated by 
mixing thermally equilibrated solutions of Mn04~ and LF 
that also contained the required quantities of KOH and 
KNO3 to maintain alkalinity and ionic strength, respec-
tively. The reaction was monitored by the decrease in 
absorbance of Mn04~ at its absorption maximum of 526 nm. 
It was verified that there is no interference from other 
reagents at this wavelength. Beer's Law was obeyed in this 
Results 
The reaction orders were determined using the slopes of 
log *obs versus log (concentration) plots by varying the 
concentration of the reductant and 0H~ while keeping 
other factors constant. With fixed concentrations of LF, 
1.0 X 10"'' mol dm"\ and alkali, 2.0 x 10"^ mol dm"\ 
at constant ionic strength, 0.10 mol dm"', the permanga-
nate concentration was varied in the range of 4.0 x 10"^ to 
6.0 X 10"'' mol dm" . All kinetic runs exhibited identical 
characteristics. The linearity of plots of log (absorbance) 
versus time, for different concentrations of permanganate, 
indicates that the order in Mn(VIl) is uniform (Fig. 1). This 
was also confirmed by the constant values of the pseudo 
first-order rate constants, ^„hs. for different Mn(Vll) 
Fig. 1 First-Older plots of the oxidation of levoHoxacin by peniian-
ganate in aqueous alkaline mediiiin. [LF] = I x I 0 " \ |0H "] = 
2 X 10"' and / = 0.10/mol dm"'. [Mn04'^lx 10" mol dm"^ = (A) 
0.4, (B) 0.8, (C) 1.0, (D) 2.0 and (E) 3.0 
Springer 
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Table 1 Effects of [LF], (Mn04 ] and (OH ] on the oxidation of 
levofloxacin by permanganate in aqueous alkaline medium at 2S °C 
and ionic strength /=0.10/mol dm" 
lO'' X (Mn04'] 10' X [LF] 10' x [OH") k^„ x 10' 
mol dm" mol dm mol dm 
-cal 
(S-n 
^ohs X (S - l ) 
10' 
0.4 
0.8 
1.0 
2.0 
3,0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
0.4 
0.6 
0.8 
1.0 
4.0 
6.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0.4 
0.8 
1.0 
2.0 
4.0 
6.0 
4.12 
4.12 
4.12 
4.12 
4.12 
3.67 
3.76 
3.12 
4.28 
5.38 
5.41 
2.19 
2.39 
2.84 
3.32 
3.61 
4.43 
4.10 
4.10 
4.10 
4.10 
4.10 
3.65 
3.74 
4.10 
4.25 
5.35 
5.40 
2.18 
2.38 
2.82 
3.30 
3.60 
4.41 
concentrations (Table 1). The LF concentration was varied 
in the range of 4.0 x lO""* to 6.0 x ]0~^ mol dm"'' at 
constant alkali and permanganate concentrations and con-
stant ionic strength of 0.10 mol dm"' at 25 °C. The /c„hs 
values increased with increase in LF over the concentration 
range shown in (Fig. 4). At low concentration of LF, the 
reaction was first order in LF and at high concentration of 
LF, the reaction was independent of LF. The effect of alkali 
on the reaction was studied at constant concentrations of 
LF and permanganate and a constant ionic strength of 
0.10 mol dm"'' at 25 °C. The alkali concentration was var-
ied in the range of 1.0 X 10~^tol.O X 10~"mol dm"\The 
rate constant increased with increase in alkali concentration 
(Fig. 5), indicating a fractional-order dependence of the rate 
on alkali concentration. 
Stoichiometry and product analysis 
Different reaction mixtures containing LF and an excess of 
Mn04" with constant OH" and KNOj concentration were 
kept in closed vessels under nitrogen atmosphere at room 
temperature. After 2 hours, the Mn(VII) concentration was 
Table 2 FT-IR frequencies i 
Compound 
Levofloxacin 
Oxidation Product 
KOH) 
3411 
3305 
(cm ) 
y{C=0) 
(722 
1626 
'•.,.y„, (COO) 
(622 
1586 
i\>„,(COO) 
1462 
1442 
assayed by measuring the ab.sorbance at 526 nm. The 
results indicated a 1:2 stoichiometry, as given in Scheme I 
The main reaction products, Mn(VI) and 9-fluoro-2,3-
dihydro-3-methy 1-5-hydroxy-10-(4-methy 1-1 -piperaziny 1 )-
7-0X0-7H pyrido [l,2,3-de]-l,4-ben20xazine-6 carboxylic 
acid, were isolated and identified with the help of TLC 
and characterized by FT-IR. The FT-IR spectra of LF 
and its complexes are similar. The (C=0) band appears at 
1,722 cm"' in the spectrum of LF; the complexes show this 
band at ca. 1,626 cm"', suggesting that the coordination of 
the iigand occurs through the carboxyiate o.xygen atom. A 
carboxylate Iigand can bind to the metal atom as a mono-
dentate Iigand. giving changes in the relative positions of 
the antisymmetric and symmetric stretching vibrations with 
the aim of deducing the coordination mode (29, 30]. The 
FT-IR spectra of the complex (Table 2) give a separation 
>100 cm"', suggesting monodentate bonding for the car-
boxylate group. 
Effects of ionic strength, dielectric constant 
and temperature 
The effect of ionic strength was studied by varying the 
potassium nitrate concentration from 0.01 toO.lO mol dm"' 
at constant concentrations of permanganate, LF and alkali. 
Increasing ionic strength had no effect on the rate constant. 
The effect of the dielectric constant (D) was studied by 
varying the Nbuianol-water content (v/v) in the reaction 
mixture with all other conditions held constant. The rate of 
reaction increa.ses with increasing /-butanol volume. The 
plot of log <:„h, versus 1/D was linear with positive slope 
(Fig. 2). 
The kinetics was also studied at four different temper-
atures with varying concentrations of LF and alkali, 
keeping other conditions constant. The rate constants were 
found to increase with increase in temperature. The rate of 
the slow step was obtained from the slopes and intercepts 
of 1/A:„hs versus 1/[LF] and !/^ „bs versus l/[OH"] plots at 
four different temperatures (25-37 °C). The activation 
energy corresponding to these rate constants was evaluated 
Scheme 1 Formation of 
hydroxylated LF and Mn(VI) 
,N., .J 
0 0 
OH 
°-\ 
+ 2 MnOV + 2 OH' 
0„ 
OH 
• • • \ 
OH •f Z.VInO/ +H2I) 
"Q Springer 
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1/D la 
Fig. 2 Effect of dielectric constant on the oxidation of levofloxacin 
by alkaline Mn04" at 25 °C 
from the Arrhenius plot of log k versus 1/7" from which 
other activation parameters were also obtained (Table 3). 
Test for free radicals 
50(1 55(1 600 
Wavelength (iini) 
Fig. 3 Spectral changes during the oxidation of levoHoxacin (LF) by 
MnOj" in alkaline medium at 25 ^C: iMnOj^l = I x 10"', 
[LF] = I X IO- \ (0H"1 = 2 X 10"' and / = 0.10/mol dm" ' 
T o test for the involvement of free radicals, acrylonitrile 
w a s added to the reaction mixture, which was then kept for 
Table 3 Activation and thermodynamic parameters for the oxidation 
of LF by alkaline permanganate with respect to the slow step of the 
reaction Scheme 2 
Temperature(K) i a \ (S"') 
Effect of Temperature with respect to the slow step of Scheme 2. 
293 10.6 
298 11.8 
303 12.2 
310 13.5 
Value 
Activation parameter 
Ea (kJmole"') 
AH (kJmole"') 
AS ± (Jk-'mole"') 
AG ± (kJmole"') 
14.9 
11.9 
•143.2 
63.10 
Effect of temperature (K) IQ-^ AT. {dm' moP') 10" V . (dm^ mol"') 
Equilibrium constants K, and K2 at different temperatures 
293 5.44 6.17 
298 7.59 6.69 
303 9.62 5.32 
310 12.43 4.34 
Thermodynamic parameters 
AHCkJmole') 
AS ± (Jk-'mole"') 
AG ± (kJmole"') 
K, values 
58.1 
123.5 
-8.7 
K2 values 
-78.6 
-89.7 
-8.35 
24 h under nitrogen. Addition of methanol, resulted in the 
precipitation of a polymer, suggesting the involvement of 
free radicals in the reaction. The blank experiment of 
reacting either permanganate and LF alone with acryloni-
trile did not induce polymerization under the same condi-
tions. Initially added acrylonitrile decreased the rate of 
reaction [.31]. 
Discussion 
Under our experimental conditions at pH > 12, the 
reduction product of Mn(VIl), i.e., Mn(VI), is stable, 
and no further reduction is initially observed [10]. 
However, on prolonged standing, the green Mn(VI) is 
reduced to Mn(IV) under our experimental conditions. 
Permanganate ion in alkaline medium exhibits various 
oxidation states, such as Mn(VII), Mn(V) and Mn(Vl). 
During this reaction, color changes from violet Mn(VlI) 
to dark green Mn(VI) through blue Mn(lV) were 
ob,served. It is clear from Fig. 3 that the concentration of 
Mn04~ decreases at 526 nm, while increases at 610 and 
460 nm are due to Mn(VI). As the reaction proceeds, a 
yellow turbidity slowly develops, and after keeping for a 
long time the solution decolourises and forms a brown 
precipitate. This suggests that the initial products might 
have undergone further oxidation resulting in a lower 
oxidation state of manganese. It appears that the alkali 
combines with permanganate to give [Mn040H]"" [32, 
33]. In the second step, [Mn040H]-" combines with 
levofloxacin to form an intermediate complex. The var-
iable order with respect to LF most probably results 
^ S p r inger 
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from the complex formation between oxidant and LF 
prior to the slow step. A plot of \lk„^^ versus 1/[LF] 
(Fig. 1) shows an intercept in agreement with complex 
formation. Further evidence for complex formation was 
obtained from the UV-vis spectra of reaction mixtures. 
Two iso.sbestic points were observed for this reaction 
(Fig. 3), indicating the presence of an equilibrium before 
the slow step of the mechanism [34, 35]. In our pro-
posed mechanism, in the complex one electron is 
transferred from levofloxacin to Mn(VII). The cleavage 
of this complex (C) is assigned as the slowest step, 
leading to the formation of an LF radical intermediate 
and Mn(VI). The radical intermediate reacts with 
another Mn(VII) species, [Mn040H]"~, to give the final 
products, Mn(VI) and the alcohol (Scheme 2). The effect 
of the ionic strength and dielectric constant on the rate 
is consistent with the involvement of a neutral molecule 
in the reaction. The suggested structure of complex (C) 
is given in Scheme 2. 
From Scheme 2, the rate law (Eq. 7) can be derived as 
follows: 
Rate = 
-d[MnO'' 
dt 
= kK|K2 (Mn04-1,(LF],|0H-
[MnO^],^ [MnO^"], + [Mn04 OH]^' + [Complex] 
= [Mn04-],.+ [MnO;] [OH^] 
+ kK|K2[MnOj] [LFJlOH"] 
[MnO;],= [MnO,-],,(l + K| [OH-l+ K|K:[LFl [OH-]) 
[MnO,-], [MnO;],.= 
1 + K| [OH-)+ K|K2[LF][0H-
(2) 
where "t" and "f' stand for total and free. Similarly, total 
[OH""] can be calculated as 
[0H-], = [OH"],4- [Mn04 • O H ] ^ " + [Complex] 
[OH-]t (3) [0H-], = 
i + K| [MnO;] + K|K2(LFJ [MnO, 
In view of the low concentrations of MnO, and 
levofloxacin used in the experiment, in Eq. 3, the terms 
A:|[Mn04-] and K^K.JMnO^-] [LF] are neglected. Thus, 
[ 0 H - ] , = [OH-], (4) 
The total [Mn04 ] can be written as 
Similarly, 
[LF1,= [LF], 
Substituting Eq. 2. 4, and 5 in Eq. 1 we get 
(5) 
Scheme 2 Proposed 
mechanism for the oxidation of 
levofloxacin by alkaline MnO^ 
K, 
M n 0 4 + 0 H , |Mn04 .0H | 
Complex (C) 
o o % ? V 
Mn 
* IMnOj.OH]^ 
* IMnOj .OHl - " 
» M n O . ^ ' 
N ^ j ° ^ \ 
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[MnOj]f= 
Rate 
[Mn04 
I +K|[0H-] + K|K2[LF][0H-
l-fK|[0H-]+K|K2[LF](0H-
kK|K2[LF][0H-
— K„bs — 1+K|[0H-1 + K'K-[LF1[0H-
(6) 
(7) 
Equation 7 is consistent with the observed orders with 
respect to different species, which can be verified by 
rearranging to Eq. 8. 
1 I I 
Kob! k K|K2[LF][0H- • + K|K2[LF]^K (8) 
According to Eq. (8), other conditions being constant, 
plots of l//:„bs versus 1/[LF] and llkot,s versus 1/[0H~] 
should be linear (Figs. 4 and 5). The slopes and intercepts 
of such plots lead to the values of K,, Kj and k (Table 3). 
With these values, the rate constants were calculated under 
different experimental conditions, and there is a reasonable 
agreement between the calculated and experimental 
values [36] (Table 1). The thermodynamic quantities for 
the first and .second equilibrium steps of Scheme 2 can be 
evaluated. The [LF] and [OH"] (as in Table 1) were varied 
at four different temperatures. Van't Hoff s plots of \ogK\ 
versus 1/7 and log/f? versus Ml gave the values of 
enthalpy of reaction AH**, entropy of reaction AS** and free 
energy of reaction AG, calculated for the first, and second 
Fig. 
l/ll>| 10 (dm mol ) 
4 Plots of 1/*:^ ^ versus 1/[LF] at four different temperatures 
c 
1/fOHl iO-'(drn'inole''j 
Fig. 5 Plots of Mk,^ versus l/[OH ] at four different temperatures 
equilibrium steps (Table 3). A comparison of the latter 
values (from K2) with those obtained for the slow step of 
the reaction shows that they mainly refer to the rate-
limiting step, supporting the fact that the reaction before 
the rate determining step is fairly fast and involves low 
activation energy [37, 38]. The moderate values of AH* 
and AS** were both favorable for electron transfer pro-
cesses. The value of AS** that is within the expected range 
for radical reactions has been ascribed to the nature of 
electron pairing and unpairing processes and the loss of 
degrees of freedom formerly available to the reactants upon 
the formation of a rigid transition state [39], The negative 
value of AS* indicates that complex (C) is more ordered 
than the reactants [40,41 ]. The enthalpy of activation and a 
relatively low value of the entropy and a higher rate 
constant of the slow step indicate that the oxidation most 
probably occurs via inner-sphere mechanism [42, 43] 
Conclusion 
It is noteworthy that the oxidant species [Mn04~] required 
the pH 12. below which the system gets disturbed and the 
reaction proceeds further to give a inore reduced of Mn(IV) 
product, which slowly develops yellow turbidity. In this 
reaction, the role of pH is crucial. The rate constant of the 
slowest step and other equilibrium constants involved in 
the mechanism were evaluated and activation parameters 
with respect to the slowest step were computed. The pro-
posed mechanism is consistent with product, mechanistic 
and kinetic studies. 
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5fl ^ 1 <'M i t 4 ^ ^ ^ i 5]- ^ ^^ tf. Ca'* < Mg'' < Co'' < Ni'^  < Zn'^  < Mn'" < Cu'^  < Fe-'\ 
^A0\: CFP; ^7j-2.7j-; ov^jjt AJ-^. iV^fl^^j. CHEF 
ABSTRACT. Spectrophotometric investigation of the interaction of Cefpodoxime proxetil (CFP) with Ca'*, 
Mg'*, Mn'*, Fe'*, Co'*, Ni'*, Cu'* and Zn"* in acidic medium showed the formation of 1:1 complex. The ab-
sorption spectrum of pure drug exhibits two prominent peaks at 270 and 345 nm. Its spectra scanned at several 
pH exhibited two isosbestic points (305 and 330 nm) indicating the presence of zwitterionic condition of drug 
in solution phase. The fluorescence emission spectra of CFP in presence of different concentrations of metal 
ions showed enhancement in fluorescence intensity which is ascribed to chelating enhancement fluorescence 
effect (CHEF). The stoichiometry of the complexes was determined by Job's and Benesi-Hildebrand method. 
The stability of the complexes follow the order Ca'''< Mg'*< Co''< Ni'*< Zn'"< Mn'"< Cu'*< Fe'". 
Keywords: CFP, Fluorescence enhancement. Stability constant. Complex formation, CHEF 
INTRODUCTION 
Cefpodoxime proxetil (CFP) is a semisynthetic 
p-lactum antibiotic known as (RS)-l(isopropox-
ycarbonyloxy) ethyl (+)-(6R, 7R)-7-[2-(2-amino-
4-thiazolyl)-2-{(Z) methoxyimino} acetamido]-
3-methoxymethy l-8-oxo-5-thia- i -azabicycio 
[4.2.0] oct-2-ene-2-carboxylate. It is an ester pro-
drug of cefpodoxime acid where a proxetil radical 
is attached to cefijodoxime acid {Fig. 1). It is the 
third generation cephalosporin ester, used in the 
treatment of upper respiratory tract and urinary 
tract infection. In biological system cefpodoxime 
undergoes ester hydrolysis and converted into cef-
podoxime acid to exhibit its antibiotic activity.'" It 
has an asymmetric carbon at position 4 and is sup-
plied as racemic mixture of R and S-enantiomers. 
Only a few methods are reported to quantify 
152-
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F/g. 1. Structure Cefpodoxime Proxetil (CFP). 
CFP,^ '" nevertheless the analytical methods of de-
tection of CFP are handful, and they employ RP-
HPLC. These methods are based on separation of 
the R- and S-isomers.' However, both the isomers 
are reported to exhibit similar biological activity, 
the use of highly sophisticated and time-consum-
ing methods is not always required for routine 
analysis of CFP from the different dosage forms. 
The discovery of cephalosporin from C.acrem-
onium culture by Brotzu* and demonstration of its 
remarkable stability towards aqueous solution 
even at pH 2 as well as its excellent in vitro activity 
against penicillin-resistant organisms by Abraham 
and Newton,' were major breakthroughs in the 
history of p-lactam antibiotics. The realization that 
fungi might be a good source for novel antibiotics 
spurred microbiologists to develop novel soil-
screening programmes for the investigation of mi-
crobial culture leading to the discovery of several 
non-classical P-lactams like carbapenem and 
oxacephems. The reactivity of P-lactam anti-
biotics is fundamentally linked to antimicrobial 
activity, it led Woodward to design and synthe-
size carbapenem group of compounds for evalua-
tion of their antibacterial activity through system-
atic screening of the soil microorganism. Numerous 
of these compounds show broad-spectrum anti-
microbial activity as predicted earlier and it was 
further substantiated by the subsequent discovery 
of thienamycin. It is unstable in its pure form and 
hence its derivatives are used which also led to the 
introduction of imipenem, which is regarded as 
one of the most effective drugs among the P-lactam 
antibiotics. Although several methods have been 
developed to determine the drug in biological flu-
ids and pharmaceutical preparations no effort 
seems to have been made to investigate the inter-
action of the drug with metal ions. 
In the present work an earnest effort has been 
made to study the interaction of the CFP with met-
al ions by fluorescence emission and absorption 
spectrophotometric measurements. Since quench-
ing or enhancement in fluorescence intensity of 
the drug in presence of metal ions occurs, the spec-
tra of the drug in presence of different concen-
trations of metal ions such as Ca'\ Mg"*, Mn ', 
Fe^ *, Co^ "^ , Ni^ *, Cu^ ,^ and Zn^*were scanned. The 
ratio of the drug to metal ions was determined by 
Job's method and Benesi-Hildebrand methods. ' 
The absorption spectra of the drug in the pH range 
2.32-11.50 were run to see the zwitterionic con-
dition, apparent ionization constant and the iso-
sbestic point which indicate the presence of differ-
ent species in solution. The stability constant of 
the complexes formed between the drug and metal 
Table 1. Stability constant and other thermodynamic parameters of CFP complexes (Job's method) 
Metal • 
Ca^^ 
Mg^^ 
Mn^^ 
Fe^* 
Co'^ 
Ni^ ^ 
Cu^^ 
Zn^^ 
logK 
25 X 
5.600 
5.915 
6.200 
6.287 
5.983 
6.130 
6.211 
6.184 
2009. yol. 53. No. 2 
35 °C 
5.846 
6.044 
6.289 
6.356 
6.122 
6.276 
6.315 
6.297 
Gibbs energy change 
(-AG)(y.mor') 
31.95 
33.75 
35.38 
35.87 
34.13 
34.97 
35.44 
35.28 
Enthalpy change 
(AH) (J.mof') 
270.22 
164.93 
49.97 
260.34 
244.95 
178.43 
240,25 
190.29 
Entropy change 
(AS) (J.mof' K ' ) 
108.13 
113.82 
118.91 
121.22 
115.38 
117.97 
119.93 
119.04 
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Table 2. Stability constant, Gibbs energy change of 
CFP copfiplexes (Benesi-Hildebrand method) at 25 "C 
Metal 
Ca^ ^ 
Mg^ ^ 
Mn'* 
Fe'^ 
Co'' 
Ni^ ^ 
/^ 2+ 
Cu 
•7 2+ 
Zn 
logK 
6.854 
6.869 
6.886 
6.919 
6.883 
6.884 
6.896 
6.889 
Gibbs energy change 
(-AG) (kJ.mol') 
39.11 
39.19 
39.29 
39.48 
39.27 
39.28 
39.34 
39.30 
R-
0.9843 
0.9784 
0.9769 
0.9914 
0.9807 
0.9845 
0.9668 
0.9706 
ion was also evaluated. 
EXPERIMENTAL 
nm. The ratio of metal to CFP was determined by 
Job's method. The linearity of CFP was found in 
the range 2x10' to 6x|0" mg/mi and the correla-
tion factor (R )^ 0.9236. 
Fluorescence study 
Solution of the CFP (TxjO'" M) and those of 
metal ions (I x 10"^  to 7x 10"^  M) were prepared. To 
prepare dilute solutions, an aliquot of stock sol-
ution was placed in a 10 ml volumetric flask and 
made up to the mark with distilled water. Spectra 
were recorded immediately after sample prepara-
tion in the optimum wavelength range 370-430 nm 
at optimum excitation wavelength of 335 nm. For 
calibration curve an aliquot of stock solution 
(1x10 to3xlO' mg/ml) was prepared which showed 
linearity with correlation factor (R") 0.9652 
Instruments 
The absorption spectra were obtained with 
Elico-SL-169 double beam UV-visible spectro-
photometer. Fluorescence emission spectra were 
scanned with Hitachi-F-2500FL-spetrophotometer. 
All potentiometric measurements were done with 
Elico-LI-120pH meter. 
Methods and materials 
Double distilled water was used throughout 
Cefpodoxime proxetil (Lupin pharmaceutical Ltd, 
India), sodium hydroxide and metal chloride 
(Merck Ltd, Mumbai, India) and HCl (Ranbaxy 
fine chem. Ltd, India) were used as received. 
Preparation of solution 
Stock solution of Cefpodoxime proxetil and 
metal salts of 1 x 10"^  M were prepared in 1 x 10" M 
HCl. Stock solution of drug was stored at 4 "C. 
Spectrophotometric method 
Solutions of equimolar concentration (IxlO"* 
M) of CFP and metal ions were prepared. The pH 
of the drug was adjusted between 2.32 to 11.50 by 
adding sodium hydroxide and hydrochloric acid 
(1X10"' M and 1 X10"^  M respectively). The absorp-
tion spectra were recorded in the range 250-380 
RESULTS AND DISCUSSION 
Spectrophotometric study 
The absorption spectrum of CFP (JxiO"' M) 
was run in the region 250-380 nm. It exhibited two 
peaks at 270 and 345 nm (Fig. 2). Since the first 
peak is very strong it was selected for further ab-
sorption studies. 
When the spectra of the drug were run at vary-
ing pH in the region 250-380 nm two isosbestic 
points, one at 305 nm and another at 330 nm were 
observed which indicated the presence of zwitter 
ionic condition in solution (Fig. 3).'" The appa-
250 270 290 310 330 350 370 
Wavelength (nm) 
Fig. 2. Absorption spectrum of CFP(I xio"" M)at pH 
5.15. 
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Fig. 3. Absorption Spectra of CFP(1>:10"'M) in (2.32-
11.50) pH range. 
rent ionization constant (pKa') of the drug was cal-
culated (8.92) by the following equation. 
pKa' = pH+log{(A,-AM)/(A-AM)} (1) 
where, Ai = absorbance of drug in basic medium, 
AM = absorbance of drug in acidic medium, A= 
absorbance of drug in aqueous medium. 
The absorption spectra corresponding to the 
metal, drug and complexes were obtained in acidic 
medium. The concentration of cations and drug 
A 
(CFP) were 1x10" M. The stoichiometry of the 
complexes was obtained by Job's methods'^'" a 
sample of resulting plots is shown in Fig. 4. The 
stability constant of chelate formed is calculated 
by following equation 
K A/A. Cv ( C ^ - A / A „ C J ( C , - A / A „ C , ) (2) 
where, K is the stability constant of the metal che-
late formed in the solution, M = metal, L = ligand, 
X = mole fraction of the ligand at maximum 
absorption. A/Aex is the ratio of the absorbance to 
that indicated by the tangent for the same wavelength. 
Cx, CM and CL are the limiting concentration of 
complex, metal ion and the drug respectively. 
The stability constant is related to the standard 
enthalpy changes AH and other thermodynamic 
function by the equation: 
AG = -2.303RTIogK = AH-TAS (3) 
where R is the gas constant T is the experimental 
I" 
It It J l}.4 KM Itjl I It li.2 lU 0./. liji } 
Mofcrn ic i io i io rCFP Molcfn ic i io i i ofCFP 
-2'- C 
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0 (1.2 (I.-I VIA O.X 1 
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Fig. 4. Continuous variation curves of CFP and metal 
complexes. 
temperature, K is the binding constant at the corre-
sponding temperature. 
From the value of stability constant at different 
temperature the enthalpy changes can be calcu-
lated by using the equation: 
LogKj/K, = [l/Ti-in~2]AH/2.303R (4) 
The negative value of AG for the complexation 
process suggests spontaneous nature of such 
process. ' The positive value of AH suggests 
that these processes are endothermic and are fa-
vourable at higher temperature. Also it is entropi-
cally favourable. The positive value of H and S in-
dicates that hydrophobic force may play a major 
2009, Vol. 53. No. 2 
156 K.S. Siddiqi. Ayaz Mohd, Aftab Aslam Parwaz Khan. Shaista Bano 
fig. 5. Mechanism of binding of CFP with metal ions: 
A. CFP, B. CFP-metal complex, C hydrolyzed form of 
complex. 
role in the interaction.'^ It is reasonable to think, 
on the basis of these results that the metal ions 
form a five membered chelate ring with CFP. 
~ 
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Fig. 6. Fluorescence enhancement (at X^x 335nm) of 
CFP in presence of metal ions. 
Fluorescence study 
The fluorescence emission spectrum of the pure 
drug is markedly different from its absorption 
spectrum in UV region. The emission spectrum 
run between 350-450 nm at excitation wavelength 
of 335 nm showed a peak at 400 nm. The addition 
of metal ions to the drug causes enhancement or 
quenching in the fluorescence spectrum. We have 
noted an enhancement in fluorescence intensity at 
400 nm in each case (Ca *, Mg *, Mn \ Fe''*, Co^  , 
Ni^ *, Cu^ * and Zn^ *) {Fig. 6) although the shape 
and position of emission spectrum remains 
unchanged. 
The stoichiometry and stability constant of the 
complexes was determined by Benesi-Hildbrand 
method. The Benesi-HiJdebrand pJots M^Qxe ex-
amine to further characterize the stoichiometry of 
the CFP-metal complexes. In case of a 1:1 com-
plex, the following equation is applicable: 
1/F-Fo = l/(F„- Fo)K [Me]„ + l/(F„- Fo) (6) 
In this approach, a graph of !/(F - Fo) versus 
l/[Me]o, was made where F is the observed fluo-
rescence at each concentration tested, Fo is the flu-
orescence intensity of anaiyte in the absence of 
metal ion, F, is the maximum fluorescence in-
tensity in presence of metal ions and [Mejo is the 
concentration of metal ion. A linear plot is re-
quired for this double reciprocal plot in order to 
conclude 1:1 stoichiometry. In such cases, a linear 
relationship has to be obtained when 1/(F - Fo) 
versus l/fMe]o is plotted. The stability constant is 
determined by dividing the intercept by the slope 
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of the straight line obtained in the double-recip-
rocal plot. {Fig. 1) 
as a visible emission. 
The reason of this enhancement lies in strong 
perturbation of the excited state upon coordination 
of the metal ion. A low lying internal charge trans-
fer state due to the presence of electron donor and 
acceptor group in the CFP is the lowest excited 
state, this state is however, a less emitting state and 
in equilibrium with the 7i-7t excited state of the 
molecule, upon coordination with metal cation the 
PCT interaction becomes weaker since the elec-
tron withdrawing group is now electron rich moi-
ety due to the deprotonation o f - N H group neces-
sary for coordination of metal cation. 
In the present work, an attempt has been made to 
study the interaction of the CFP with metal ions by 
fluorescence emission, absorption spectrophoto-
metric and measurements. Since enhancement in 
fluorescence intensity o f the CFP in presence of 
the metal ions occurs, the spectra of the drug in 
presence of different concentrations of several 
metal ions were scanned. The ratio of the drug to 
metal ions was determined by Job's and Benesi-
Hildbrand method. The absorption spectra o f the 
CFP was run at different pH to see the zwitterionic 
condition, apparent ionization constant and the 
isosbestic point indicating the presence of differ-
ent species in solution. The stability constant of 
the complex formed between the drug and metal 
ion was also evaluated. 
Influence of metal ion concentrations 
The influence of metal ions concentration was 
studied in the range of 1 x 10"*-l Ox 10"^  M. The flu-
orescence study of interaction CFP with metal 
ions in acidic aqueous medium showed 1:1 
stoichiometry. Both these study also support the 
formation of 1:1 CFP:Metal complex, with the 
possibility of metal ions chelating with CFP by p-
actum carbonyl carbon and acidamide nitrogen. 
In general, the phenomenon of enhancement is 
observed because the complexation by cations 
causes increase in the redox potential of the donor 
so that the relevant HOMO energy decreases to a 
level lower than that of fluorophore. Consequently 
the excited state energy of fluorophore is dumped 
CONCLUSION 
In this paper the nature and magnitude of the in-
teraction of CFP with biologically important metal 
ion was investigated by fluorescence spectra and 
UV spectra. The experimental result indicated the 
formation of I :l complex of CFP with metal ions 
in acidic medium by Job's and Benesi-Hildbrand 
method. The absorption spectra at different pH 
showed the presence of two isosbestic point in-
dicating the existence of zwitterionic condition. 
The thermodynamic parameters showed that the 
interaction between CFP and metal ion was spon-
taneous, and that the hydrophobic force was a ma-
jor factor in the interaction. 
2009, Vol. 53. No. 2 
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ABSTRACT. A Kitietics pathway of oxidation of Cefpodoxime Proxetil by permanganate in alkaline medium 
at a constant ionic strength has been studied spectrophotometrically. The reaction showed first order kinetics in 
permanganate ion concentration and an order less than unity in cefpodoxime acid and alkali concentrations. 
Increasing ionic strength of the medium increase the rate. The oxidation reaction proceeds via an 
alkali-permanganate species which forms a complex with cefpodoxime acid. The latter decomposes slowly, 
followed by a fast reaction between a free radical of cefpodoxime acid and another molecule of permanganate 
to give the products. Investigations of the reaction at different temperatures allowed the determination of 
activation parameters with respect to the slow step of proposed mechanism and fallows first order kinetics. The 
proposed mechanism and the derived rate laws are consistent with the observed kinetics. 
Keywords: Cepfodoxime proxetil. Permanganate, Kinetics, Themodynamics 
BSTRODUCTION thiazol-4-yl)-2-methoxyiminoacetamido]-3-meth 
oxymethyl-3-cephem-4-carboxylic acid) (Fig. 1). 
Cefpodoxime proxetil (CFP) is one of the several CFP is an ester prodrug of Cefpodoxime acid (CFA), 
new cephems administered orally as inactive esters where a proxetil radical is attached to CFA. It is an 
of the antibiotic Cefpodoxime. It is (l-[isopropoxy- orally absorbed, broad spectrum, third generation 
carbonyl)oxy] ethyl ester of (z)-7-[2-(2-amino-1,3- cephalosporin ester implicated in the treatment of 
-709-
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;', 
Fig. 1. Structure of Cefpodoxime Proxetil (CFP). 
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F/g. 2. Degradation Pathway of Cefix)doxime Proxetil to 
Cefpodoxime acid. 
tron reduction followed by a quick reaction. In 
this paper a simple and sensitive kinetic spectropho-
tometric method has been developed to establish 
the thermodynamic parameters of Cepfodoxime 
acid. The method is based on the oxidation of the 
drug by permanganate in alkaline medium. The 
present studies is aimed at checking the reactivity 
of CFA toward permanganate, at determining the 
redox chemistry of the Mn(VII) in such media, and 
at arriving at a plausible mechanism. 
EXPERIMENTAL 
Apparatus 
AShimadzuUV-visible 1601 spectrophotometer 
was used for all spectral measurements, pH-metric 
measurements were done with Elico-Ll 120 pH 
meter and a water bath shaker NSW 133, India was 
used to control the temperature. 
upper respiratory tract and urinary tract infections. 
In the biological system, CFP undergoes ester hy-
drolysis and is converted into CFA to exhibit its 
antibiotic activity.'"^ CFP has an asymmetric carbon 
at position 4 and is supplied as racemic mixture of 
R- and S-enantiomers. Few methods are reported 
to quantify CFA. '* The P-lactum antibiotic is known 
to degrade by hydrolysis in alkaline solution {Fig. 
2). Hydrogen peroxide is used for degradation 
study in the development of pharmaceuticals. The 
HCI, NaOH, NH2OH and H2O2 at appropriate con-
centration were evaluated as degradation agents 
for cleaning or decontamination.' Permanganate ion 
oxidizes a larger variety of substrate and finds ex-
tensive application in organic synthesis.^"'^ During 
oxidation permanganate is reduced to various oxi-
dation states in acidic, alkaline and neutral media. 
The mechanism of oxidation depends on the sub-
strate and medium.'^ The process Mn(Vll) to Mn(I V) 
can be divided into a number of partial steps and 
examined discretely. The MnCh appears only a after 
the complete consumption of Mn04'. No mechanistic 
information is available to distinguish between a 
direct one-electron reduction of Mn(Vn) to Mn(VI) 
or a hypopermanganate ion is formed in a two-elec-
Materials 
The Cepfodoxime Proxetil was obtained from 
(Lupin pharmaceutical Ltd. India). Pharmaceutical 
preparations containing the studied compounds 
were purchased from commercial sources in the local 
market. The permanganate solution was prepared 
and standardized against oxalic acid. Potassium 
permanganate solution was prepared as described 
by Carrington and Symons." NaOH (Merck Ltd, 
Mumbai, India) and NaCI04 (Ranbaxy fine chem. 
Ltd, India) were employed to maintain the required 
alkalinity and ionic strength, respectively. 
Reagents 
Double distilled, de-ionized water was used th-
roughout. The chemicals u.sed were of analytical 
grade. Stock solutions of the compounds were 
wrapped with carbon paper to protect them from 
photodecomposition. 
Kinetic procedure 
The oxidation of (CFA) by permanganate ion was 
followed under pseudo- first order conditions where 
CFA concentration was greater than manganese 
(VII) at 25 °C. The reaction was initiated by mixing 
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previously thermostated solutions of MnO/ and 
(CFA), which also contained required quantities of 
NaOH and NaCI04 to maintain alkaline medium 
and ionic strength, respectively. The temperature 
was maintained at 25 °C: The reaction was moni-
tored by a the decrease in absorbance of Mn04, at 
its absorption maximum of 525 nm. Earlier it was 
verified that there is no interference from other 
reagents at this wavelength. Application officer's 
Law for permanganate at 525 nm had earlier been 
verified, giving e, was found to be 2083 ± 50 dm 
mof' cm'. The reaction was followed more than 
three half lives The first order rate constants kobs 
were evaluated by plots of log [Mn04] vs. time. 
The first order plots in almost all cases were linear 
up to 85% of the reaction and kobs were reproducible 
at 525 nm and an increasing absorbance of Mn(VI) 
at 610 nm during the course of the reaction {Fig. 5). 
The effect of dissolved oxygen on the rate of reac-
tion was checked by preparing the reaction mixture 
and following the reaction in nitrogen atmosphere. 
No significant difference between the results obtain-
ed under nitrogen and in the presence of air was 
observed. Added carbonate had also no eflFect on 
the reaction rate. Regression analysis of experi-
mental data to obtain the regression coefficient r 
and the standard deviation S of points from the 
regression line was performed using a Microsoft 
excel-2007 program. 
RESULTS 
The absorption spectrum of CFP was exhibited 
two peaks at 270 and 345 nm {Fig. 3).'* After addi-
tion of potassium permanganate in the same medium 
is oxidized the (CFA) and exhibits a green colour 
of manganate ion, appears which absorbs at 610 
nm. It was empirically found that the blue colour 
originated from a mixture of violet Mn04' and green 
1.6 
1.41 
a, 1-2 
^ 1 
CD 
•e 0.8 
o 
^ 06 
< 0.4 
0.2 
A 
250 270 350 370 290 310 330 
Wavelength 
Fig. 3. Absorption spectrum of CFP. 
colour Mn04'" rather than form the formation of 
hypopermanganate. The formation of Mn (Vll) was 
also evidence by the decrease of the absorbance of 
Mn(VlI) at 525 nm and the increase of that of Mn( VI) 
at 610 nm during the course of reaction {Fig. 5).The 
intensity of the colour increases with time and hence 
a kinetic method based on the spectrophotometric 
measurement was developed. 
Stoichiometiy of the reaction 
The reaction mixture containing an excess of 
permanganate over (CFA) were mixed in the pre-
sence of 5.0 X i O" mol dm'' NaOH and at constant 
ionic strength / = 0.10 mol dm'' were kept in a 
closed container under a nitrogen atmosphere at 25 
"C. After 1 h the manganese (Vll) concentration 
was assayed by measuring the absorbance at 610 
nm. The results indicated that 2 mols of manganese 
(Vll) consumed 1 mol of (CFA). Therefore, the 
reaction mechanism is proposed on the basis of the 
literature background' and our experimental study 
as shown in eq 1. 
Reaction order 
The reaction order were evaluated from the slope 
of log kobs versus log concentration plots by the 
varying concentration of (CFA) and alkali keeping 
other factors constant. 
y + 2Mn04- + 2 OH" 
HjN 
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Fig. 4. First order plots for the oxidation ofCFA by alka-
line MnO'" at 25 "C; [CFA ] = 1.0 x lO'; [OH-] = 2 x 
10"'; / = 0.10/mol dml [Mn(Vll)] x lO'mol dm'; (1) 
0.6, (2) 0.8, (3) 1.0, (4) 2.0, and (5) 3.0. 
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Fig. 5. Spectral changes during the oxidation of [CFA] by 
alkalineMnO"' at 25 °C; (Mn{VII)] = 1.0 x 10"*, [CFA] = 
1.0x10"' [OH] = 2x10% / = 0.10/mol dm"'. 
Effect of Concentration of Manganese (VII) 
At constant concentration of (CFA), 1.0 x 10"^ mol 
clm"\ and alkali, 5.0 x i O"^  mol dm", and at constant 
ionic strength, 0.10 mo! dm'". The oxidant KMn04 
concentration was varied in the range of 6 x 10"^-
6 X 10 mol dm". All kinetic runs exhibited identical 
characteristics. The linearity of plots of log (absor-
bance) vs time, for different concentrations of per-
manganate, indicates order in manganese(VII) con-
centration as unity {Fig. 4). This was also confirmed 
by the constant values of pseudo first order rate 
constants, o^bs, for different manganese(Vll) con-
centrations {Table i). 
Effect of NaOH Concentration 
The effect of increasing cone of alkali on the 
Table 1. Effect of variation of [KMn04] .[CFA] and 
[OH] on the oxidation of cefpodoxime acid by alkaline 
[KMn04l at 25°C and ionic strength / = 0.10/mol dm ' 
lO'x 
[KMn04] 
mol dm 
10 X [CFA] 
mol dm 
IO-x[OH"] 
mol dm' 
lO'kobs 
(S"') 
JO^kcal 
(S') 
0.6 
0.8 
1.0 
2,0 
3.0 
4.0 
6.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
1.8 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
1.8 
1.08 
1.09 
1.08 
1.07 
1.10 
1.08 
1.09 
0.984 
1.05 
1.06 
1.37 
1.60 
1.72 
1.99 
0.984 
1.03 
1.07 
1.06 
1.60 
1.75 
2,02 
1.09 
1.09 
1.09 
1,09 
1,09 
1,09 
1,09 
0.983 
1.06 
1.07 
1.36 
1.58 
1.73 
1.98 
0.985 
1.04 
1.06 
1.07 
1.59 
1,76 
2.01 
reaction was examined at constant concentration 
of drug and permanaganate ion at 25 °C. The alkali 
concentration was varied in the range of 0.6 x ] 0"" 
to 1.0 X 10"' mol dm" . The A:obs values increased 
with increase in concentration of alkali. 
Effect of ICFAJ 
The effect of (CFA) concentration on the reaction 
was studied at constant concentrations of alkali and 
permanganate and at a constant ionic strength of 
0.10 mol dm'^  at 25 °C. The substrate, (CFA) was 
varied in the range of 5.0 x 10"* - 5.0 x lO""* mol 
dm" . The kobs values increased with increase in 
concentration of (CFA) {Table 1). 
Effect of Ionic Strength 
The effect of ionic strength was studied by vary-
ing the NaCI04 concentration from 0.01 to 0.10 mol 
dm" at constant concentrations of permanganate, 
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(CFA), and alkali. It was found that increasing ionic 
strength had no effect on the rate of reaction. 
Effect of temperature 
The kinetics was studied at four different tem-
peratures under varying concentrations of (CFA), 
and alkali, keeping other conditions constant. The 
rate constants were found to increase with increase 
in temperature. The rate constant (k) of the slow 
step of Scheme 1 were obtained from the slopes 
and intercepts of ]/kobs versus 1/[CFA] and 1/kobs 
versus 1/[0H"] plots at four different temperatures. 
The energy of activation corresponding to these rate 
constants was evaluated from the Arrhenius plot of 
log k versus 1/T and from which other activation 
parameters were obtained {Table 2). 
Polymerization Study 
The possibility of free radicals was examined as 
follows: the reaction mixture, to which a the reaction 
mixture with methanol, precipitate resulted, sugge-
sting that the there was participation of free radicals 
in the reaction. 
DISCUSSION 
At the observe experimental condition at pH > 
12 the reductant product of Mn(Vll) might be stopp-
ed. " Although During our study the colour of the 
solution undergoes a series of change from blue to 
green. It is probable that green color originated from 
the permanganate ion. The spectrum of green solu-
Table 2. Activation and Thermodynamic parameters for 
the oxidation of cefpodoxime acid by KlVln04 in alka-
line medium and / = 0.10/moi dm' with respect to slow 
stepof5c/ieme 1 
Temperature (K) 
(a) Effect of Temperature 
293 
298 
303 
308 
(b) Activation Pramete 
Ea(kj mole') 
AH{kj mole') 
AS* (jk mole ) 
AG* (kj mole') 
Temperature (K) Ki { dm' mo!') 
(c) Effect of Temperature 
293 
298 
303 
308 
Thermodynamic 
Parameters 
AH (kJ mole') 
AS'(jk mole') 
AG*(kj mole') 
15.41 
17.74 
19.55 
21.71 
g Ki values 
76.5 
128 
-5.6 
10^k(S'') 
2.7 
2.9 
4.8 
5.1 
values 
65.4 
61.7 
-120.4 
19.11 
I0"-K;(dm'mor') 
30.14 
26.69 
20.54 
18.76 
using K2 values 
-61.7 
-63.2 
-6.71 
tion was identical to that of Mn04"'. It is probable 
that the blue color originated from the violet of 
permanganate and the green from manganate, ex-
cluding the accumulation of hypomanganate. It is 
evident from the {Fig. 5) that the concentration of 
MnO "decreases at 525 nm due to Mn(VII) and 
increases at 610 nm due to Mn(Vl). As the reaction 
proceeds, slowly yellow turbidity develops, and 
after keeping for a long time the solution decolorizes 
and forms a brown precipitate. This suggests that 
the products formed might have undergone further 
oxidation resulting in a lower oxidation state of 
manganese. The results imply that first the alkali 
combines with permanganate to give an alkali-
permanganate species [Mn04 • OH]'' in a prior 
equilibrium step, which is in accordance with lite-
rature and also experimentally observed order 
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in OH" ion concentration. In the second step [Mn04-
OH]^'combines with CFAto form an intermediate 
complex. The fractional order with respect to CFA 
presumably results from the complex formation 
between oxidant and substrate prior to the slow step. 
The reaction between permanganate and CFA is 
supported by Michaelis-Menten plot which is linear 
with positive intercept which is in agreement with 
complex formation. Within the complex one-elect-
ron is transferred from CFA to Mn(VII). Then this 
complex (C) decomposes in a slow step to form a 
species derived from CFA. All the results indicate 
a mechanism as given in Scheme 1. 
Rate= -^ t '^"°^ l = kKiKzlMnOVHCFAHOH], (2) 
dl 
The total [MnO"*"] can be written as 
[Mn04-]t = [Mn04-]f + [MnOA.OHf-* [Complex] 
= [Mn04],+ [MnO^lOH] +KiK2[Mn04-][CFA][OH] 
= [Mn04), (1+ KiIOH-] + KiK2lCFA][0H]) 
[Mn04-1, 
(3) [Mn04-),= 1+K,[0H-] + KiK2[CFA][0H-] 
where "t" and " f stand for total and free. Si-
milarly, total [OH] can be calculated as 
[OH-], = [OH], + [Mn04.0H]2 + [Complex] 
[OH], (4) 
[0H-], = 
1+ Ki[Mn04] + KiK2[CFA][Mn04-) 
In view of the low concentrations of MnO/ and 
CFA used in the experiment, in eq 4 the terms 
Ki [MUOA] and A:iA:2[Mn04'][CFA] can be neglect-
ed in comparison with unity. 
Thus, 
[OH], = [OH], 
Similarly, 
[CFA], = [UFA], 
(5) 
(6) 
Substituting equation 3, 5, and 6 in equation 2 
and omitting the subscripts, we get 
Rate = 
kKiK2[Mn04l[CFA][OH] 
1+ Ki[OH-] + K,K2[CFA][0H] 
(7) 
Equation 7 confirms all the observed orders with 
respect to different species, which can be verified 
by rearranging to eq 8. 
1 
' ^ (8) kobs kKiK2(CFA](OHl kKjlCFA] k 
According to eq 8, other conditions being con-
stant, plots of l/tobs versus I/[CFA] and I//robs 
versus I/[OH] should be linear and are found to be 
so {Figs 6a and 6b). The slopes and intercepts of 
such plots lead to the values of A^ i,A^ 2. and/: (7ai/e 
2). The value of A^i is in good agreement with the 
literature Using these constants, the rate constants 
were calculated over different experimental condi-
tions, and there is a reasonable agreement between 
the calculated and the experimental values, which 
for the proposed mechanism (Table I). The thermo-
dynamic quantities for the first and second equili-
brium step of Scheme I can be evaluated as follows: 
The [CFA] and [OH'] as in Table i were varied at 
four different temperature. The spectral evidence of 
the complex formation was obtained from U V-Vis 
spectral study."' It is also proved kinetically by the 
non zero intercept of the plots of 1/kobs versus 1/ 
[CFA] (r> 0.9997, S < 0.0148) (f/g. 6b). Accord-
ing to the rate law the plots of I /kobs versus I /[OH"] 
(r > 0.9987, S<0.0124) and \/kobs versus \/[CPA] 
(r > 0.9998, S< 0.0151) should be linear (F/g.s 6a 
and b) from the slope and intercept, the value of k, 
Ki and K2 could be derived as 2.87 x ] 0"^ , 13.8 dm^ 
mole", and 22.36 dm mole" respectively. The rate 
constant were calculated from these values (Table I) 
which supports the proposed mechanism. The re-
action rate of CFA increased with increasing inten-
sity of the complex. The kinetics was studied at four 
different temperature and concentration of CFA and 
MaOH keeping all other conditions constant. The 
rate constant was found to increase with increasing 
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Fig. 6. (a) Rate law plots 1/kobs versus 1/ [OH] of oxi-
dation of cefpodoxime acid by KMn04 in alkaline me-
dium at different temperatures (circumstance as in Table 
I). (b) Rate law plots 1 /kobs versus 1/ [CPP] of oxidation 
of cefpodoxime acid by KMn04 in alkaline medium at 
different temperatures (circumstance as in Table I). 
temperature. The rate constant k of the slow step of 
Scheme I were obtained from the slope and inter-
cept of 1/kobs versus l/[CFA] and I/kobs versus 1/ 
[OH"] plots at four different temperatures. The 
activation parameters corresponding to these con-
stant were evaluated from the Arrhenius plot of log 
k versus 1/T and are listed in Table 2. The experi-
mental value of AH* and AS* were both favorable 
for electron transfer process. The high negative 
value of AS* indicate that interaction of the reaction 
ions of similar charges form an activated complex 
and is more ordered than the reactants due to loss of 
degree of freedom. The hydroxy! ion concentration 
i.e. Table 1 was verified at four different temperature 
and the K| value were determined from a (Fig. 6a) 
as shown in Table 2. Similarly CFA concentration 
as in Table 1 was varied at four different temp and 
Revalues were determined at each temp {Fig. 6b) 
as listed in Table 2. The effect of temp on reaction 
rate is well known and important in the various 
activation parameters of the reaction product. A 
Arrehenius plot was made for the variation of Ki 
with temperature (i.e. logKi versus I AT). The values 
of the enthalpy change of the first equilibrium step 
K| of the reaction (AH), enthalpy of the reaction (AS) 
and free energy of raction (AG) were calculated as 
listed in Table 2. Similarly thermodynamic para-
meters for second step K? are calculated such as 
enthalpy; entropy and free energy of activation of 
the reaction product were calculated using Eyring 
equation. 
Log K/T = [log kb/h + S/2.302R] - AH/2.303R 1 fT 
The plot of log Kj/T versus 1/T was linear with 
correlation coefficient of-0.9996 AH' was evaluated 
from the slope (- AH/ 2.303R 1 /T) and AS* from the 
intercept [log kb/h + S/2.302R] of the compiled 
Eyring plot. The Gibbs free energy of activation 
was determined by AG* = -2.303 RT log K at room 
temperature. These values are given in Table 2.The 
proposed mechanism supported by the above ther-
modynamic parameter. A comparison of the later 
values (from Kj) with those obtained for the slow 
step of the reaction shows that these values mainly 
refer to the rate-limiting step, supporting the fact 
that the reaction before rate determining step is 
fairly fast and involves low activation energy." 
The negative value of indicate that the complex 
(C) is more ordered than the reactant.^ * A detailed 
mechanistic explanafion is given in Scheme 2. 
CONCLUSION 
It is interesting to note that the oxidant species 
[MnO "] required a pH > 12 below which the system 
becomes anxious and the reaction proceeds to 
Mn(IV) which slowly develops yellow turbidity. The 
oxidant, manganese(VII), exists in alkali media as 
alkali-permanganate species [Mn040H]^", which 
takes part in the chemical reaction. The role of 
hydroxy! ions is essential to the chemical reaction. 
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Scheme 2. Mechanistic Interpretation for the Oxidation 
of CFA by Alkaline Permanganate 
The given mechanism is consistent with all the 
experimental evidence. The rate constant of slowest 
step involved in the mechanism are evaluated and 
activation parameters with respect to slowest step 
of reaction were computed. The overall mechanistic 
sequence described here is consistent with the final 
product, mechanistic and kinetic studies. 
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Abstract: Kinetics and mechanism of substitution of cyanide ion in 
hexacyanoferrate(II) by EDTA catalysed by mercury(II) has been studied 
spectrophotometrically at 365 nm in potassium hydrogen phthalate buffer of pH 
= 5.0 and ionic strength, I = 0.1 M, maintained by (KNO;,) at 25 °C. Effect of the 
pH and concentration of the EDTA, [Fe(CN)''"6] on the rate of reaction has been 
studied. The kinetics and mechanism of the reaction has been shown through 
dissociative mechanism. The mechanism of ligand substitution in the complex 
together with the kinetic data has been shown. The catalytic activity of 
mercury(II) has also been studied as a function of its concentration. The 
maximum reaction product was detected at pH = 5 after which a decline in 
absorption occurs followed by precipitation. It is an inexpensive method to 
identify and remove the cyanide ion in solution even in very low concentration of 
the order of 10''M. 
Keyword: Kinetics, Hexacyanoferrate(ll), EDTA, Mercury(ll), Thermodynamics, Mechanism. 
Introduction 
It has been demonstrated that of all the heavy metals mercury(II) easily forms bonds to 
cyanide and slowly removes it from hexacyanoferrate(II). Kinetics and mechanism of ligand 
replacement in low spin Fe(II) complex has been done, although it is limited to the study of 
pentacyano(L)ferrate(II) compIex'"\ Few studies have been done in aqueous electrolyte and 
micellar media to acquire an in depth knowledge of the mechanistic scheme^'^. The 
oxidation kinetics of the hexacyanoferrate(II) complex by various reagents in acidic and 
basic media have been studied and all these investigation have been applied to specific 
analytical problems"^"'l K4[Fe(CN)6'*"] hardly undergoes exchange reaction as CN itself is a 
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very strong ligand although slow exchange of labelled CN' group or aminopyridine has been 
demonstrated. Under UV light reversible aquation occurs leading to the formation'' of 
[Fe(CN)5H20]-^ ". However, only mono substituted [Fe(CN)5L]-^ ' have been obtained either 
through photochemical or by dissociation reaction or by metal catalysed substitution reaction . 
[Fe(CN),'] + H2O >• [Fe(CN)5H20]-•+CN- (1) 
Hexacyanoferrate(ll) reacts with EDTA according to the following equation 
[Fe(CN)5H20]-'- + EDTA >• [ Fe(CN)5EDTA]'- + H.O (2) 
CN- +H2O • HCN + OH (3) 
Mercury(II) readily forms complex with cyanide ion but decomposition occurs in UV 
light. 
Hg'" + [Fe(CN)6'-] + H2O >- [Fe(CN)5H20]'-+ HgCN" (4) 
HgCN^ H" *- HCN + Hg'" (5) 
In the present work, we have studied the kinetics of substitution of CN by EDTA, 
catalysed by Hg"* A probable mechanism of the reaction has been proposed. Any attempt to 
study the substitution of CN' by phenanthroline, pyridine, hydrazine and piperazine resulted 
in precipitation even in low concentration. 
Experimental 
Double distilled, de-ionized water was used throughout. The chemicals used were of analytical 
grade. Stock solutions of the compounds were wrapped with carbon paper to protect them from 
photodecomposition. The mercury(Il) and hexacyanoferrate(II) solutions were diluted just 
before use. The desired pH= 5 of the reaction mixture was maintained by adding KHP-NaOH 
buffer'^ . The ionic strength was maintained at 0.1 M by adding appropriate amount of KNO3 
Apparatus 
The absorption spectra were obtained with double beam UV-vis spectrophotometer (Elico-
SL-I69). pH-metric measurements were done with Elico-LI 120 pH meter. 
Procedure 
All the solutions were thermally equilibrated for about 30 minutes at 25 °C and 2.0 mL of 
each EDTA, phthalate buffer of pH = 5.0 and mercury(II) chloride were mixed in a flask 
and left for 10 min to ensure complete reaction. Finally, 2.0 mL of [Fe(CN)(,]'^ - was added to 
this mixture and the wavelength of maximum absorption (365 nm) was determined (Figure 1). 
Effect of pH 
The reaction was studied first by fixed time kinetic method in the pH ranges 1-13. Figure 2 shows 
plots of absorbance (measured at t =5 and 10 minutes after mixing the reagents) versus pH of the 
reaction mixture. It was found that, with increasing pH the absorbance increases and attains 
a maximum between pH 5.0 to 5.5. However, above this pH the absorption decreases which 
is due to the deficiency of protons. The rate is reduced at low pH value due to the formation 
of various protonated forms of [Fe(CN)6]''- which are less reactive than [Fe(CN)6''"] itself'^ . 
Effect of EDTA 
The complex formation with EDTA is influenced by a change in the pH of solution which is 
perhaps due to ionization of the metal complex at low pH and hydrolysis of the metal ion at 
higher pH. The effect of EDTA was examined as a function of its concentration at a fixed 
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pH 5. A plot of initial rate versus EDTA is shown in Figure 3. Almost constant rate was 
obtained in the concentration range 2x10'^ to 7x10"^ M and finally decrease at still higher 
concentrations. A fixed concentration 4x 10"" M was thus selected as optimum. 
1.5- . C 
200 300 400 
Wavelenth 
500 
Figure 1. Absorption spectra of reactants and products: (A) [EDTA] = IXIO ; (B) [Fe(CN)6] 
= 5X10""M (C) [Fe(CN)6f = 4 X 1 0 ' M , [EDTA] = 4X10'' M, [Hg'l = 3X10'^  M and pH = 5.0 
6 
pH 
11 16 
Figure 2, Effect of pH on Hg-"^  catalysed substitution of CN in hexacyanoferrate(II) by 
EDTA ion at [FeCCN)^'] = 5X10-' M, EDTA = SXlO"' M, [Hg'l = 3X10^ M, Temp = 25 "C 
and I = 0.1 MCKNOj). 
10 
9 
U) 
> 
0 5 10 15 20 
[EDTA], M 
Figure 3. Effect of EDTA on initial rate at [Fe(CN)6"] = 3.5X10"'M, [Hg^l = 3x10"' M 
pH = 5, Temp =25 "C and I = 0.1 M (KNO3) 
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Effect of[Fe(CN)f,f' on the initial rate 
Dependence in fFe(CN)6"'"] was found, changing from first order at lower concentration to 
higher concentration not zeroth order. Keeping all parameters constant, effect of the 
concentration of [Fe(CN)6''"] on the reaction rate was studied in the concentration range 
5x10'" to 2x10"^ M, Figure 4.A variable order . 
0 
C\J CM C\J 
-log[Fe (CN)6l 
Figure 4. Dependence of the initial rate on [Fe(CN)6 ] in presence of [Hg""^ ] at [EDTA] 
3X10'"M, [Hg-1 = 3x10 ^ M, pH 5.0, temp = 25 "C and 0.2 M (KNO;,). 
Effect of [Hg^*] on initial rate 
The concentration of mercury(II) was kept between 1x10''' to 2X10'"'M and those of the 
[FeCCN)^ '' ] and EDTA were kept constant. The pH and temperature were maintained at 5 
and 25 °C respectively. The results are shown in Figure 5. The large variation in [Hg'*] was 
selected in order to test the linearity between initial rate and [Hg"*] for its analytical 
application and also the changing role in [Hg"*] mixture. A plot of the absorbance measured 
after an interval of one min versus [Hg^*] as a function of pH is given in Figure 5. 
1.25 n 
jr 0.65 
1 21 26 6 11 16 
[HgOj], M 
Figure 5. Dependence of the initial rate of substitution of CN' in [FeCCN)^ " ] by EDTA on 
[HgCb] at [FeCCNV/'] =3.5x10'^ M, [EDTA] = 3x10'" M, pH = 5, temp = 25 V and I = 
0.1 MIKNO,). 
It clearly indicates that the rate increases linearly until the ratio of the [Fe(CN)ft'* ] and [Hg^ ]^ 
reaches 1:1 .When the concentration of [Hg^^ ] exceeds that of [FeCCNOe"*"] the absorption begins to 
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decrease and follows a non-linear pattern. The intercept computed from the initial linear 
portion of the Figure 5 provides the rate due to the uncatalyzed path. However, decline in the 
rate of reaction at higher [Hg^*] is probably due to the formation of a binary adduct, 
[Fe(CN)6'*". HgCl2]. In a separate experiment it was observed that a white precipitate is 
formed immediately after mixing [Fe(CN)6 '] with [Hg^*] in 1:2 molar ratio which rapidly 
turned blue, confirming the formation of a binuclear complex. A similar observation has also 
been made by Beck . 
Ejfect of temperature and ionic strength 
The rate of the [Hg"*] catalyzed ligand exchange between [Fe(CN)(,* ] and EDTA was 
studied as a function of temperature in range 20-30 "C. The higher temperature was 
avoided due to the possibility of decomposition of [Fe(CN)"iEDTA]^. The Arrhenius 
equation was used to determine the activation energy (Ea) for the catalyzed reaction and 
the other activation parameters, viz. enthalpy of activation (AH") and entropy of activation 
(AS^) were calculated using Eyring equation. The values of activation parameters are 
found to be Ea = 78.2 kJ mol"', AS* = -48.67 JK"' mole"' and AH* = -52.5 kJ mole'.The 
effect of ionic strength on the initial rate of reaction was also studied employing (KNO3) 
for maintaining ionic strength in the 0.015 to 0.2 M range. The higher ionic strength was 
avoided due to the limited solubility of (KNO3). When KCl was used to maintain the ionic 
strength the rate was found to decrease considerably. This is probably due to a subsequent 
decrease in [Hg *] or [HgCr] along with the concentration of an ion-pair formation 
between [Fe(CN)6*'] and [Hg^^'^ 
Results and Discussion 
The following Scheme for the mercury(Il) catalyzed ligand exchange between [Fe(CN)6''"] 
and EDTA has been proposed: 
[Fe(CN)6]J-+Hg^* + H jO-*^ ^ [Fe(CN)6^- (Hg 2+x H2O ) (6) 
X N H g 
(CNOsFe-' 
-HgCN k2 (slow) 
3-[Fe(CN)5H20] 
-H2O 
Fast ,, K3 
[Fe(CN)5EDTA] 
+EDTA 
3-
(7) 
(8) 
(9) 
(10) 
H g C N % H \ Hg^-" + H C N (11) 
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Formation of the complex, [Fe(CN)5EDTA]^' through the catalyzed path can be written as: 
d [ Fe(CN)5EDTA]^ 
dt K2 [Al 
(12) 
While, that for the uncatalyzed path the 
rate = k'[Fe(CN)6'] (13) 
where, k' is a composite rate constant involving a concentration term. If the rate 
determining step is taken to be the composition of the activated complex (A'), the activity of 
the mercury(II) at low concentration can be easily explained by the above mechanism. The 
overall rate for uncatalyzed reaction can be expressed through equation (13) using a non 
limiting concentration of EDTA. 
Rate = 
d [Fe(CN)5EDTA]''' 
dt 
= k'[Fe(CN)fi'-] + k^ K [Fe(CN)e,'-][Hg-1[H20] 
l+KtFelCN),-*! 
(14) 
The second term in the above equation refers to the rate of the catalyzed reaction and 
explains the variable order dependence in [Fe(CN)6"]. K is defined as the equilibrium 
constant for the association of the mercury (II) with water and [Fe(CN)6'' ]. Since water is in 
a large excess, the equation (14) is reduced to equation (15) 
Rate = k'[Fe(CN)6'"] + k'2K[Hg-1[Fe(CN)6'-] (15) 
Now equation (15) yields the observed rate constant (kobs) as expressed by equation (16) 
k„bs = k'+k'2K[Hg'l (16) 
where, k'2 = k2+ [H2O]. 
A plot of the initial rate versus [Hg"*] at low [Fe(CN)(s'' ] is given in Figure 6. In case of 
higher [Fe(CN)(,'*'], equation (14) takes the form of equation (17). 
Rate = k' [Fe(CN)(,'] + k.'lHg-^ (17) 
15 
CO 
10 
Hg^ ^ 
Figure 6. [Fe(CN)6'-] = 8x10^ M, [EDTA] = SXlO"^  M, pH = 5, temp. = 25 "C, I = 0.1 M (KNO3). 
The value of the initial rate (V|) as a function of [Hg^ ^^ ] at low [Fe(CN)(,''"] is listed in 
Table 1. The value of the k' and k{ have been calculated from the plot Figure 6 of initial rate 
versus [Hg^"] using equation (17) at specified experimental condition. The rate constant k' and 
k2 are found to be 4.17x10"^ s"' and 2.50 ,s' respectively, at I = 0.1 M, pH = 5, temp - 25 °C 
.The value of ki' and k2S0 obtained are substituted in equation (17) to evaluate the equilibrium 
constant K at various [Hg"*] at low [Fe(CN)6''"]. The K (Table 1) and the average value of 
log K (2.80) in our case is comparable with that reported by Beck for |Fe(CN)(,'' . Hg(CN)2] 
complex (logK = 2.38)'^. Although the values of kj have been calculated employing high 
[Fe(CN)6''"] using equation (17) it can be obtained even at low [Fe(CN)(,'' ] using equation (18) 
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Table 1. Calculation of K by varying [Hg'l at constant [FeCCN)^ ""]. [Fe(CN)6' ] = 8xlO' M, 
[Hg^l = 5X10'- M, pH = 5, temp= 25 "C and I = 0.1 M (KNO3), 
[Hg^1xlO' ,M VixlO^ 
2 3.5 
4 5.9 
6 7.9 
8 10.6 
10 12.6 
Average log K =2.80 
k,- Rate-kTFe(CN).''"l 
K(calcd.) 
709.07 
660.02 
610.60 
625.80 
601.80 
(18) 
K[Fe(CN)e,'-l fHg'l fH.Oj 
However, the values calculated from this equation are almost identical. The ionic 
behavior of [Hg"*] may be represented by the following reactions. 
Hg2^  + Ci ^ = ^ HgCr (19) 
HgCr +Cf ^ ^ * = ^ HgCl2 (20) 
It has been shown that when Hg(N03)2 reacts with [Fe(CN)6''"] in solution the resultant 
was Hg2[Fe(CN)(i'*"]' , which has also been verified from the absorption spectra of both the 
reacting components and the eventual product. This is quite obvious because the [Hg""^ ] is 
more electropositive than K"" ion. The activation energy calculated for this reaction is a little 
less than the reported values in the literature'^ "'^ ' for the replacement of CN in nearly similar 
reaction systems. The entropy of activation is negative and is expected if the virtual 
solvations of the activated complex and its highly charged dissociation products are 
considered. Thus, the activation parameters provide further support to the proposed 
mechanism. 
Conclusion 
In the present work we have studied the kinetics of substitution of CN' by EDTA catalyzed 
with [Hg^"]. A probable mechanism of the reaction has been proposed. The results presented 
here clearly demonstrate work, EDTA as a chelating agent was used for the neutralization of 
CN" in complex formation which is more effective and inexpensive. The values of 
thermodynamic parameters for complex formation are found to be Ea = 78.2 kJ mol', AS*" = 
-48.67 JK"' mole"' and AH'' = -52.5 kJ mole"'. The negative value of shows the exothermic 
nature of reaction. 
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Binding Constant: Fluorescence Quenching of 
Ciprofloxacin with Fe(III) and Zn(II) 
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Absorbaiice and fluorescence spectral pattern of ciprot'io,xncin in 
absence and presence ol' Fe(IlI) and Zn(ll) has been studied at room 
temperature and under physiological condition. The I'luorescence s|3cctra 
of the drug in presence of the different ciuantities and different concen-
trations of the Fe( 111) and Zn( ID showed the quenching ol ciprolloxacm. 
It was observed that with increasing quantity of the quencher the einission 
intensity decreases with negligible variation in the peak position. The 
absorption spectra of the drug at different pH exhibits two isosbestic 
points at 320 and 350 nm indicating the presence of ih?ee chemical 
species in solution. The ratio of the two reacting components, the drug 
and the metal ions was detennined by absorption and fluorescence spectro-
photometrically. 
Key Words: Ciprofloxacin, HCI, Fluorescence quenching. Binding 
constant. Stability constant. 
INTRODUCTION 
Ciprofloxacin is [l-cyclopropyl-6-nuoro-L4-dihydfo-4-oxo-7-(piperazinyl)-
quinolone-3-carboxylic acid] one of the fluoioquinolones used as broad spectrum 
drug against gram positive and gram negative bacteria. It has been found that liie 
activity of quinoione drugs is completely lost if consumed with atitacids containing 
aluminum or magnesium because the drug is neutralized. At higher pH precipitation 
occurs and the drug is made unavailable for absorption' ^ The mechatiism of inter-
action of quinoione with metal ions is based on the chelation of the metal with the 
carbonyl and carboxyl groups of the drug (Fig. I). The antibacterial activity of the 
drug has also been found to be reduced manifold after chelation' of the metal ions 
via these groups. 
Fig. I. Structure of ciproflo.xacin 
1958 Siddiqi (•;«/. Asian J. Clu-ni. 
The interaction of fluoroquinolones with metal ions has attracted considerable 
interest not only for the development of analytical techniques but also to provide 
information about the mechanism of action of the pharmaceutical preparation*". 
Since the metal ions cause fluorescence quenching of the dioig, spectrofluorimetric 
method for quantitative determination of the quinolone type drugs has been devel-
oped^* besides titrimetric" spectrophotometeric'", electrochemical", electrophoretic'-
and chromatographic'^ techniques. 
The maximum solubility ofthe ciprofloxacin has been reported at 37 "C. which 
al.so happens to be the normal temperature of human body although the inteiaction 
of drug with metal ions has been studied in a wide range ot temperature between 25 
-60 "C'""\ Since we have to mimic the biological system under physiological condi-
tion we have studied, the interaction of Fedll) and Zn(ll) with ciprofloxacin at 
room temperature using absorption and fluorescence emission spectrophotometry 
at pH 3.98. The stability ofthe Fe(lll) and Zn(Il) complexes has been calculated by 
spectrophotometric and fluorescence emission spectrophotometric techniques. The 
fluorescence spectj'oscopy has been widely used to monitor the molecular interaction 
because of its high sensitivity, reproducibility and relatively easy use. Since no 
detailed fluorescence study on the binding interaction of ciprofloxacin with Fe(lll) 
and Zn(II) has been done so fbr, a through investigation was therefore made using 
this technique. Such interactions between ciprofloxacin and these metal ions can 
cause fluorescence quenching. Therefore, valuable information's such as binding 
mechanism, binding constant and binding sites can be obtained using fluorescence 
quenching study of ciprofloxacin by these metal cations. In addition the thermody-
namic parameters ofthe process were also proposed in this work. 
EXPERIMENTAL 
Fluorescence emission spectra were scanned using a Hitachi-F-25f)0 FL-spectro-
photometer. The absorption spectra were obtained with Elico-SL-169 double beam 
UV-Vis spectrophotometer. All potentiometric measurements were carried out w ith 
Elico-LI-12(JpH meter. 
Ciprofloxacin was purchased from Windlas Biotech. Ltd.(India). All solvents 
and chemicals were of analytical grade. Double distilled water was used throughout. 
Sodium hydroxide, Fe(N0.i):!.9H:0 (Merck Ltd., Mumbai. India) ZnCl: (anhydrous) 
(SDH Pvt. Ltd. India) and hydrochloric acid (Ranbaxy fine chem, Ltd., India) were 
used as received. 
Preparation of solutions: The stock solution of ciprofloxacin HCI (5 x 10" M) 
prepared in 1 x 10' M HCI was stored at 4 °C and those of the metal salts (1x10^ M) 
were prepared in double distilled water, respectively. All working solutions were 
prepared by dilution with double distilled water. 
Spectrophotometeric methods: Solutions of equimolar concentration (1 x 
10"' M) of ciprofloxacin HCI and metal ions were prepared. The pH of the drug was 
adjusted between 2.12 to 10..50 by adding sodium hydroxide and hydrochloric acid 
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(1 X 10 ' M lo 1 X 10^ M). The absorption spectra were recorded in the range 230-
360 nm. The ratio of metal to ciprofloxacin.HCi was determined by Job's method. 
The linearity of ciprofloxacin HCI was found in the range 3.5 x 10"^ -7.5 x lO"* mg/mL 
and the correlation factor (R^) 0.9629. 
Fluorescence spectrophotomcteric methods: Solution of the ciprofloxacin 
(5x 10''M) and those of metal ions (1 x lO 'Mto 10.5 x 10'M) were prepared. To 
prepare dilute solutions, an aliquot of st(x;k solution was placed in a 10 mL volumetric 
flask and made up to the mark with distilled water. Spectra were recorded immedi-
ately aftei' sample preparation in the optimum wavelength range 300-600 nm at 
optimum excitation wavelength of 315 nm. For calibration curve an aliquot ofstock 
solution (5 X 10'-1 x 10-'' mg/mL) was prepared which showed linearity with corre-
lation factor (R-) 0.9739. 
RESULTS AND DISCUSSION 
Absorption studies: The absorption spectru)u of ciprofloxacin run a( room 
temperature and at constant pH 3.98 displayed a strong peak at 272 nm and a weak 
absorption at 315 nm (Fig. 2). When the UV spectra of the drug were run at varying 
pH, at room temperature and, under physiological condition, the strong peak was 
shifted to lower wavelength while the broad peak was shifted to higher wavelength. 
The decrease in the position and intensity of the first peak is attributed to the extent 
of ionization of the carboxylic group while the increase in the intensity and height 
of the peak at 315 nm occurs as a consequence of protonation of the piperazinyl 
nitrogen on 7-cajbon atom. Two isosbestic points appearing at 320 and 350 nm 
indicated the presence of three chemical species in solution (Fig. 3) similar to those 
observed bv Bark and Barrel)'^ 
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Fig .2. Absorption .spectrum of ciprofloxacin 
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Fig. 3. Absorption spectra ot 'c iprol loxacin 
(I X l ( r 'M)a id i tTe ien tpH(2 . l2 - IO . .SO) 
m 2.5 "C 
I960 Siddiqi ei ul. AMUIII J. Cheni. 
The apparent ionization constant (pKa') of the drug was calculated (6.871) by 
the following equation. 
pKa' = pH + log {(A, - AM )/(A - AM) ) (1) 
where, Ai = Absorbance of drag in basic medium, AM = Absorbance of drug in 
acidic medium, A = Absorbance of drug in aqueous medium. The pure drug has 
maximum solubility at pH 5 although it increases in the presence of Fe(II) and 
Fe(lll) ions". 
Tlie stabilit>' constant of the complexes were calculated by the continuous vaiiation 
method using the following equation: 
K ^ A/A„Cx 
(C^^-A/A, ,Cx) (CL-nA/A„Cx)" '"^ 
where. K is the stability constant of the metal chelate formed in solution, M = 
metal, L = ligand, n = X/(l-X) where X is the mole fraction of the ligand at maximum 
absorption. A/A..^  is the ratio of the observed absorbance to that indicated by the 
tangent for the same waveleagth. Cx. CM and Ci are the limiting concentration. 
metal ion concentration and the ligand concentrations, respectively. 
The continuous variation curves are shown in Fig. 4. The ratio of ciprofloxacin: 
metal, is 2:1, which is quite obvious. The fairly large value of log k of the two 
complexes (Table-1) suggests that they are pretty stable in acidic medium only. 
The drag under this condition mu.st be acting as ionophore since the solubility of 
the drag is maximum in presence of Fe(III). However, precipitation occurs when 
the .solution becomes alkaline'^'". 
Fig. 4. 
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Continuous variation curves of equimolar solutions of cipronoxacin and (A) Fe(III) 
and (B) Zn(II) at 25 "C 
Fluorescence study: The absorption spectrum of the drag is markedly different 
from its emission spectram, which is attributed to different molecular geometries 
(Fig. 5) in ground and excited states. The piperazinyl group of ciprofloxacin acts as 
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TABLE-! 
STABILITY CONSTANT (log K AND -AG OF THE FORMED 
CHELATES AT 25 "C BY ABSORPTION STUDY 
Metal logK AG (kJ mol') 
Fe(lll) 
Zn(II) 
9.378 
9.381 
-53.509 
-53.526 
Basic medium 
Zwitterion 
Acidic medium 
Increasing acidity 
Zwitter ion condition decreasing 
Fig. 5. Zwitterion formation and intramolecular charge transfer of drug in solution phase 
at var>'ing pH 
electron donor while the keto group acts as electron acceptor. Since all investigations 
were done in acidic medium, ciprofloxacin exists in zwitter ionic form. The peaks 
in the absorption spectra are due to intramolecular charge transfer, the greater the 
number of resonating structures the stronger the fluorescence emission. 
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The tluurescence spectra are very sensitive to the nature of the rnelal quencher, 
which is reflected from the emission spectra of the drug in presence of the Fe(lll) 
and Zn(Il) quencher. They showed a consistent decrease in the intensity of lluores-
cence with increasing concentration of the metal ion until it was nearly completely 
quenched (Fig. 6) as a consequence of the complex formation between the metal 
ions and ciprofloxacin. 
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Fig, 6. The t'kiorescence emission spectra of drug quenched [A) Fe(Ill) and {B) ZnlH) 
Many workers''''" have studied the interaction of diiig with metal ions at temper-
ature exceeding 37 °C in order to show the Stem-Volmer plot although such experi-
ments above body temperature do not mimic the biological system. We, therefore, 
did all the experiments at room temperature. The fluorescence intensity increases 
rapidly with decrease in temperature. The lower stability at higher temperature also 
suppoils lowering in quenching. The fluorophore is quenched both by collision and 
complex formation with the metal ions. The complex formation is mainly due to 
ion dipole interaction. 
Fluorescence quenching refers to any process in which the fluorescence intensity 
of a given fluorophore decreases upon adding a quencher. Assuming that the fluore-
.scence intensity of a tluorophore-quencher complex is negligible as compared to 
an unquenched fluorophore, the intensity in the absence (F„) and presence (F) of 
the quencher is expressed by Stern-Volmer equation 
F „ / F = 1+Ksv[Ql (3) 
where IQl is the concentration of quencher, Ksv is the Stern-Volmer constant which 
is the equilibrium constant of the complex formed in the static quenching process. 
If a system obeys the Stern-Volmer equation, a plot of F./F-l vs. \Q\ will give 
straight line with a slope of Ksv and y-axis intercept. Fig. 8 represents the quenching 
of ciprofloxacin by Fe(lII) and Znlll), respectively. The linearity of Stern-Volmer 
plot (Fig. 7) increases with increasing concentration of quencher. The values of 
Ksv -And correlation coefficient are shown in Table-2. 
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TABLE-2 
STERN-VOLMER CONSTANT (Ksv, BINDING CONSTANT (log k), 
BINDING SITE AND REGRESSION COEFFICIENT AT 25 and 35 °C 
Metal 
Fe(ni) 
Zn(II) 
ICsv/mol' 
25°C 35°C 
3.36x10^ 2.77x10"' 
2.97x10-* 2.48x10^ 
logK 
25 °C 35 °C 
9.42 9.58 
9.46 9.60 
t 
25 °C 
1.88 
1.89 
1 
35 °C 
1.97 
2.01 
R-
25 °C 
0.982 
0.981 
35 °C 
0.950 
0.965 
The metal ions with large nuclear charge and small size will experience greater 
ion-dipole interaction and hence the emission intensity in the case otZnlllj should 
be less than that for Fe(III) although FedII) has greater nuclear charge and smaller 
ionic radius. 
The large value of stability constant of the complexes formed in solution reflects 
strong interaction between ciprofloxacin and the metal ions. 
Binding coastant and binding sites: For static quenching, the relationship 
between intensity and the concentration of quencher can be described by the binding 
constant formula-'-': 
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log(F,.-F)/F = log K + n log (Q) (4) 
where K is the binding constant (Table-3), n is the number of binding sites per 
ciprofloxacin. After the fluorescence quenching intensities on ciprofloxacin at 315 nm 
were measured, the double-logarithm algorithm was assessed by eqn. 4. Fig. S 
shows double4ogarithm cune and Table-2 gives the couesponding calculated results. 
The linear correlation coefficient for all the curves are larger than 0.94.'i. indicating 
that the interaction between metal ions and ciprofloxacin agrees well with the site-
binding model underlying eqn. 4. The results illustrate that there is a strong binding 
force between ciprofloxacin and metal ions and approximately two binding site 
would be formed in each case which is consistent with the previous studies that in 
acidic medium ciprofloxacin and metal ions form 2:1 complex. 
TABLE-3 
THERMODYNAMICS PARAMETERS AT 25 AND 35 "C 
Metal 
Fe(IIl) 
Zn(ll) 
AG (U mol') 
25 °C 35 °C 
-53.77 -56.54 
-54.01 -56.62 
118.59 
98.94 
AS(kJmol' K') 
25°C 35°C 
180.85 183.96 
181.57 184.16 
Thermodynamic parameters and nature of binding forces: Considering the 
dependence of the binding constant on the temperature a thermodynamic process 
was considered to be responsible for this interaction. Therefore, the theimody-
naniic parameters dependent on temperature were analyzed in order to fuilhcr charact-
erize the forces acting between drug and metal ions. The thermodynamic parameters 
enthalpy changes (AH), entropy changes (AS) and free energy changes (AG) are the 
main evidences to determine the binding mode. If the temperature does not vary 
significantly, the enthalpy changes (AH) can be regarded as constant. The free energy 
change (AG) can be estimated from the following equation, ba.sed on the binding 
constant at different temperatures. 
AG = -2.303 RT log K (3) 
where R is the gas constant, T is the experimental temperature and K is the binding 
constant at the corresponding temperature. 
From the value of stability constant at different temperature the enthalpy changes 
can be calculated by using equation: 
logKVKi = [irri-l/T:JAH/2.303R (4i 
The entropy changes can be calculated by using equation: 
AG = AH-TAS (5) 
Thermodynamics parameters for the interaction of metal ions and ciprofloxacin 
are shown in Table-3. The negative value of AG means that the interaction process 
is spontaneous. The -i-ve AS value obtained for all investigated complex is character-
istic of chelation. It occurs because the water molecules that are normally arranged 
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in an orderly fashion around the ciprofloxacin and metal ions have acquired a random 
configuration as a result of chelation. This is referred as gain in contlgurational 
entropy". The +ve value of AH indicate ihat the processes are endothermic and 
binding between metal ions and ciprolloxacin is mainly AS-driven. with little contri-
bution from the enthalpy factor. 
Conclusion 
It is concluded that the drug stays as zwitter ions, ionization of carboxylic 
group and protonation of piperazinyl group occurs. The two isosbestic points indicate 
the presence of three chemical species in solution. The result shows that the complex 
of ciprofloxacin with Fe(lll) and Zn(ir) are fairly stable. The thermodynamic para-
meters showed that the interaction between ciprofloxacin and metal ion was spontan-
eous and that the hydrophobic force was a major factor in the interaction. 
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